WO2023023654A1 - Methods and compositions for treating fibrotic diseases - Google Patents
Methods and compositions for treating fibrotic diseases Download PDFInfo
- Publication number
- WO2023023654A1 WO2023023654A1 PCT/US2022/075226 US2022075226W WO2023023654A1 WO 2023023654 A1 WO2023023654 A1 WO 2023023654A1 US 2022075226 W US2022075226 W US 2022075226W WO 2023023654 A1 WO2023023654 A1 WO 2023023654A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- age
- seq
- antibody
- protein
- cells
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 69
- 201000010099 disease Diseases 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 52
- 230000003176 fibrotic effect Effects 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 104
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 100
- 239000000427 antigen Substances 0.000 claims abstract description 64
- 108091007433 antigens Proteins 0.000 claims abstract description 63
- 102000036639 antigens Human genes 0.000 claims abstract description 63
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 claims abstract description 48
- 229960005486 vaccine Drugs 0.000 claims abstract description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 41
- UENLDOJJKXLRJI-ZETCQYMHSA-N (2s)-6-amino-2-(2-carboxyethylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NCCC(O)=O UENLDOJJKXLRJI-ZETCQYMHSA-N 0.000 claims abstract description 18
- 230000004048 modification Effects 0.000 claims abstract description 9
- 238000012986 modification Methods 0.000 claims abstract description 9
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 claims abstract description 7
- VTYFITADLSVOAS-NSHDSACASA-N 1-(L-norleucin-6-yl)pyrraline Chemical compound OC(=O)[C@@H](N)CCCCN1C(CO)=CC=C1C=O VTYFITADLSVOAS-NSHDSACASA-N 0.000 claims abstract description 6
- 108010053481 Antifreeze Proteins Proteins 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 177
- 241000282414 Homo sapiens Species 0.000 claims description 48
- 206010016654 Fibrosis Diseases 0.000 claims description 41
- 150000001413 amino acids Chemical group 0.000 claims description 37
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 36
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 32
- 239000002671 adjuvant Substances 0.000 claims description 27
- 206010039710 Scleroderma Diseases 0.000 claims description 21
- 230000006378 damage Effects 0.000 claims description 20
- 230000002163 immunogen Effects 0.000 claims description 20
- 230000007882 cirrhosis Effects 0.000 claims description 17
- 230000037390 scarring Effects 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 14
- 241000282472 Canis lupus familiaris Species 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 13
- 241000282326 Felis catus Species 0.000 claims description 12
- 210000000987 immune system Anatomy 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 241000283690 Bos taurus Species 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 11
- 239000003053 toxin Substances 0.000 claims description 11
- 231100000765 toxin Toxicity 0.000 claims description 11
- 108700012359 toxins Proteins 0.000 claims description 11
- 241000283707 Capra Species 0.000 claims description 10
- 108010052285 Membrane Proteins Proteins 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 102000014914 Carrier Proteins Human genes 0.000 claims description 8
- 108010078791 Carrier Proteins Proteins 0.000 claims description 8
- 241001416177 Vicugna pacos Species 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- -1 AGE-albumin Proteins 0.000 claims description 7
- 208000002260 Keloid Diseases 0.000 claims description 7
- 206010023330 Keloid scar Diseases 0.000 claims description 7
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 7
- 102000018697 Membrane Proteins Human genes 0.000 claims description 7
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 7
- 230000001969 hypertrophic effect Effects 0.000 claims description 7
- 210000001117 keloid Anatomy 0.000 claims description 7
- 201000009925 nephrosclerosis Diseases 0.000 claims description 7
- 241000282832 Camelidae Species 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 6
- 241000283086 Equidae Species 0.000 claims description 6
- 102000001554 Hemoglobins Human genes 0.000 claims description 6
- 108010054147 Hemoglobins Proteins 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 101710088194 Dehydrogenase Proteins 0.000 claims description 5
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 5
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 5
- 208000003510 Nephrogenic Fibrosing Dermopathy Diseases 0.000 claims description 5
- 206010067467 Nephrogenic systemic fibrosis Diseases 0.000 claims description 5
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 5
- 208000016780 Scleredema Diseases 0.000 claims description 5
- 206010055953 Scleroedema Diseases 0.000 claims description 5
- 208000001941 Scleromyxedema Diseases 0.000 claims description 5
- 241000282887 Suidae Species 0.000 claims description 5
- 206010028537 myelofibrosis Diseases 0.000 claims description 5
- 208000009928 nephrosis Diseases 0.000 claims description 5
- 231100001027 nephrosis Toxicity 0.000 claims description 5
- 208000007754 scleredema adultorum Diseases 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 241000894007 species Species 0.000 claims description 5
- 239000002753 trypsin inhibitor Substances 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000893 fibroproliferative effect Effects 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 239000002122 magnetic nanoparticle Substances 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 206010005042 Bladder fibrosis Diseases 0.000 claims description 3
- 238000008416 Ferritin Methods 0.000 claims description 3
- 102000005548 Hexokinase Human genes 0.000 claims description 3
- 108700040460 Hexokinases Proteins 0.000 claims description 3
- 102000004867 Hydro-Lyases Human genes 0.000 claims description 3
- 108090001042 Hydro-Lyases Proteins 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 3
- 102000004895 Lipoproteins Human genes 0.000 claims description 3
- 102000005890 Spectrin Human genes 0.000 claims description 3
- 108010019965 Spectrin Proteins 0.000 claims description 3
- 206010065584 Urethral stenosis Diseases 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229960005348 antithrombin iii Drugs 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 238000010494 dissociation reaction Methods 0.000 claims description 3
- 230000005593 dissociations Effects 0.000 claims description 3
- 230000003511 endothelial effect Effects 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229940012952 fibrinogen Drugs 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 3
- 239000004325 lysozyme Substances 0.000 claims description 3
- 229960000274 lysozyme Drugs 0.000 claims description 3
- 229940092253 ovalbumin Drugs 0.000 claims description 3
- 229940127126 plasminogen activator Drugs 0.000 claims description 3
- 239000005495 thyroid hormone Substances 0.000 claims description 3
- 229940036555 thyroid hormone Drugs 0.000 claims description 3
- 239000012581 transferrin Substances 0.000 claims description 3
- 201000001988 urethral stricture Diseases 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 2
- 108010051456 Plasminogen Proteins 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- NDDZLVOCGALPLR-GNSUAQHMSA-N docosanoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 NDDZLVOCGALPLR-GNSUAQHMSA-N 0.000 claims description 2
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010055267 advanced glycation end products-bovine serum albumin Proteins 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 94
- 241000699670 Mus sp. Species 0.000 description 72
- 238000011282 treatment Methods 0.000 description 52
- 206010028980 Neoplasm Diseases 0.000 description 40
- 210000004072 lung Anatomy 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 31
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 230000004761 fibrosis Effects 0.000 description 25
- 229960001561 bleomycin Drugs 0.000 description 24
- 230000009758 senescence Effects 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 108010006654 Bleomycin Proteins 0.000 description 21
- 241001529936 Murinae Species 0.000 description 21
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 19
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 19
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- 239000000779 smoke Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 230000032683 aging Effects 0.000 description 15
- 230000010094 cellular senescence Effects 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 235000019504 cigarettes Nutrition 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 13
- 102400001301 Gasdermin-B, C-terminal Human genes 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 208000020832 chronic kidney disease Diseases 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 12
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 229960002963 ganciclovir Drugs 0.000 description 12
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 230000036039 immunity Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000002255 vaccination Methods 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000004199 lung function Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 229940125381 senolytic agent Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000002485 urinary effect Effects 0.000 description 10
- 241000282836 Camelus dromedarius Species 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000007795 chemical reaction product Substances 0.000 description 9
- 230000002500 effect on skin Effects 0.000 description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 241000283073 Equus caballus Species 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000000090 biomarker Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 229960004279 formaldehyde Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000000651 myofibroblast Anatomy 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 108010071390 Serum Albumin Proteins 0.000 description 6
- 102000007562 Serum Albumin Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000036428 airway hyperreactivity Effects 0.000 description 6
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000036252 glycation Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 5
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 5
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 5
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 5
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 5
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 5
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 5
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 5
- 102100036407 Thioredoxin Human genes 0.000 description 5
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229960002448 dasatinib Drugs 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- NUXSIDPKKIEIMI-LURJTMIESA-N N(6)-carboxymethyl-L-lysine Chemical compound OC(=O)[C@@H](N)CCCCNCC(O)=O NUXSIDPKKIEIMI-LURJTMIESA-N 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000024203 complement activation Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000001050 pharmacotherapy Methods 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229940124272 protein stabilizer Drugs 0.000 description 4
- 208000001076 sarcopenia Diseases 0.000 description 4
- 230000009327 senolytic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- BDUHCSBCVGXTJM-WUFINQPMSA-N 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazol-1-yl]-oxomethyl]-2-piperazinone Chemical compound CC(C)OC1=CC(OC)=CC=C1C1=N[C@@H](C=2C=CC(Cl)=CC=2)[C@@H](C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-WUFINQPMSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 3
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010073306 Exposure to radiation Diseases 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 3
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 3
- 208000004852 Lung Injury Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 201000004073 acute interstitial pneumonia Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013357 binding ELISA Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 231100000515 lung injury Toxicity 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
- 229960002329 methacholine Drugs 0.000 description 3
- 108091005601 modified peptides Proteins 0.000 description 3
- 102000035118 modified proteins Human genes 0.000 description 3
- 108091005573 modified proteins Proteins 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229950004847 navitoclax Drugs 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000005048 vimentin Anatomy 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- NUXSIDPKKIEIMI-UHFFFAOYSA-N 2-azaniumyl-6-(carboxylatomethylazaniumyl)hexanoate Chemical compound OC(=O)C(N)CCCCNCC(O)=O NUXSIDPKKIEIMI-UHFFFAOYSA-N 0.000 description 2
- 206010066728 Acute interstitial pneumonitis Diseases 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 238000003691 Amadori rearrangement reaction Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- 102000000018 Chemokine CCL2 Human genes 0.000 description 2
- 108010049048 Cholera Toxin Proteins 0.000 description 2
- 102000009016 Cholera Toxin Human genes 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000282838 Lama Species 0.000 description 2
- 241000282852 Lama guanicoe Species 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 206010067472 Organising pneumonia Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 102100035071 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000006491 bone marrow cancer Diseases 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000037219 healthy weight Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108700016226 indium-bleomycin Proteins 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002206 pro-fibrotic effect Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000028617 response to DNA damage stimulus Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100028734 1,4-alpha-glucan-branching enzyme Human genes 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- KHJWSKNOMFJTDN-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KHJWSKNOMFJTDN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Polymers CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004485 Berylliosis Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 241000824799 Canis lupus dingo Species 0.000 description 1
- 206010054936 Cardiac cirrhosis Diseases 0.000 description 1
- 101150056960 Casp8 gene Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102100035359 Cerebellar degeneration-related protein 2-like Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000023355 Chronic beryllium disease Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009691 Clubbing Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 206010011763 Cystic fibrosis lung Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100021860 Endothelial cell-specific molecule 1 Human genes 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010053249 Glycogen Storage Disease Type IV Diseases 0.000 description 1
- 208000011123 Glycogen storage disease due to glycogen branching enzyme deficiency Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000737792 Homo sapiens Cerebellar degeneration-related protein 2-like Proteins 0.000 description 1
- 101000897959 Homo sapiens Endothelial cell-specific molecule 1 Proteins 0.000 description 1
- 101001055307 Homo sapiens Immunoglobulin heavy constant delta Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100026211 Immunoglobulin heavy constant delta Human genes 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010062070 Peritonitis bacterial Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 206010050897 Portal hypertensive gastropathy Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108091006335 Prostaglandin I receptors Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010039230 Protein Kinase C-delta Proteins 0.000 description 1
- 102100037340 Protein kinase C delta type Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010050207 Skin fibrosis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 241001416176 Vicugna Species 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 230000008371 airway function Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940047712 aluminum hydroxyphosphate Drugs 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910001593 boehmite Inorganic materials 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000002817 coal dust Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- WDRWZVWLVBXVOI-QTNFYWBSSA-L dipotassium;(2s)-2-aminopentanedioate Chemical compound [K+].[K+].[O-]C(=O)[C@@H](N)CCC([O-])=O WDRWZVWLVBXVOI-QTNFYWBSSA-L 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940017733 esbriet Drugs 0.000 description 1
- ZNMRDZZRAFJOKY-UHFFFAOYSA-N ethanesulfonic acid methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-indole-6-carboxylate Chemical compound CCS(=O)(=O)O.CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)N=C(C3=CC=CC=C3)C4=C(NC5=C4C=CC(=C5)C(=O)OC)O ZNMRDZZRAFJOKY-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 208000036449 fibrotic liver disease Diseases 0.000 description 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
- DKZNJXJLTVYBRA-UHFFFAOYSA-N furan-2-yl-[5-(furan-2-yl)-1h-imidazol-2-yl]methanone Chemical compound C=1C=COC=1C(=O)C(N1)=NC=C1C1=CC=CO1 DKZNJXJLTVYBRA-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108091005996 glycated proteins Proteins 0.000 description 1
- 108010004903 glycosylated serum albumin Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010921 in-depth analysis Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000012484 label-free interaction analysis Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 235000013919 monopotassium glutamate Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940015847 ofev Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000011146 organic particle Substances 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000002325 prokinetic agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940038774 squalene oil Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- Fibrosis is the formation of excess fibrous connective tissue in an organ or in tissue.
- Connective tissue such as extracellular matrix proteins, is produced by fibroblasts in response to pro-fibrotic factors including transforming growth factor beta (TGFp), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF) and interleukin 4 (IL-4).
- TGFp transforming growth factor beta
- CGF connective tissue growth factor
- PDGF platelet-derived growth factor
- IL-4 interleukin 4
- Fibroblasts may differentiate into myofibroblasts through an epithelial to mesenchymal transition largely mediated by TGF
- 31 Transforming growth factor-p1 (TGF-
- HA hyaluronan
- EGFR epidermal growth factor receptor
- CD44 co-localization in lipid rafts
- Myofibroblasts are key mediators of profibrotic conditions and proliferate in response to TGFp signaling (Harris, W. T. et al., “Myofibroblast differentiation and enhanced TGF- signaling in cystic fibrosis lung disease”, PLoS One, Vol. 8, No. 8, 8 pages (2013)).
- Fibrosis can result from specific trauma such as surgical complications, exposure to radiation, burns or physical injury.
- Some therapeutic treatments such as the administration of chemotherapeutic drugs or exposure to ionizing radiation (radiotherapy) as used in treating cancer, are known to cause fibrosis as a side effect.
- Certain cancers such as myelofibrosis (bone marrow cancer), can also cause fibrosis.
- Fibrotic diseases can develop in many parts of the body in humans and animals and may affect organs including the lungs (interstitial lung disease, pulmonary fibrosis, acute lung injury), liver (liver fibrosis, cirrhosis), kidneys (kidney disease, nephrosclerosis), heart (cardiovascular disease) and eyes (macular degeneration, vitreal retinopathy) (Wynn, T. A., “Fibrotic disease and the TH1/TH2 paradigm”, Nature Reviews Immunology, Vol. 4, No. 8, p. 583-594 (2004)). Fibrotic diseases that are characterized by excessive connective tissue accumulation and progressive tissue contraction are known as fibroproliferative disorders (Bitterman, P.B. et al., “Fibroproliferative disorders”, Chest, Vol. 99, No. 3, pp. 81S-84S (1991)).
- fibroproliferative disorders include scleroderma (systemic and local), hypertrophic scarring, keloid scarring, cirrhosis, nephrosis and restenosis.
- Pulmonary fibrosis (scarring of the lungs) is a respiratory disease characterized by the development of fibrous tissue in the walls of the air sacs of the lungs. The formation of scar tissue impairs the ability of the lungs to oxygenate blood, which often presents as shortness of breath (dyspnea). Other symptoms of pulmonary fibrosis include a chronic dry or hacking cough, fatigue, weakness, chest pain or discomfort, loss of appetite, unexplained weight loss and clubbing of the tips of the fingers and toes. The scarring caused by pulmonary fibrosis is permanent and the loss of lung function cannot be restored.
- Pulmonary fibrosis may result from a variety of different sources.
- Known causes of pulmonary fibrosis include autoimmune diseases that produce inflammation or scarring in the lungs, such as rheumatoid arthritis, scleroderma and autoimmune muscle diseases; occupational exposure to small inorganic particles, such as asbestos, beryllium, coal dust, silica and heavy metal dusts; environmental exposure to small organic particles, such as animal proteins, bacteria and molds; radiation exposure, including environmental radiation and cancer radiotherapy; bacterial or viral infections; and exposure to medications, such as nitrofurantoin, sulfasalazine, amiodarone, propranolol, phenytoin, methotrexate, bleomycin and oxaliplatin (Pulmonary Fibrosis Foundation, “About PF”, available online at www.pulmonaryfibrosis.org/life-with-pf/about-pf, accessed on July 18, 2017).
- Idiopathic pulmonary fibrosis may result from DNA abnormalities, and inheritable forms of idiopathic pulmonary fibrosis include familial pulmonary fibrosis (FPF) and familial interstitial pneumonia (FIP) (Id ).
- FPF familial pulmonary fibrosis
- FIP familial interstitial pneumonia
- pulmonary fibrosis There is no standard treatment for pulmonary fibrosis. Lifestyle changes such as not smoking and maintaining a healthy weight can improve symptoms of pulmonary fibrosis. Pulmonary rehabilitation exercise programs can help to preserve lung function. Oxygen therapy may be used to improve oxygen delivery to the body.
- Various pharmacotherapies have been investigated for treating pulmonary fibrosis including corticosteroids (immunosuppressant/anti-inflammatory), cyclophosphamide (anti-inflammatory), azathioprine (immunosuppressant), mycophenolate mofetil (immunosuppressant), N-acetylcysteine (antioxidant) and proton pump inhibitors (gastric acid reducer).
- Nintedanib (OFEV®) and pirfenidone (ESBRIET®) are the only U.S. Food and Drug Administration-approved medications for treating idiopathic pulmonary fibrosis. However, these medications slow the progression of idiopathic pulmonary fibrosis, but do not treat the disease or prevent its onset. Severe cases of pulmonary fibrosis may be treated with lung transplantation. There are no pharmacotherapies for treating or preventing the onset of pulmonary fibrosis.
- liver fibrosis is the formation of fibrous tissue in the liver.
- Cirrhosis is the most well-known fibrotic liver disease and may be caused by alcoholism, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hereditary hemochromatosis, Wilson’s disease, Indian childhood cirrhosis, alpha 1-antitrypsin deficiency (A1AD), cardiac cirrhosis, galactosemia, glycogen storage disease type IV, cystic fibrosis and exposure to hepatoxic drugs or toxins.
- A1AD alpha 1-antitrypsin deficiency
- cardiac cirrhosis galactosemia
- glycogen storage disease type IV cystic fibrosis and exposure to hepatoxic drugs or toxins.
- Cirrhosis may lead to complications such as ascites, esophageal variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, portal hypertensive gastropathy, infection and hepatocellular carcinoma.
- cirrhosis may be reduced by vaccination against specific diseases that cause cirrhosis, such as hepatitis B or hepatitis C.
- cirrhosis that develops as a side effect may be managed by treating the underlying disease, such as by administering interferon and corticosteroids to patients experiencing cirrhosis due to hepatitis.
- Treatment options for cirrhosis are limited.
- Further liver damage may be prevented with lifestyle changes including abstaining from alcohol, avoiding acetaminophen and maintaining a healthy diet. Liver transplantation may ultimately be necessary for patients who experience liver failure or cannot control the complications of cirrhosis.
- Dermal fibrosis is the formation of fibrous tissue in the skin. Fibrotic skin disorders include keloid scarring, hypertrophic scarring, scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema and eosinophilic fasciitis. Dermal fibrosis may be a minor aesthetic inconvenience, or may result in severe health complications.
- scleroderma may affect major organs such as the lungs (loss of lung function, severe lung disease and lung tissue scarring), heart (scarring and weakness of the heart, swelling of the heart muscle and irregular heartbeat) and kidneys (high blood pressure and kidney failure) (“Scleroderma Living With It”, National Institute of Arthritis and Musculoskeletal and Skin Diseases, available online at www.niams.nih.gov/health-topics/scleroderma#tab-living-with (2016)).
- keloid and hypertrophic scars may be treated with local steroid injections, pressure dressings, topical chemotherapy drugs, laser light therapy, pulsed-dye laser therapy, radiation therapy, surgical excision, silicone gel sheeting application and administration of hyaluronic acid (WO 2014/179262).
- Other treatments for dermal fibrosis focus on the symptoms and complications of the specific fibrotic disorder.
- scleroderma therapies include calcium channel blockers, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, acetaminophen, corticosteroids, narcotics, antacids, histamine H2-receptor antagonists, proton pump inhibitors, prokinetic agents, somatostatin agonists, antibiotics, prostaglandin derivatives, endothelin receptor antagonists, IP receptor agonists, phosphodiesterase type 5 (PDE5) inhibitors, anti-fibrotic agents, anti-inflammatory agents, tyrosine kinase inhibitors, immunosuppressants and alkylating agents (“Current treatments available for scleroderma patients”, Scleroderma Research Foundation, available online at www.srfcure.org/for-patients/current-treatments (2016)).
- ACE angiotensin converting enzyme
- NSAIDs non-steroidal
- Kidney fibrosis may be further classified based on the location of the affected tissue, such as nephrosclerosis (the nephron), glomerulosclerosis (the glomerulus) or tubulointerstitial renal fibrosis (the interstitium).
- Chronic kidney disease (CKD) a progressive disease, is frequently caused by kidney fibrosis.
- CKD chronic kidney disease
- Two primary factors that promote CKD are diabetes and high blood pressure (“About chronic kidney disease: symptoms and causes”, National Kidney Foundation, available online at www.kidney.org/atoz/content/about- chronic-kidney-disease (2020)).
- urinary fibrosis The damage caused by urinary fibrosis is permanent. Further damage may be reduced by managing underlying conditions that contribute to urinary fibrosis, especially diabetes and high blood pressure. Lifestyle changes such as not smoking, limiting alcohol intake and maintaining a healthy weight can prevent further worsening of kidney fibrosis. Dietary changes such as adopting a low-salt and low- fat diet may also help. If untreated, urinary fibrosis may lead to loss of kidney function, end-stage renal disease or kidney failure. Individuals with kidney failure must undergo regular dialysis to cleanse the blood or receive a kidney transplant, if they are healthy enough for the procedure and are able to find a suitable donor. Pharmacotherapies for treating urinary fibrosis are limited and primarily focus on controlling symptoms, reducing complications and slowing the progression of the disease.
- Desmoplasia refers to growth of dense connective tissue or stroma, and it may occur as result of injury or neoplasia.
- the stromal reaction in cancer is similar to the stromal reaction induced by injury or wound repair, causing scar-like tissue to be built around the cancer.
- the surrounding stroma plays a very important role in the progression of cancer. It has been suggested that tumor cells cause the proliferation of fibroblasts and subsequent secretion of collagen (El-Torky, M., et al., Collagens in scar carcinoma of the lung, The American Journal of Pathology, vol. 121, no. 2, pp. 322-326 (1985)).
- Senescent cells are cells that are partially-functional or non-functional and are in a state of proliferative arrest. Senescence is a distinct state of a cell, and is associated with biomarkers, such as activation of the biomarker p16 lnk4a , and expression of p-galactosidase. Senescence begins with damage or stress (such as overstimulation by growth factors) of cells.
- AGEs Advanced glycation end-products
- AGEs also referred to as AGE-modified proteins or peptides, or glycation end-products
- AGE-modified proteins or peptides or glycation end-products
- Maho K. et al., Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation, Biochem Biophys Res Commun., Vol. 258, 123, 125 (1999)
- This process begins with a reversible reaction between the reducing sugar and the amino group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product.
- AGEs may also be formed from other processes.
- the advanced glycation end product, N e -(carboxymethyl)lysine is a product of both lipid peroxidation and glycoxidation reactions.
- AGEs have been associated with several pathological conditions including inflammation, atherosclerosis, stroke, endothelial cell dysfunction, and neurodegenerative disorders (Bierhaus A, “AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept,” Cardiovasc Res, Vol. 37(3), 586-600 (1998)).
- AGE-modified proteins are also a marker of senescent cells. This association between AGEs and senescence is well known in the art. See, for example, Gruber, L. (WO 2009/143411, 26 Nov. 2009), Ando, K. etal. (Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation, Biochem Biophys Res Commun., Vol. 258, 123, 125 (1999)), Ahmed, E.K. etal. (“Protein Modification and Replicative Senescence of WI-38 Human Embryonic Fibroblasts” Aging Cells, vol. 9, 252, 260 (2010)), Vlassara, H. et al.
- Ahmed, E.K. et al. indicates that glycation end-products are “one of the major causes of spontaneous damage to cellular and extracellular proteins” (Ahmed, E.K. et al., see above, page 353). Accordingly, the accumulation of glycation endproducts is associated with senescence and lack of function.
- MG methyl glyoxal
- Damage or stress to mitochondrial DNA also sets off a DNA damage response which induces the cell to produce cell cycle blocking proteins. These blocking proteins prevent the cell from dividing. Continued damage or stress causes mTOR production, which in turn activates protein synthesis and inactivates protein breakdown. Further stimulation of the cells leads to programmed cell death (apoptosis).
- p16 is a protein involved in regulation of the cell cycle, by inhibiting the S phase (synthesis phase). It can be activated during ageing or in response to various stresses, such as DNA damage, oxidative stress or exposure to drugs. p16 is typically considered a tumor suppressor protein, causing a cell to become senescent in response to DNA damage and irreversibly preventing the cell from entering a hyperproliferative state. However, there has been some ambiguity in this regard, as some tumors show overexpression of p16, while others show downregulated expression. Evidence suggests that overexpression of p16 is some tumors results from a defective retinoblastoma protein (“Rb").
- Rb defective retinoblastoma protein
- p16 acts on Rb to inhibit the S phase, and Rb downregulates p16, creating negative feedback.
- Defective Rb fails to both inhibit the S phase and downregulate p16, thus resulting in overexpression of p16 in hyperproliferating cells (Romagosa, C. et al., p16 lnk4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors, Oncogene, Vol. 30, 2087-2097 (2011)).
- Senescent cells are associated with secretion of many factors involved in intercellular signaling, including pro-inflammatory factors; secretion of these factors has been termed the senescence-associated secretory phenotype, or SASP (Freund, A. “Inflammatory networks during cellular senescence: causes and consequences” Trends Mol Med. 2010 May;16(5):238-46). Autoimmune diseases, such as Crohn’s disease and rheumatoid arthritis, are associated with chronic inflammation (Ferraccioli, G. etal.
- Chronic inflammation may be characterized by the presence of pro- inflammatory factors at levels higher than baseline near the site of pathology, but lower than those found in acute inflammation.
- Senescent cells also upregulate genes with roles in inflammation including IL-1 p, IL-8, ICAM1, TNFAP3, ESM1 and CCL2 (Burton, D.G.A. et al., “Microarray analysis of senescent vascular smooth muscle cells: a link to atherosclerosis and vascular calcification”, Experimental Gerontology, Vol. 44, No. 10, pp. 659-665 (October 2009)).
- ROS reactive oxygen species
- the p16/Rb pathway leads to the induction of ROS, which in turn activates the protein kinase C delta creating a positive feedback loop that further enhance ROS, helping maintain the irreversible cell cycle arrest; it has even been suggested that exposing cancer cells to ROS might be effective to treat cancer by inducing cell phase arrest in hyperproliferating cells (Rayess, H. et al., Cellular senescence and tumor suppressor gene p16, Int J Cancer, Vol. 130, 1715-1725 (2012)).
- mice that were treated to induce senescent cell elimination were found to have larger diameters of muscle fibers as compared to untreated mice. Treadmill exercise tests indicated that treatment also preserved muscle function. Continuous treatment of transgenic mice for removal of senescent cells had no negative side effects and selectively delayed age-related phenotypes that depend on cells. This data demonstrates that removal of senescent cells produces beneficial therapeutic effects and shows that these benefits may be achieved without adverse effects.
- Vaccines have been widely used since their introduction by Edward Jenner in the 1770s to confer immunity against a wide range of diseases and afflictions.
- Vaccine preparations contain a selected immunogenic agent capable of stimulating immunity to an antigen.
- antigens are used as the immunogenic agent in vaccines, such as, for example, viruses, either killed or attenuated, and purified viral components.
- Antigens used in the production of cancer vaccines include, for example, tumor-associated carbohydrate antigens (TACAs), dendritic cells, whole cells and viral vectors. Different techniques are employed to produce the desired amount and type of antigen being sought. For example, pathogenic viruses are grown either in eggs or cells. Recombinant DNA technology is often utilized to generate attenuated viruses for vaccines.
- TACAs tumor-associated carbohydrate antigens
- dendritic cells dendritic cells
- whole cells whole cells
- viral vectors Different techniques are employed to produce the desired amount and type of antigen being sought. For example, pathogenic viruses are grown either in eggs or cells. Recombinant DNA technology is often utilized to generate attenuated viruses for vaccines.
- Vaccines may therefore be used to stimulate the production of antibodies in the body and provide immunity against antigens.
- the immune system may destroy or remove cells that express the antigen.
- the invention is a method of treating or preventing the onset of a fibrotic disease comprising administering to a subject a composition comprising an anti-AGE antibody.
- the invention is a method of treating or preventing the onset of a fibrotic disease comprising administering to a subject a vaccine comprising an AGE antigen.
- fibrotic disease means a disease or disorder characterized by the formation of fibrous tissue.
- fibrotic diseases include interstitial lung disease, pulmonary fibrosis, liver fibrosis, cirrhosis, urinary fibrosis, kidney fibrosis, nephrosclerosis, nephrosis, cardiovascular disease, macular degeneration, vitreal retinopathy, scleroderma (systemic and local), hypertrophic scarring, keloid scarring, restenosis, myelofibrosis, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis.
- fibrotic disease does not include atherosclerosis.
- Pulmonary fibrosis means a disease or disorder characterized by the formation of fibrous tissue in the lungs.
- Pulmonary fibrosis includes idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), sarcoidosis, familial pulmonary fibrosis (FPF), familial interstitial pneumonia (FIP), asbestosis, silicosis, berylliosis, hypersensitivity pneumonitis, atypical pneumonia, pneumocystis pneumonia, tuberculosis, respiratory syncytial virus, acute interstitial pneumonitis/pneumonia (also known as Hamman-Rich syndrome), chronic obstructive pulmonary disease (COPD), emphysema and mesothelioma.
- IPF idiopathic pulmonary fibrosis
- NIP nonspecific interstitial pneumonia
- COP cryptogenic organizing pneumonia
- sarcoidosis familial
- liver fibrosis means a disease or disorder characterized by the formation of fibrous tissue in the liver. Liver fibrosis includes cirrhosis.
- dermal fibrosis means a disease or disorder characterized by the formation of fibrous tissue in the skin.
- Dermal fibrosis includes keloid scarring, hypertrophic scarring, scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema and eosinophilic fasciitis.
- Urinary fibrosis means a disease or disorder characterized by the formation of fibrous tissue in the kidneys, ureter, bladder or the urethra.
- Urinary fibrosis includes kidney fibrosis, nephrosclerosis, nephrosis, glomerulosclerosis, tubulointerstitial renal fibrosis, bladder fibrosis and urethral stricture. Urinary fibrosis may also be referred to as “renal fibrosis”.
- peptide means a molecule composed of 2-50 amino acids.
- protein means a molecule composed of more than 50 amino acids.
- AGE-modified protein AGE-modified peptide
- glycation end-product refers to modified proteins or peptides that are formed as the result of the reaction of sugars with protein side chains that further rearrange and form irreversible cross-links. This process begins with a reversible reaction between a reducing sugar and an amino group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product. Once formed, the Amadori product undergoes further rearrangement to produce AGEs.
- AGE-modified proteins and antibodies to AGE-modified proteins are described in U.S.
- AGEs may be identified by the presence of AGE modifications (also referred to as AGE epitopes or AGE moieties) such as 2-(2- furoyl)-4(5)-(2-furanyl)-1 H-imidazole (“FFI”); 5-hydroxymethyl-1-alkylpyrrole-2- carbaldehyde (“Pyrraline”); 1-alkyl-2-formyl-3,4-diglycosyl pyrrole (“AFGP”), a non- fluorescent model AGE; carboxymethyllysine; carboxyethyllysine; and pentosidine.
- ALI another AGE, is described in Al-Abed.
- AGE antigen means a substance that elicits an immune response against an AGE-modified protein or peptide of a cell.
- the immune response against an AGE-modified protein or peptide of a cell does not include the production of antibodies to the non-AGE-modified protein or peptide.
- an antibody that binds to an AGE-modified protein on a cell means an antibody, antibody fragment or other protein or peptide that binds to an AGE-modified protein or peptide which preferably includes a constant region of an antibody, where the protein or peptide which has been AGE-modified is a protein or peptide normally found bound on the surface of a cell, preferably a mammalian cell, more preferably a human, cat, dog, horse, camelid (for example, camel or alpaca), cattle, sheep, pig, or goat cell.
- an antibody that binds to an AGE-modified protein on a cell does not include an antibody or other protein which binds with the same specificity and selectivity to both the AGE-modified protein or peptide, and the same non-AGE- modified protein or peptide (that is, the presence of the AGE modification does not increase binding).
- AGE-modified albumin is not an AGE-modified protein on a cell, because albumin is not a protein normally found bound on the surface of cells.
- An antibody that binds to an AGE-modified protein on a cell “anti-AGE antibody” or “AGE antibody” only includes those antibodies which lead to removal, destruction, or death of the cell.
- antibodies which are conjugated, for example to a toxin, drug, or other chemical or particle Preferably, the antibodies are monoclonal antibodies, but polyclonal antibodies are also possible.
- senescent cell means a cell which is in a state of proliferative arrest and expresses one or more biomarkers of senescence, such as activation of p16 lnk4a or expression of senescence-associated P-galactosidase. Also included are cells which express one or more biomarkers of senescence, do not proliferate in vivo, but may proliferate in vitro under certain conditions, such as some satellite cells found in the muscles of ALS patients.
- the term “senolytic agent” means a small molecule with a molecular weight of less than 900 daltons that destroys senescent cells.
- the term “senolytic agent” does not include antibodies, antibody conjugates, proteins, peptides or biologic therapies.
- variant means a nucleotide, protein or amino acid sequence different from the specifically identified sequences, wherein one or more nucleotides, proteins or amino acid residues is deleted, substituted or added. Variants may be naturally-occurring allelic variants, or non-naturally-occurring variants. Variants of the identified sequences may retain some or all of the functional characteristics of the identified sequences.
- percent (%) sequence identity is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Preferably, % sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program is publicly available from Genentech, Inc.
- ALIGN-2 (South San Francisco, CA), or may be compiled from the source code, which has been filed with user documentation in the U.S. Copyright Office and is registered under U.S. Copyright Registration No. TXU510087.
- the ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
- the % sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B.
- FIG. 1 is a graph of the response versus time in an antibody binding experiment.
- FIG. 2 is a graph illustrating the effect of senescent cell clearance on peripheral capillary oxygen saturation (SpCh) in bleomycin exposed mice.
- FIG. 3A is a graph illustrating the effect of senescent cell clearance with ganciclovir on lung elastance in 3MR mice exposed to bleomycin.
- FIG. 3B is a graph illustrating the effect of senescent cell clearance with ganciclovir on dynamic lung compliance in 3MR mice exposed to bleomycin.
- FIG. 3C is a graph illustrating the effect of senescent cell clearance with ganciclovir on static lung compliance in 3MR mice exposed to bleomycin.
- FIG. 4 is a graph illustrating the effect of senescent cell clearance on peripheral capillary oxygen saturation (SpOa) in mice after 2 months and 4 months of cigarette smoke (CS) exposure.
- AP AP20187;
- GAN ganciclovir;
- Navi Navitoclax (ABT-263);
- Nutlin Nutlin 3A.
- fibrotic diseases have established that inflammation is involved in fibrosis.
- Pro-inflammatory factors such as TGF , PDGF, IL-1 p, IL-6, IL-10, IL-13 and IFN-y, and reactive oxygen species have been recognized as mediators of fibrosis (Bataller, R. et al., “Liver fibrosis”, The Journal of Clinical Investigation, Vol. 115, No. 2, p. 209-218 (2005)).
- inflammatory cells and their secreted inflammatory factors have been recognized as the primary factors in activating dermal fibroblasts to become fibrotic (Shaw, T. J.
- Senescent cells have been implicated in a number of fibrotic diseases.
- Senescent biomarkers such as p16, p21 and senescence-associated - galactosidase (SA-0-gal) have been observed in fibroblasts and epithelial cells in human and mouse idiopathic lung fibrosis tissue (Schafer, M. J. et al., “Cellular senescence mediates fibrotic pulmonary disease”, Nature Communications, Vol. 8, No. 14532, 11 pages (2017)).
- Pathogenic models of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis both involve premature cellular senescence of progenitor cells, which results in stem cell exhaustion and disease progression (Chilosi, M.
- Senescent cells in the lungs contribute to excess extracellular matrix deposition in an aged mouse model and in elderly human samples (Calhoun, C. et al., “Senescent cells contribute to the physiological remodeling of aged lungs”, Journals of Gerontology: Biological Sciences, Vol. 71 , No. 2, p. 153-160 (2016)).
- the cell surface protein vimentin has been recognized as a marker of cellular senescence in mice that have been immunized with senescent mouse lung fibroblasts, and the IgM antibody clone 9H4 was found to bind to cell surface vimentin on senescent cells (Frescas, D. et al., “Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody", Proceedings of the National Academy of Sciences, p. E1668- E1677 (2017)).
- CKD Cellular senescence and the SASP participate in the pathological process of CKD, and CKD accelerates the progression of cellular senescence and the secretion of inflammatory factors through the SASP (Wang, W-J. et al., “Cellular senescence, senescence-associated secretory phenotype, and chronic kidney disease", Oncotarget, Vol. 8, No. 38, pp. 64520-64533 (2017)).
- Senescent cells increase in the glomeruli in response to renal injury and aging, and increased senescent markers have been detected in glomerulosclerosis (Valentijn, F.A. et al., “Cellular senescence in the aging and diseased kidney”, Journal of Cell Communication and Signaling, Vol.
- CML and pentosidine have also been identified in glomerulosclerosis, FSGS, hypertensive nephrosclerosis and lupus nephritis (Tanji, N. et al., “Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease”, Journal of the American Society of Nephrology, Vol. 11 , pp. 1656-1666 (2000)).
- Desmoplasia forms around tumors, acting as a barrier to drugs and even small molecules.
- the tumor cells are maintained by the cancer-associated fibroblasts that form the desmoplasia, and the tumor cells contribute to the growth of the desmoplasia.
- Senescent fibroblasts are present in the desmoplasia.
- AGEs have been detected in higher staining of surrounding fibroblast foci in fibrotic lungs of IPF patients, compared to control patients (Machahua, C., et aL, Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis, Respiratory Research, vol. 17, no. 144, pp. 1-
- Eliminating or reducing the senescent fibroblasts would reduce the size of the desmoplasia, and it would enhance the permeability of the tumor to antibodies, natural killer cells (NK), immune effectors and other therapeutics, which would enhance the efficacy of the immune response or pharmaceuticals for treating cancer.
- NK natural killer cells
- senescent cells can be used to treat fibrotic diseases. Elimination of senescent fibroblasts in mice by administration of a combination of the senolytic agents dasatinib and quercetin improved lung function (Schafer, M. J. et al.).
- the therapeutic benefits of removing senescent cells has been demonstrated in vivo in an art-accepted model in treating age-related diseases such as sarcopenia (US 9,161,810) and treating metastatic cancer (WO 2017/143073).
- age-related diseases such as sarcopenia (US 9,161,810) and treating metastatic cancer (WO 2017/143073).
- the identification of a link between cellular senescence and fibrotic diseases allows for similar treatment possibilities.
- the present invention uses enhanced clearance of cells expressing AGE-modified proteins or peptides (AGE-modified cells) to treat, ameliorate or prevent the onset of fibrotic diseases by removing or killing senescent cells. This may be accomplished by administering anti-AGE antibodies to a subject.
- Vaccination against AGE-modified proteins or peptides of a cell may also be used to control the presence of AGE-modified cells in a subject.
- the continuous and virtually ubiquitous surveillance exercised by the immune system in the body in response to a vaccination allows maintaining low levels of AGE-modified cells in the body.
- Vaccination against AGE-modified proteins or peptides of a cell removes or kills senescent cells.
- the process of senescent cell removal or destruction allows vaccination against AGE-modified proteins or peptides of a cell to be used to treat or prevent the onset of fibrotic diseases.
- Individuals may receive repeated vaccinations or boosters on a periodic basis to maintain their immunity.
- Anti-AGE antibodies are known in the art and are commercially available. Examples include those described in U.S. 5,702,704 (Bucala) and U.S. 6,380,165 (Al-Abed et al.).
- the antibody may bind to one or more AGE-modified proteins or peptides having an AGE modification such as FFI, pyrraline, AFGP, ALI, carboxymethyllysine (CML), carboxyethyllysine (CEL) and pentosidine, and mixtures of such antibodies.
- the antibody is non-immunogenic to the animal in which it will be used, such as non-immunogenic to humans; companion animals including cats, dogs and horses; and commercially important animals, such camels (or alpaca), cattle (bovine), sheep, pig, and goats. More preferably, the antibody has the same species constant region as antibodies of the animal to reduce the immune response against the antibody, such as being humanized (for humans), felinized (for cats), caninized (for dogs), equuinized (for horses), camelized (for camels or alpaca), bovinized (for cattle), ovinized (for sheep), porcinized (for pigs), or caperized (for goats).
- the antibody is identical to that of the animal in which it will be used (except for the variable region), such as a human antibody, a cat antibody, a dog antibody, a horse antibody, a camel antibody, a bovine antibody, a sheep antibody, a pig antibody, or a goat antibody. Details of the constant regions and other parts of antibodies for these animals are described below.
- the antibody may be monoclonal or polyclonal.
- the antibody is a monoclonal antibody.
- Preferred anti-AGE antibodies include those which bind to proteins or peptides that exhibit a carboxymethyllysine or carboxyethyllysine AGE modification.
- Carboxymethyllysine also known as N(epsilon)-(carboxymethyl)lysine, N(6)- carboxymethyllysine, or 2-Amino-6-(carboxymethylamino)hexanoic acid
- carboxyethyllysine also known as N-epsilon-(carboxyethyl)lysine
- CML- and CEL-modified proteins or peptides are recognized by the receptor RAGE which is expressed on a variety of cells. CML and CEL have been well-studied and CML- and CEL-related products are commercially available.
- Cell Biolabs, Inc. sells CML-BSA antigens, CML polyclonal antibodies, CML immunoblot kits, and CML competitive ELISA kits (www.cellbiolabs.com/cml-assays) as well as CEL-BSA antigens and CEL competitive ELISA kits (www.cellbiolabs.com/cel-n- epsilon-carboxyethyl-lysine-assays-and-reagents).
- a preferred antibody includes the variable region of the commercially available mouse anti-glycation end-product antibody raised against carboxymethyl lysine conjugated with keyhole limpet hemocyanin, the carboxymethyl lysine MAb (Clone 318003) available from R&D Systems, Inc. (Minneapolis, MN; catalog no. MAB3247), modified to have a human constant region (or the constant region of the animal into which it will be administered).
- Commercially-available antibodies such as the carboxymethyl lysine antibody corresponding to catalog no. MAB3247 from R&D Systems, Inc., may be intended for diagnostic purposes and may contain material that is not suited for use in animals or humans.
- commercially-available antibodies are purified and/or isolated prior to use in animals or humans to remove toxins or other potentially-harmful material.
- the anti-AGE antibody preferably has a low rate of dissociation from the antibody-antigen complex, or ka (also referred to as kback or off-rate), preferably at most 9 x 10 -3 , 8 x 10 -3 , 7 x 10' 3 or 6 x 10 3 (sec 1 ).
- the anti-AGE antibody preferably has a high affinity for the AGE-modified protein of a cell, which may be expressed as a low dissociation constant KD of at most 9 x 10’ 6 , 8 x 10' 6 , 7 x 10’ 6 , 6 x 10’ 6 , 5 x 10’ 6 , 4 x 10- 6 or 3 x 10‘ 6 (M).
- the binding properties of the anti-AGE antibody are similar to, the same as, or superior to the carboxymethyl lysine MAb (Clone 318003) available from R&D Systems, Inc. (Minneapolis, MN; catalog no.
- the anti-AGE antibody may destroy AGE-modified cells through antibodydependent cell-mediated cytotoxicity (ADCC).
- ADCC is a mechanism of cell- mediated immune defense in which an effector cell of the immune system actively lyses a target cell whose membrane-surface antigens have been bound by specific antibodies.
- ADCC may be mediated by natural killer (NK) cells, macrophages, neutrophils or eosinophils.
- NK natural killer
- the effector cells bind to the Fc portion of the bound antibody.
- the anti-AGE antibody may also destroy AGE-modified cells through complement-dependent cytotoxicity (CDC). In CDC, the complement cascade of the immune system is triggered by an antibody binding to a target antigen.
- CDC complement-dependent cytotoxicity
- the anti-AGE antibody may be conjugated to an agent that causes the destruction of AGE-modified cells.
- agents may be a toxin, a cytotoxic agent, magnetic nanoparticles, and magnetic spin-vortex discs.
- a toxin such as pore-forming toxins (PFT) (Aroian R. et al., “Pore-Forming Toxins and Cellular Non-lmmune Defenses (CNIDs),” Current Opinion in Microbiology, 10:57-61 (2007)) conjugated to an anti-AGE antibody may be injected into a patient to selectively target and remove AGE-modified cells.
- the anti-AGE antibody recognizes and binds to AGE-modified cells. Then, the toxin causes pore formation at the cell surface and subsequent cell removal through osmotic lysis.
- Magnetic nanoparticles conjugated to the anti-AGE antibody may be injected into a patient to target and remove AGE-modified cells.
- the magnetic nanoparticles can be heated by applying a magnetic field in order to selectively remove the AGE- modified cells.
- Magnetic spin-vortex discs which are magnetized only when a magnetic field is applied to avoid self-aggregation that can block blood vessels, begin to spin when a magnetic field is applied, causing membrane disruption of target cells.
- Magnetic spin-vortex discs, conjugated to anti-AGE antibodies specifically target AGE-modified cell types, without removing other cells.
- Antibodies are Y-shaped proteins composed of two heavy chains and two light chains. The two arms of the Y shape form the fragment antigen-binding (Fab) region while the base or tail of the Y shape forms the fragment crystallizable (Fc) region of the antibody.
- Antigen binding occurs at the terminal portion of the fragment antigen-binding region (the tips of the arms of the Y shape) at a location referred to as the paratope, which is a set of complementarity determining regions (also known as CDRs or the hypervariable region).
- the complementarity determining regions vary among different antibodies and gives a given antibody its specificity for binding to a given antigen.
- the fragment crystallizable region of the antibody determines the result of antigen binding and may interact with the immune system, such as by triggering the complement cascade or initiating antibody-dependent cell-mediated cytotoxicity (ADCC).
- ADCC antibody-dependent cell-mediated cytotoxicity
- bi-specific antibodies When antibodies are prepared recombinantly, it is also possible to have a single antibody with variable regions (or complementary determining regions) that bind to two different antigens, with each tip of the Y shape being specific to one of the antigens; these are referred to as bi-specific antibodies.
- a humanized anti-AGE antibody according to the present invention may have the human constant region sequence of amino acids shown in SEQ ID NO: 22.
- the heavy chain complementarity determining regions of the humanized anti-AGE antibody may have one or more of the protein sequences shown in SEQ ID NO: 23 (CDR1H), SEQ ID NO: 24 (CDR2H) and SEQ ID NO: 25 (CDR3H).
- the light chain complementarity determining regions of the humanized anti-AGE antibody may have one or more of the protein sequences shown in SEQ ID NO: 26 (CDR1L), SEQ ID NO: 27 (CDR2L) and SEQ ID NO: 28 (CDR3L).
- the heavy chain of a humanized anti-AGE antibody may have or may include the protein sequence of SEQ ID NO: 1.
- the variable domain of the heavy chain may have or may include the protein sequence of SEQ ID NO: 2.
- the complementarity determining regions of the variable domain of the heavy chain (SEQ ID NO: 2) are shown in SEQ ID NO: 41, SEQ ID NO: 42 and SEQ ID NO: 43.
- the kappa light chain of a humanized anti-AGE antibody may have or may include the protein sequence of SEQ ID NO: 3.
- the variable domain of the kappa light chain may have or may include the protein sequence of SEQ ID NO: 4.
- the arginine (Arg or R) residue at position 128 of SEQ ID NO: 4 may be omitted.
- variable domain of the light chain (SEQ ID NO: 4) are shown in SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46.
- the variable regions may be codon-optimized, synthesized and cloned into expression vectors containing human immunoglobulin G1 constant regions.
- the variable regions may be used in the preparation of non-human anti-AGE antibodies.
- the antibody heavy chain may be encoded by the DNA sequence of SEQ ID NO: 12, a murine anti-AGE immunoglobulin G2b heavy chain.
- the protein sequence of the murine anti-AGE immunoglobulin G2b heavy chain encoded by SEQ ID NO: 12 is shown in SEQ ID NO: 16.
- the variable region of the murine antibody is shown in SEQ ID NO: 20, which corresponds to positions 25-142 of SEQ ID NO: 16.
- the antibody heavy chain may alternatively be encoded by the DNA sequence of SEQ ID NO: 13, a chimeric anti-AGE human immunoglobulin G1 heavy chain.
- the protein sequence of the chimeric anti-AGE human immunoglobulin G1 heavy chain encoded by SEQ ID NO: 13 is shown in SEQ ID NO: 17.
- the chimeric anti-AGE human immunoglobulin includes the murine variable region of SEQ ID NO: 20 in positions 25-142.
- the antibody light chain may be encoded by the DNA sequence of SEQ ID NO: 14, a murine anti-AGE kappa light chain.
- the protein sequence of the murine anti-AGE kappa light chain encoded by SEQ ID NO: 14 is shown in SEQ ID NO: 18.
- the variable region of the murine antibody is shown in SEQ ID NO: 21, which corresponds to positions 21-132 of SEQ ID NO: 18.
- the antibody light chain may alternatively be encoded by the DNA sequence of SEQ ID NO: 15, a chimeric anti- AGE human kappa light chain.
- the protein sequence of the chimeric anti-AGE human kappa light chain encoded by SEQ ID NO: 15 is shown in SEQ ID NO: 19.
- the chimeric anti-AGE human immunoglobulin includes the murine variable region of SEQ ID NO: 21 in positions 21-132.
- a humanized anti-AGE antibody according to the present invention may have or may include one or more humanized heavy chains or humanized light chains.
- a humanized heavy chain may be encoded by the DNA sequence of SEQ ID NO: 30, 32 or 34.
- the protein sequences of the humanized heavy chains encoded by SEQ ID NOs: 30, 32 and 34 are shown in SEQ ID NOs: 29, 31 and 33, respectively.
- a humanized light chain may be encoded by the DNA sequence of SEQ ID NO: 36, 38 or 40.
- the protein sequences of the humanized light chains encoded by SEQ ID NOs: 36, 38 and 40 are shown in SEQ ID NOs: 35, 37 and 39, respectively.
- the humanized anti-AGE antibody maximizes the amount of human sequence while retaining the original antibody specificity.
- a complete humanized antibody may be constructed that contains a heavy chain having a protein sequence chosen from SEQ ID NOs: 29, 31 and 33 and a light chain having a protein sequence chosen from SEQ ID NOs: 35, 37 and 39.
- anti-AGE antibodies may be obtained by humanizing murine monoclonal anti-AGE antibodies.
- Murine monoclonal anti-AGE antibodies have the heavy chain protein sequence shown in SEQ ID NO: 47 (the protein sequence of the variable domain is shown in SEQ ID NO: 52) and the light chain protein sequence shown in SEQ ID NO: 57 (the protein sequence of the variable domain is shown in SEQ ID NO: 62).
- a preferred humanized heavy chain may have the protein sequence shown in SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 or SEQ ID NO: 51 (the protein sequences of the variable domains of the humanized heavy chains are shown in SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55 and SEQ ID NO: 56, respectively).
- a preferred humanized light chain may have the protein sequence shown in SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60 or SEQ ID NO: 61 (the protein sequences of the variable domains of the humanized light chains are shown in SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65 and SEQ ID NO: 66, respectively).
- a humanized anti-AGE monoclonal antibody is composed a heavy chain having a protein sequence selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51 and a light chain having a protein sequence selected from the group consisting of SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60 and SEQ ID NO: 61.
- Humanized monoclonal anti-AGE antibodies composed of these protein sequences may have better binding and/or improved activation of the immune system, resulting in greater efficacy.
- the protein sequence of an antibody from a non-human species may be modified to include the variable domain of the heavy chain having the sequence shown in SEQ ID NO: 2 or the kappa light chain having the sequence shown in SEQ ID NO: 4.
- the non-human species may be a companion animal, such as the domestic cat or domestic dog, or livestock, such as cattle, the horse or the camel.
- the non-human species is not the mouse.
- the heavy chain of the horse (Equus caballus) antibody immunoglobulin gamma 4 may have or may include the protein sequence of SEQ ID NO: 5 (EMBL/GenBank accession number AY445518).
- the heavy chain of the horse (Equus caballus) antibody immunoglobulin delta may have or may include the protein sequence of SEQ ID NO: 6 (EMBL/GenBank accession number AY631942).
- the heavy chain of the dog (Canis familiaris) antibody immunoglobulin A may have or may include the protein sequence of SEQ ID NO: 7 (GenBank accession number L36871).
- the heavy chain of the dog (Canis familiaris) antibody immunoglobulin E may have or may include the protein sequence of SEQ ID NO: 8 (GenBank accession number L36872).
- the heavy chain of the cat (Felis catus) antibody immunoglobulin G2 may have or may include the protein sequence of SEQ ID NO: 9 (DDBJ/EMBL/GenBank accession number KF811175).
- Camelus bactrianus Camelus bactrianus
- llamas Lia glama, Lama paces and Lama vicugna
- alpacas Vicugna paces
- guanacos Liama guanicoe
- camelids also have heavy chain immunoglobulin G antibodies that do not contain light chains and exist as heavy chain dimers. These antibodies are known as heavy chain antibodies, HCAbs, single-domain antibodies or sdAbs, and the variable domain of a camelid heavy chain antibody is known as the VHH.
- the camelid heavy chain antibodies lack the heavy chain CH1 domain and have a hinge region that is not found in other species.
- the variable region of the Arabian camel (Camelus dromedarius) single-domain antibody may have or may include the protein sequence of SEQ ID NO: 10 (GenBank accession number AJ245148).
- the variable region of the heavy chain of the Arabian camel (Camelus dromedarius) tetrameric immunoglobulin may have or may include the protein sequence of SEQ ID NO: 11 (GenBank accession number AJ245184).
- heavy chain antibodies are also found in cartilaginous fishes, such as sharks, skates and rays.
- IgNAR immunoglobulin new antigen receptor
- VNAR variable domain of an IgNAR
- IgNAR immunoglobulin new antigen receptor
- the IgNAR exists as two identical heavy chain dimers composed of one variable domain and five constant domains each. Like camelids, there is no light chain.
- the protein sequences of additional non-human species may be readily found in online databases, such as the International ImMunoGeneTics Information System (www.imgt.org), the European Bioinformatics Institute (www.ebi.ac.uk), the DNA Databank of Japan (ddbj.nig.ac.jp/arsa) or the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).
- online databases such as the International ImMunoGeneTics Information System (www.imgt.org), the European Bioinformatics Institute (www.ebi.ac.uk), the DNA Databank of Japan (ddbj.nig.ac.jp/arsa) or the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).
- An anti-AGE antibody or a variant thereof may include a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 or SEQ ID NO: 51, including post-translational modifications thereof.
- a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-AGE antibody including that sequence retains the ability to bind to AGE.
- An anti-AGE antibody or a variant thereof may include a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 41 , SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, or SEQ ID NO: 56, including post-translational modifications thereof.
- variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-AGE antibody including that sequence retains the ability to bind to AGE.
- substitutions, insertions, or deletions may occur in regions outside the variable region.
- An anti-AGE antibody or a variant thereof may include a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60 or SEQ ID NO: 61, including post-translational modifications thereof.
- a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-AGE antibody including that sequence retains the ability to bind to AGE.
- substitutions, insertions, or deletions may occur in regions outside the variable region.
- An anti-AGE antibody or a variant thereof may include a light chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 21, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65 or SEQ ID NO: 66, including post-translational modifications thereof.
- variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-AGE antibody including that sequence retains the ability to bind to AGE.
- substitutions, insertions, or deletions may occur in regions outside the variable region.
- the antibody may have the complementarity determining regions of commercially available mouse anti-glycation end-product antibody raised against carboxymethyl lysine conjugated with keyhole limpet hemocyanin (CML-KLH), the carboxymethyl lysine MAb (Clone 318003) available from R&D Systems, Inc. (Minneapolis, MN; catalog no. MAB3247).
- CML-KLH keyhole limpet hemocyanin
- the antibody may have or may include constant regions which permit destruction of targeted cells by a subject’s immune system.
- Bi-specific antibodies which are anti-AGE antibodies directed to two different epitopes, may also be used. Such antibodies will have a variable region (or complementary determining region) from those of one anti-AGE antibody, and a variable region (or complementary determining region) from a different antibody.
- Antibody fragments may be used in place of whole antibodies.
- immunoglobulin G may be broken down into smaller fragments by digestion with enzymes. Papain digestion cleaves the N-terminal side of inter-heavy chain disulfide bridges to produce Fab fragments.
- Fab fragments include the light chain and one of the two N-terminal domains of the heavy chain (also known as the Fd fragment).
- Pepsin digestion cleaves the C-terminal side of the inter-heavy chain disulfide bridges to produce F(ab’)2 fragments.
- F(ab’)2 fragments include both light chains and the two N-terminal domains linked by disulfide bridges.
- Pepsin digestion may also form the Fv (fragment variable) and Fc (fragment crystallizable) fragments.
- the Fv fragment contains the two N-terminal variable domains.
- the Fc fragment contains the domains which interact with immunoglobulin receptors on cells and with the initial elements of the complement cascade.
- Pepsin may also cleave immunoglobulin G before the third constant domain of the heavy chain (CH3) to produce a large fragment F(abc) and a small fragment pFc’.
- Antibody fragments may alternatively be produced recombinantly. Preferably, such antibody fragments are conjugated to an agent that causes the destruction of AGE-modified cells.
- polyclonal antibodies can be raised in a mammalian host by one or more injections of an immunogen, and if desired, an adjuvant.
- an immunogen and if desired, an adjuvant.
- the immunogen (and adjuvant) is injected in a mammal by a subcutaneous or intraperitoneal injection.
- the immunogen may be an AGE-modified protein of a cell, such as AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE- ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin such as AGE-bovine serum albumin (AGE-BSA), AGE-human serum albumin and ovalbumin, AGE- crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE- apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-l and II, AGE- hemoglobin, AGE-Na7K + -ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-
- AGE- modified cells such as AGE-modified erythrocytes, whole, lysed, or partially digested, may also be used as AGE antigens.
- adjuvants include Freund’s complete, monophosphoryl Lipid A synthetic-trehalose dicorynomycolate, aluminum hydroxide (alum), heat shock proteins HSP 70 or HSP96, squalene emulsion containing monophosphoryl lipid A, a2-macroglobulin and surface active substances, including oil emulsions, pleuronic polyols, polyanions and dinitrophenol.
- an immunogen may be conjugated to a polypeptide that is immunogenic in the host, such as keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, cholera toxin, labile enterotoxin, silica particles or soybean trypsin inhibitor.
- KLH keyhole limpet hemocyanin
- serum albumin serum albumin
- bovine thyroglobulin bovine thyroglobulin
- cholera toxin cholera toxin
- labile enterotoxin silica particles
- silica particles silica particles
- soybean trypsin inhibitor AGE- KLH.
- pAbs may be made in chickens, producing IgY molecules.
- Monoclonal antibodies may also be made by immunizing a host or lymphocytes from a host, harvesting the mAb-secreting (or potentially secreting) lymphocytes, fusing those lymphocytes to immortalized cells (for example, myeloma cells), and selecting those cells that secrete the desired mAb.
- Other techniques may be used, such as the EBV-hybridoma technique.
- Non-human antibodies may be made less immunogenic to humans by engineering the antibodies to contain a combination of non-human and human antibody components.
- a chimeric antibody may be produced by combining the variable region of a non-human antibody with a human constant region.
- a humanized antibody may be produced by replacing the complementarity determining regions (CDRs) of a human antibody with those of a non-human antibody.
- CDRs complementarity determining regions
- antibodies may be made less immunogenic to other species by being substantially “ized” to a given animal, such as cat, dog, horse, camel or alpaca, cattle, sheep, pig, or goat, at the amino acid level.
- the mAbs may be purified from the culture medium or ascites fluid by conventional procedures, such as protein A-sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, ammonium sulfate precipitation or affinity chromatography.
- human monoclonal antibodies can be generated by immunization of transgenic mice containing a third copy IgG human trans-loci and silenced endogenous mouse Ig loci or using human-transgenic mice. Production of humanized monoclonal antibodies and fragments thereof can also be generated through phage display technologies.
- a "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- Preferred examples of such carriers or diluents include water, saline, Ringer’s solutions and dextrose solution. Supplementary active compounds can also be incorporated into the compositions.
- Solutions and suspensions used for parenteral administration can include a sterile diluent, such as water for injection, saline solution, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- the antibodies may be administered systemically, such as by intravenous injection or infusion.
- the antibodies may be administered locally with a pharmaceutically acceptable carrier suitable for the administration site, such as by percutaneous injection into an affected organ, topical administration at the site of dermal fibrosis or administration via nebulizer for pulmonary fibrosis.
- compositions suitable for injection include sterile aqueous solutions or dispersions for the extemporaneous preparation of sterile injectable solutions or dispersion.
- Suitable carriers include physiological saline, bacteriostatic water, CREMOPHOR EL® (BASF; Parsippany, NJ) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid so as to be administered using a syringe.
- Such compositions should be stable during manufacture and storage and must be preserved against contamination from microorganisms such as bacteria and fungi.
- compositions that can delay absorption include agents such as aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating antibodies, and optionally other therapeutic components, in the required amount in an appropriate solvent with one or a combination of ingredients as required, followed by sterilization. Methods of preparation of sterile solids for the preparation of sterile injectable solutions include vacuum drying and freeze-drying to yield a solid.
- the antibodies may be delivered as an aerosol spray from a nebulizer or a pressurized container that contains a suitable propellant, for example, a gas such as carbon dioxide.
- a suitable propellant for example, a gas such as carbon dioxide.
- Antibodies may also be delivered via inhalation as a dry powder, for example using the iSPERSETM inhaled drug delivery platform (PULMATRIX, Lexington, Mass.).
- the use of anti-AGE antibodies which are chicken antibodies (IgY) may be non-immunogenic in a variety of animals, including humans, when administered by inhalation.
- An appropriate dosage level of each type of antibody will generally be about 0.01 to 500 mg per kg patient body weight. Preferably, the dosage level will be about 0.1 to about 250 mg/kg; more preferably about 0.5 to about 100 mg/kg. A suitable dosage level may be about 0.01 to 250 mg/kg, about 0.05 to 100 mg/kg, or about 0.1 to 50 mg/kg. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg.
- each type of antibody may be administered on a regimen of 1 to 4 times per day, such as once or twice per day, antibodies typically have a long half-life in vivo. Accordingly, each type of antibody may be administered once a day, once a week, once every two or three weeks, once a month, or once every 60 to 90 days.
- a subject that receives administration of an anti-AGE antibody may be tested to determine if the administration has been effective to treat fibrotic diseases.
- a subject may be considered to have received an effective antibody treatment if he or she demonstrates an improvement in symptoms between subsequent measurements or over time.
- the efficacy of treatment may be determined with a diagnostic test that is suitable for a given fibrotic disease. For example, liver fibrosis may be monitored with a liver biopsy and pulmonary fibrosis may be monitored with high-resolution computed tomography, pulmonary function tests, bronchoscopy or bronchoalveolar lavage. Alternatively, the concentration and/or number of senescent cells may be measured over time. Administration of antibody and subsequent testing may be repeated until the desired therapeutic result is achieved.
- Unit dosage forms can be created to facilitate administration and dosage uniformity.
- Unit dosage form refers to physically discrete units suited as single dosages for the subject to be treated, containing a therapeutically effective quantity of one or more types of antibodies in association with the required pharmaceutical carrier.
- the unit dosage form is in a sealed container and is sterile.
- Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.
- AGE antigens include AGE-modified proteins or peptides such as AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin such as AGE-bovine serum albumin (AGE-BSA), AGE-human serum albumin and ovalbumin, AGE-crystallin, AGE-plasminogen activator, AGE- endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-l and II, AGE-hemo
- AGE-modified cells such as AGE-modified erythrocytes, whole, lysed, or partially digested, may also be used as AGE antigens.
- Suitable AGE antigens also include proteins or peptides that exhibit AGE modifications (also referred to as AGE epitopes or AGE moieties) such as carboxymethyllysine (CML), carboxyethyllysine (CEL), pentosidine, pyrraline, FFI, AFGP and ALL
- the AGE antigen may be an AGE-protein conjugate, such as AGE conjugated to keyhole limpet hemocyanin (AGE-KLH). Further details of some of these AGE-modified proteins or peptides and their preparation are described in Bucala.
- Particularly preferred AGE antigens include proteins or peptides that exhibit a carboxymethyllysine or carboxyethyllysine AGE modification.
- Carboxymethyllysine also known as N(epsilon)-(carboxymethyl)lysine, N(6)-carboxymethyllysine, or 2- Amino-6-(carboxymethylamino)hexanoic acid
- carboxyethyllysine also known as N-epsilon-(carboxyethyl)lysine
- proteins or peptides and lipids as a result of oxidative stress and chemical glycation and have been correlated with juvenile genetic disorders.
- CML- and CEL-modified proteins or peptides are recognized by the receptor RAGE which is expressed on a variety of cells.
- CML and CEL have been well-studied and CML- and CEL-related products are commercially available.
- Cell Biolabs, Inc. sells CML-BSA antigens, CML polyclonal antibodies, CML immunoblot kits, and CML competitive ELISA kits (www.cellbiolabs.com/cml-assays) as well as CEL-BSA antigens and CEL competitive ELISA kits (www.cellbiolabs.com/cel-n-epsilon-carboxyethyl-lysine- assays-and-reagents).
- AGE antigens may be conjugated to carrier proteins to enhance antibody production in a subject. Antigens that are not sufficiently immunogenic alone may require a suitable carrier protein to stimulate a response from the immune system.
- suitable carrier proteins include keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, cholera toxin, labile enterotoxin, silica particles and soybean trypsin inhibitor.
- KLH keyhole limpet hemocyanin
- serum albumin serum albumin
- bovine thyroglobulin cholera toxin
- labile enterotoxin silica particles
- soybean trypsin inhibitor e.g., the carrier protein is KLH (AGE-KLH).
- KLH has been extensively studied and has been identified as an effective carrier protein in experimental cancer vaccines.
- Preferred AGE antigen-carrier protein conjugates include CML-KLH and CEL-KLH.
- Immunity is a long-term immune response, either cellular or humoral.
- a cellular immune response is activated when an antigen is presented, preferably with a co-stimulator to a T-cell which causes it to differentiate and produce cytokines.
- the cells involved in the generation of the cellular immune response are two classes of T-helper (Th) cells, Th1 and Th2.
- Th1 cells stimulate B cells to produce predominantly antibodies of the lgG2A isotype, which activates the complement cascade and binds the Fc receptors of macrophages, while Th2 cells stimulate B cells to produce IgG 1 isotype antibodies in mice, lgG4 isotype antibodies in humans, and IgE isotype antibodies.
- the human body also contains “professional” antigen-presenting cells such as dendritic cells, macrophages, and B cells.
- a humoral immune response is triggered when a B cell selectively binds to an antigen and begins to proliferate, leading to the production of a clonal population of cells that produce antibodies that specifically recognize that antigen and which may differentiate into antibody-secreting cells, referred to as plasma-cells or memory-B cells.
- Antibodies are molecules produced by B-cells that bind a specific antigen.
- the antigen-antibody complex triggers several responses, either cell-mediated, for example by natural killers (NK) or macrophages, or serum-mediated, for example by activating the complement system, a complex of several serum proteins that act sequentially in a cascade that result in the lysis of the target cell.
- Immunological adjuvants are the component(s) of a vaccine which augment the immune response to the immunogenic agent.
- Adjuvants function by attracting macrophages to the immunogenic agent and then presenting the agent to the regional lymph nodes to initiate an effective antigenic response.
- Adjuvants may also act as carriers themselves for the immunogenic agent.
- Adjuvants may induce an inflammatory response, which may play an important role in initiating the immune response.
- Adjuvants include mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes and squalene.
- Aluminum compounds are the most widely used adjuvants in human and veterinary vaccines. These aluminum compounds include aluminum salts such as aluminum phosphate (AIPO4) and aluminum hydroxide (AI(OH)3) compounds, typically in the form of gels, and are generically referred to in the field of vaccine immunological adjuvants as "alum.”
- Aluminum hydroxide is a poorly crystalline aluminum oxyhydroxide having the structure of the mineral boehmite.
- Aluminum phosphate is an amorphous aluminum hydroxyphosphate.
- Negatively charged species can absorb onto aluminum hydroxide gels at neutral pH
- positively charged species can absorb onto aluminum phosphate gels at neutral pH. It is believed that these aluminum compounds provide a depot of antigen at the site of administration, thereby providing a gradual and continuous release of antigen to stimulate antibody production. Aluminum compounds tend to more effectively stimulate a cellular response mediated by Th2, rather than Th1 cells.
- Emulsion adjuvants include water-in-oil emulsions (for example, Freund's adjuvants, such as killed mycobacteria in oil emulsion) and oil-in-water emulsions (for example, MF-59).
- Emulsion adjuvants include an immunogenic component, for example squalene (MF-59) or mannide oleate (Incomplete Freund's Adjuvants), which can induce an elevated humoral response, increased T cell proliferation, cytotoxic lymphocytes and cell-mediated immunity.
- Liposomal or vesicular adjuvants include paucilamellar lipid vesicles
- Paucilamellar vesicles can be prepared by mixing, under high pressure or shear conditions, a lipid phase comprising a nonphospholipid material (for example, an amphiphile surfactant; see U.S. Pat. Nos.
- a sterol optionally a sterol, and any water-immiscible oily material to be encapsulated in the vesicles (for example, an oil such as squalene oil and an oil-soluble or oil-suspended antigen); and an aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids.
- a sterol optionally a sterol, and any water-immiscible oily material to be encapsulated in the vesicles
- an oil such as squalene oil and an oil-soluble or oil-suspended antigen
- an aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids.
- Liposomal or vesicular adjuvants are believed to promote contact of the antigen with immune cells, for example by fusion of the vesicle to the immune cell membrane, and preferentially stimulate
- adjuvants include Mycobacterium bovis bacillus Calmette- Guerin (BCG), quill-saponin and unmethylated CpG dinucleotides (CpG motifs). Additional adjuvants are described in U.S. Patent Application Publication Pub. No. US 2010/0226932 (September 9, 2010) and Jiang, Z-H. et al. “Synthetic vaccines: the role of adjuvants in immune targeting”, Current Medicinal Chemistry, Vol. 10(15), pp. 1423-39 (2003). Preferable adjuvants include Freund’s complete adjuvant and Freund’s incomplete adjuvant.
- the vaccine may optionally include one or more preservatives, such as antioxidants, antibacterial and antimicrobial agents, as well as combinations thereof.
- preservatives such as antioxidants, antibacterial and antimicrobial agents, as well as combinations thereof.
- examples include benzethonium chloride, ethylenediamine-tetraacetic acid sodium (EDTA), thimerosal, phenol, 2-phenoxyethanol, formaldehyde and formalin; antibacterial agents such as amphotericin B, chlortetracycline, gentamicin, neomycin, polymyxin B and streptomycin; antimicrobial surfactants such as polyoxyethylene-9, 10-nonyl phenol (Triton N-101 , octoxynol-9), sodium deoxycholate and polyoxyethylated octyl phenol (Triton X-I00).
- the production and packaging of the vaccine may eliminate the need for a preservative. For example, a vaccine that has been sterilize
- compositions include pharmaceutically acceptable excipients, such as stabilizers, thickening agents, toxin detoxifiers, diluents, pH adjusters, tonicity adjustors, surfactants, antifoaming agents, protein stabilizers, dyes and solvents.
- pharmaceutically acceptable excipients such as stabilizers, thickening agents, toxin detoxifiers, diluents, pH adjusters, tonicity adjustors, surfactants, antifoaming agents, protein stabilizers, dyes and solvents.
- excipients examples include hydrochloric acid, phosphate buffers, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, potassium chloride, potassium chloride, sodium chloride, polydimethylsilozone, brilliant green, phenol red (phenolsulfon-phthalein), glycine, glycerin, sorbitol, histidine, monosodium glutamate, potassium glutamate, sucrose, urea, lactose, gelatin, sorbitol, polysorbate 20, polysorbate 80 and glutaraldehyde.
- hydrochloric acid phosphate buffers, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, potassium chloride, potassium chloride, sodium chloride, polydimethylsilozone, brilliant green, phenol red (phenolsulfon-phthalein), glycine, glycerin, sorbitol, histidine, monosodium glutamate, potassium glut
- the vaccine may contain from 1 pg to 100 mg of at least one AGE antigen, including 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 400, 800 or 1000 pg, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80 or 90 mg.
- the amount used for a single injection corresponds to a unit dosage.
- the vaccine may be provided in unit dosage form or in multidosage form, such as 2-100 or 2-10 doses.
- the unit dosages may be provided in a vial with a septum, or in a syringe with or without a needle.
- the vaccine may be administered intravenously, subdermally or intraperitoneally.
- the vaccine is sterile.
- the vaccine may be administered one or more times, such as 1 to 10 times, including 2, 3, 4, 5, 6, 7, 8 or 9 times, and may be administered over a period of time ranging from 1 week to 1 year, 2-10 weeks or 2-10 months. Furthermore, booster vaccinations may be desirable, over the course of 1 year to 20 years, including 2, 5, 10 and 15 years.
- a subject that receives a vaccine for AGE-modified proteins or peptides of a cell may be tested to determine if he or she has developed an immunity to the AGE- modified proteins or peptides. Suitable tests may include blood tests for detecting the presence of an antibody, such as immunoassays or antibody titers.
- An immunity to AGE-modified proteins or peptides may also be determined by monitoring the concentration and/or number of senescent cells over time.
- a subject may also be tested to determine if the vaccination has been effective to treat fibrotic diseases.
- a subject may be considered to have received an effective vaccination if he or she demonstrates an improvement in symptoms between subsequent measurements or overtime, or by measuring the concentration and/or number of senescent cells. Vaccination and subsequent testing may be repeated until the desired therapeutic result is achieved.
- the vaccination process may be designed to provide immunity against multiple AGE moieties.
- a single AGE antigen may induce the production of AGE antibodies which are capable of binding to multiple AGE moieties.
- the vaccine may contain multiple AGE antigens.
- a subject may receive multiple vaccines, where each vaccine contains a different AGE antigen.
- Any mammal that could develop fibrotic diseases may be treated by the methods herein described. Humans are a preferred mammal for treatment. Other mammals that may be treated include mice, rats, goats, sheep, pigs, cows, horses and companion animals, such as dogs or cats. Alternatively, any of the mammals or subjects identified above may be excluded from the patient population in need of treatment for fibrotic diseases.
- a subject may be identified as in need of treatment based on a diagnosis with at least one fibrotic disease, or with a disease that is known to contribute to fibrosis.
- Fibrotic diseases include interstitial lung disease, pulmonary fibrosis, liver fibrosis, cirrhosis, urinary fibrosis, kidney fibrosis, kidney disease, chronic kidney disease (CKD), nephrosclerosis, nephrosis, glomerulosclerosis, bladder fibrosis, urethral stricture, cardiovascular disease, macular degeneration, vitreal retinopathy, scleroderma (systemic and local), restenosis, myelofibrosis (bone marrow cancer), keloid scarring, hypertrophic scarring, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema and eosinophilic fasciitis.
- CKD chronic kidney disease
- nephrosclerosis ne
- Fibrotic diseases include desmoplasia, as fibrotic tissue in the surrounding stroma plays a very important role in the progression of cancer. Diagnosis may involve any suitable diagnostic test or procedure for a given disease or disorder. A subject may also be identified as in need of treatment after experiencing physical trauma that is known to result in fibrosis, such as surgical complications, administration of chemotherapeutic drugs, exposure to radiation, burns or physical injury.
- Subjects may also be identified as in need of treatment based on detection of advanced glycation end products in a sample obtained from the subject. Suitable samples include blood, skin, serum, saliva and urine. The diagnostic use of anti- AGE antibodies is discussed in more detail in International Publication No. WO 2018/204679.
- the Present Application includes 66 nucleotide and amino acid sequences in the Sequence Listing filed herewith. Variants of the nucleotide and amino acid sequences are possible. Known variants include substitutions, deletions and additions to the sequences shown in SEQ ID NO: 4, 16 and 20. In SEQ ID NO: 4, the arginine (Arg or R) residue at position 128 may optionally be omitted. In SEQ ID NO: 16, the alanine residue at position 123 may optionally be replaced with a serine residue, and/or the tyrosine residue at position 124 may optionally be replaced with a phenylalanine residue. SEQ ID NO: 20 may optionally include the same substitutions as SEQ ID NO: 16 at positions 123 and 124. In addition, SEQ ID NO: 20 may optionally contain one additional lysine residue after the terminal valine residue.
- Example 1 In vivo study of the administration of anti-glycation end-product antibody [115] To examine the effects of an anti-glycation end-product antibody, the antibody was administered to the aged CD1(ICR) mouse (Charles River Laboratories), twice daily by intravenous injection, once a week, for three weeks (Days 1, 8 and 15), followed by a 10 week treatment-free period.
- the test antibody was a commercially available mouse anti-glycation end-product antibody raised against carboxymethyl lysine conjugated with keyhole limpet hemocyanin, the carboxymethyl lysine MAb (Clone 318003) available from R&D Systems, Inc. (Minneapolis, MN; catalog no. MAB3247). A control reference of physiological saline was used in the control animals.
- mice referred to as “young” were 8 weeks old, while mice referred to as “old” were 88 weeks ( ⁇ 2 days) old. No adverse events were noted from the administration of the antibody.
- the different groups of animals used in the study are shown in Table 1.
- Pre Subset of animals euthanized prior to treatment start for collection of adipose tissue.
- Example 2 Affinity and kinetics of test antibody
- Example 1 The affinity and kinetics of the test antibody used in Example 1 were analyzed using Na,Na-bis(carboxymethyl)-L-lysine trifluoroacetate salt (Sigma-Aldrich, St. Louis, MO) as a model substrate for an AGE-modified protein of a cell. Label-free interaction analysis was carried out on a BIACORETM T200 (GE Healthcare, Pittsburgh, PA), using a Series S sensor chip CM5 (GE Healthcare, Pittsburgh, PA), with Fc1 set as blank, and Fc2 immobilized with the test antibody (molecular weigh of 150,000 Da).
- the running buffer was an HBS-EP buffer (10 mM HEPES, 150 mM NaCI, 3 mM EDTA and 0.05% P-20, pH of 7.4), at a temperature of 25 °C.
- Software was BIACORETM T200 evaluation software, version 2.0. A double reference (Fc2-1 and only buffer injection), was used in the analysis, and the data was fitted to a Langmuir 1:1 binding model.
- Example 3 Construction and production of murine anti-AGE lgG2b antibody and chimeric anti-AGE lgG1 antibody
- Murine and chimeric human anti-AGE antibodies were prepared.
- the DNA sequence of murine anti-AGE antibody lgG2b heavy chain is shown in SEQ ID NO: 12.
- the DNA sequence of chimeric human anti-AGE antibody lgG1 heavy chain is shown in SEQ ID NO: 13.
- the DNA sequence of murine anti-AGE antibody kappa light chain is shown in SEQ ID NO: 14.
- the DNA sequence of chimeric human anti- AGE antibody kappa light chain is shown in SEQ ID NO: 15.
- the gene sequences were synthesized and cloned into high expression mammalian vectors. The sequences were codon optimized. Completed constructs were sequence confirmed before proceeding to transfection.
- HEK293 cells were seeded in a shake flask one day before transfection, and were grown using serum-free chemically defined media.
- the DNA expression constructs were transiently transfected into 0.03 liters of suspension HEK293 cells. After 20 hours, cells were sampled to obtain the viabilities and viable cell counts, and titers were measured (Octet QKe, ForteBio). Additional readings were taken throughout the transient transfection production runs. The cultures were harvested on day 5, and an additional sample for each was measured for cell density, viability and titer.
- Example 3 The binding of the murine (parental) and chimeric anti-AGE antibodies described in Example 3 was investigated by a direct binding ELISA.
- An anti- carboxymethyl lysine (CML) antibody (R&D Systems, MAB3247) was used as a control.
- CML was conjugated to KLH (CML-KLH) and both CML and CML-KLH were coated overnight onto an ELISA plate.
- HRP-goat anti-mouse Fc was used to detect the control and murine (parental) anti-AGE antibodies.
- HRP-goat anti-human Fc was used to detect the chimeric anti-AGE antibody.
- the antigens were diluted to 1 pg/mL in 1x phosphate buffer at pH 6.5.
- a 96- well microtiter ELISA plate was coated with 100 pL/well of the diluted antigen and let sit at 4°C overnight. The plate was blocked with 1x PBS, 2.5% BSA and allowed to sit for 1-2 hours the next morning at room temperature.
- the antibody samples were prepared in serial dilutions with 1x PBS, 1% BSA with the starting concentration of 50 pg/mL. Secondary antibodies were diluted 1 :5,000. 100 pL of the antibody dilutions was applied to each well. The plate was incubated at room temperature for 0.5-1 hour on a microplate shaker.
- the plate was washed 3 times with 1x PBS. 100 pL/well diluted HRP-conjugated goat anti-human Fc secondary antibody was applied to the wells. The plate was incubated for 1 hour on a microplate shaker. The plate was then washed 3 times with 1x PBS. 100 pL HRP substrate TMB was added to each well to develop the plate. After 3-5 minutes elapsed, the reaction was terminated by adding 100 pL of 1N HCL A second direct binding ELISA was performed with only CML coating. The absorbance at OD450 was read using a microplate reader.
- the OD450 absorbance raw data for the CML-only ELISA is shown in the plate map below. 24 of the 96 wells in the well plate were used. Blank wells in the plate map indicate unused wells.
- control and chimeric anti-AGE antibodies showed binding to both CML and CML-KLH.
- the murine (parental) anti-AGE antibody showed very weak to no binding to either CML or CML-KLH.
- Data from repeated ELISA confirms binding of the control and chimeric anti-AGE to CML. All buffer control showed negative signal.
- Humanized antibodies were designed by creating multiple hybrid sequences that fuse select parts of the parental (mouse) antibody sequence with the human framework sequences. Acceptor frameworks were identified based on the overall sequence identity across the framework, matching interface position, similarly classed CDR canonical positions, and presence of N-glycosylation sites that would have to be removed. Three humanized light chains and three humanized heavy chains were designed based on two different heavy and light chain human acceptor frameworks. The amino acid sequences of the heavy chains are shown in SEQ ID NO: 29, 31 and 33, which are encoded by the DNA sequences shown in SEQ ID NO: 30, 32 and 34, respectively.
- the amino acid sequences of the light chains are shown in SEQ ID NO: 35, 37 and 39, which are encoded by the DNA sequences shown in SEQ ID NO: 36, 38 and 40, respectively.
- the humanized sequences were methodically analyzed by eye and computer modeling to isolate the sequences that would most likely retain antigen binding. The goal was to maximize the amount of human sequence in the final humanized antibodies while retaining the original antibody specificity.
- the light and heavy humanized chains could be combined to create nine variant fully humanized antibodies.
- the three heavy chains and three light chains were analyzed to determine their humanness.
- Antibody humanness scores were calculated according to the method described in Gao, S. H., et al., “Monoclonal antibody humanness score and its applications”, BMC Biotechnology, 13:55 (July 5, 2013).
- the humanness score represents how human-like an antibody variable region sequence looks. For heavy chains a score of 79 or above is indicative of looking human-like; for light chains a score of 86 or above is indicative of looking human-like.
- the humanness of the three heavy chains, three light chains, a parental (mouse) heavy chain and a parental (mouse) light chain are shown below in Table 6:
- variable region sequences were designed by first synthesizing the variable region sequences. The sequences were optimized for expression in mammalian cells. These variable region sequences were then cloned into expression vectors that already contain human Fc domains; for the heavy chain, the lgG1 was used.
- the binding of the humanized antibodies may be evaluated, for example, by dose-dependent binding ELISA or cell-based binding assay.
- Example 6 An AGE-RNAse containing vaccine in a human subject.
- AGE-RNAse is prepared by incubating RNAse in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-RNAse solution is dialyzed and the protein content is measured. Aluminum hydroxide or aluminum phosphate, as an adjuvant, is added to 100 pg of the AGE-RNAse. Formaldehyde or formalin is added as a preservative to the preparation. Ascorbic acid is added as an antioxidant.
- the vaccine also includes phosphate buffer to adjust the pH and glycine as a protein stabilizer. The composition is injected intravenously into a subject with idiopathic pulmonary fibrosis.
- Example 7 Injection regimen for an AGE-RNAse containing vaccine in a human subject.
- Example 8 An AGE-hemoglobin containing vaccine in a human subject
- AGE-hemoglobin is prepared by incubating human hemoglobin in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-hemoglobin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 6, except AGE-hemoglobin is substituted for AGE-RNAse. Administration is carried out as in Example 6, or as in Example 7.
- Example 9 An AGE-human serum albumin containing vaccine in a human subject.
- AGE-human serum albumin is prepared by incubating human serum albumin in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-human serum albumin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 6, except AGE-human serum albumin is substituted for AGE-RNAse. Administration is carried out as in Example 6, or as in Example 7.
- Example 10 Carboxymethyllysine-modified protein vaccine for a human subject
- a vaccine is prepared by combining a carboxymethyllysine-modified protein as an AGE antigen, aluminum hydroxide as an adjuvant, formaldehyde as a preservative, ascorbic acid as an antioxidant, a phosphate buffer to adjust the pH of the vaccine and glycine as a protein stabilizer.
- the vaccine is injected subcutaneously into a subject with myelofibrosis.
- Example 11 Carboxyethyllysine-modified peptide vaccine for a human subject
- a vaccine is prepared by combining a carboxyethyllysine-modified peptide conjugated to KLH as an AGE antigen, aluminum hydroxide as an adjuvant, formaldehyde as a preservative, ascorbic acid as an antioxidant, a phosphate buffer to adjust the pH of the vaccine and glycine as a protein stabilizer.
- the vaccine is injected subcutaneously into a subject with chronic kidney disease.
- Example 12 In vivo study of the administration of a carboxymethyl lysine monoclonal antibody
- 4T1 murine breast tumor cells (ATCC CRL-2539) were cultured in RPM1 1640 medium containing 10% fetal bovine serum, 2 mM glutamine, 25 pg/mL gentamicin, 100 units/mL penicillin G Na and 100 pg/mL streptomycin sulfate. Tumor cells were maintained in tissue culture flasks in a humidified incubator at 37 °C in an atmosphere of 5% CO2 and 95% air.
- the cultured breast cancer cells were then implanted in the mice.
- 4T1 cells were harvested during log phase growth and re-suspended in phosphate buffered saline (PBS) at a concentration of 1 x 10 6 cells/mL on the day of implant.
- Tumors were initiated by subcutaneously implanting 1 x 10 5 4T1 cells (0.1 mL suspension) into the right flank of each test animal. Tumors were monitored as their volumes approached a target range of 80-120 mm 3 .
- Tumor weight was approximated using the assumption that 1 mm 3 of tumor volume has a weight of 1 mg.
- the four treatment groups are shown in Table 8 below:
- An anti-carboxymethyl lysine monoclonal antibody was used as a therapeutic agent.
- 250 mg of carboxymethyl lysine monoclonal antibody was obtained from R&D Systems (Minneapolis, MN).
- Dosing solutions of the carboxymethyl lysine monoclonal antibody were prepared at 1 and 0.5 mg/mL in a vehicle (PBS) to provide the active dosages of 10 and 5 pg/g, respectively, in a dosing volume of 10 mL/kg.
- Dosing solutions were stored at 4 °C protected from light.
- %TGI Percent tumor growth inhibition
- %lnhibition (1-Mean Count of Focitreated/Mean Count of Focicontroi) x 100.
- Treatment efficacy was also evaluated by the incidence and magnitude of regression responses observed during the study.
- Treatment may cause partial regression (PR) or complete regression (CR) of the tumor in an animal.
- PR partial regression
- CR complete regression
- the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm 3 for one or more of these three measurements.
- the tumor volume was less than 13.5 mm 3 for three consecutive measurements during the course of the study.
- Example 13 Treatment of fibrotic lung diseases by removal of senescent cells
- mice develop lung fibrosis within 7-14 days after bleomycin treatment (see, e.g., Limjunyawong et al., 2014, Physiological Reports 2:e00249; Daniels et al, 2004, J. Clin. Invest. 114: 1308- 1316).
- Bleomycin was administered to anesthetized 6-8 week old 3MR mice by intratracheal aspiration (2.5U/kg of bleomycin in 50 pT PBS) using a microsprayer syringe (Penn- Century, Inc.) as described in Daniels et al. (2004, J. Clin. Invest 114: 1308-1316). Control mice were administered saline. The day following bleomycin treatment, ganciclovir (GCV) (25mg/kg in PBS) was administered. 3MR mice were treated via intraperitoneal injection with ganciclovir for 5 consecutive days, followed by 5 days of rest, followed by a second treatment cycle of 5 consecutive days. Untreated mice received an equal volume of vehicle.
- GCV ganciclovir
- BAL Bronchoalveolar lavage
- INK- ATT AC pl6 lnk4a apoptosis through targeted activation of caspase
- transgenic mice have an FK506- binding protein (FKBP)-caspase 8 (Casp8) fusion polypeptide under the control of the pl6 lnk4a promoter (see, e.g., Baker et al, Nature, supra; Int'l Patent Application Publication No. WO/2012/177927).
- FKBP FK506- binding protein
- Casp8 caspase 8
- a synthetic drug that induces dimerization of a membrane bound myristoylated FKBP-Casp8 fusion protein senescent cells specifically expressing the FKBP-Casp8 fusion protein via the pl6 lnk4a promoter undergo programmed cell death (apoptosis) (see, e.g., Baker, Nature, supra, Figure 1 therein).
- a second study also assesses the effect of clearance of senescence cells using a senolytic agent in C57BL6/J mice that have bleomycin induced lung injury.
- Bleomycin is administered to 6 week old C57BL6/J mice as described above.
- a senolytic agent is administered during the first and third week post-bleomycin treatment. Control mice are treated with vehicle.
- clearance of senescent cells and lung function/histopathology is assessed.
- mice were exposed to cigarette smoke.
- the effect of a senolytic agent on the mice exposed to smoke is assessed by senescent cell clearance, lung function, and histopathology.
- Each lighted cigarette (3R4F research cigarettes containing 10.9 mg of total particulate matter (TPM), 9.4 mg of tar, and 0.726 mg of nicotine, and 11.9 mg carbon monoxide per cigarette [University of Kentucky, Lexington, KY]) was puffed for 2 seconds and once every minute for a total of 8 puffs, with the flow rate of 1.05 L/min, to provide a standard puff of 35 cm 3 .
- the smoke machine was adjusted to produce a mixture of side stream smoke (89%) and mainstream smoke (11%) by smoldering 2 cigarettes at one time.
- the smoke chamber atmosphere was monitored for total suspended particulates (80-120 mg/m 3 ) and carbon monoxide (350 ppm).
- An additional 70 animals that did not receive exposure to cigarette smoke were used as controls for the experiment.
- mice are killed by i.p. injection of pentobarbital for in-depth analysis of lung histopathology as previously described (Rangasamy et al, 2004, J. Clin. Invest. 114: 1248-1259). Briefly, lungs are inflated with 0.5% low-melting agarose at a constant pressure of 25 cm. Part of the lung tissue is collected for RNA extraction and qRT-PCR analysis of senescent markers. Other parts of lungs are fixed in 10% buffered formalin and embedded in paraffin. Sections (5 urn) are stained with hematoxylin and eosin. Mean alveolar diameter, alveolar length, and mean linear intercepts are determined by computer- assisted morphometry with Image Pro Plus software (Media Cybernetics).
- 3MR or INK-ATTAC mice The potential therapeutic effect of clearance of senescent cells after COPD is fully developed may be assessed in 3MR or INK-ATTAC mice.
- Six week-old 3MR or INK-ATTAC mice are chronically exposed to cigarette smoke for 6 months as described above.
- 3MR or INK- ATTAC mice are treated with ganciclovir (5 consecutive days of treatment followed by 16 days off drug) or AP20187 (3x/week), respectively, until 9 months following the start of smoke exposure, when assessment of senescent cell clearance, lung function, and histopathology is performed.
- Example 14 Treatment of idiopathic pulmonary fibrosis
- a patient presents with idiopathic pulmonary fibrosis. She is administered an anti-AGE antibody by inhalation using a nebulizer.
- the anti-AGE antibody will specifically bind to cells expressing cell-surface AGEs, such as senescent myofibroblasts, and allow her immune system to destroy those cells. Killing and removing senescent cells will treat her idiopathic pulmonary fibrosis and prevent the disease from worsening.
- Example 15 T reatment of scleroderma
- a patient presents with scleroderma on his right arm. He is administered a topical cream containing an anti-AGE antibody.
- the anti-AGE antibody will specifically bind to cells expressing cell-surface AGEs, such as senescent myofibroblasts, and allow his immune system to destroy those cells. Killing and removing senescent cells will treat his scleroderma and prevent further progression of the disease.
- TGF-p1 Transforming growth factor-
- HA hyaluronan
- EGFR epidermal growth factor receptor
Abstract
A method of treating or preventing the onset of a fibrotic disease comprises administering to a subject a composition comprising an anti-AGE antibody. The anti- AGE antibody binds an AGE antigen comprising at least one protein or peptide that exhibits AGE modifications selected from the group consisting of FFI, pyrraline, AFGP, ALI, carboxymethyllysine, carboxyethyllysine and pentosidine. A method of treating or preventing the onset of a fibrotic disease comprises administering to a subject a vaccine comprising an AGE antigen.
Description
METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES
BACKGROUND
[01] Fibrosis is the formation of excess fibrous connective tissue in an organ or in tissue. Connective tissue, such as extracellular matrix proteins, is produced by fibroblasts in response to pro-fibrotic factors including transforming growth factor beta (TGFp), connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF) and interleukin 4 (IL-4). Fibroblasts may differentiate into myofibroblasts through an epithelial to mesenchymal transition largely mediated by TGF|3 (Midgley, A. C. et al., “Transforming growth factor-p1 (TGF-|31)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts”, Journal of Biological Chemistry, Vol. 288, No. 21 , p. 14824-14838 (2013)). Myofibroblasts are key mediators of profibrotic conditions and proliferate in response to TGFp signaling (Harris, W. T. et al., “Myofibroblast differentiation and enhanced TGF- signaling in cystic fibrosis lung disease”, PLoS One, Vol. 8, No. 8, 8 pages (2013)).
[02] Fibrosis can result from specific trauma such as surgical complications, exposure to radiation, burns or physical injury. Some therapeutic treatments, such as the administration of chemotherapeutic drugs or exposure to ionizing radiation (radiotherapy) as used in treating cancer, are known to cause fibrosis as a side effect. Certain cancers, such as myelofibrosis (bone marrow cancer), can also cause fibrosis.
[03] Fibrotic diseases can develop in many parts of the body in humans and animals and may affect organs including the lungs (interstitial lung disease, pulmonary fibrosis, acute lung injury), liver (liver fibrosis, cirrhosis), kidneys (kidney disease, nephrosclerosis), heart (cardiovascular disease) and eyes (macular degeneration, vitreal retinopathy) (Wynn, T. A., “Fibrotic disease and the TH1/TH2 paradigm”, Nature Reviews Immunology, Vol. 4, No. 8, p. 583-594 (2004)). Fibrotic diseases that are characterized by excessive connective tissue accumulation and
progressive tissue contraction are known as fibroproliferative disorders (Bitterman, P.B. et al., “Fibroproliferative disorders”, Chest, Vol. 99, No. 3, pp. 81S-84S (1991)).
Examples of fibroproliferative disorders include scleroderma (systemic and local), hypertrophic scarring, keloid scarring, cirrhosis, nephrosis and restenosis.
[04] Pulmonary fibrosis (scarring of the lungs) is a respiratory disease characterized by the development of fibrous tissue in the walls of the air sacs of the lungs. The formation of scar tissue impairs the ability of the lungs to oxygenate blood, which often presents as shortness of breath (dyspnea). Other symptoms of pulmonary fibrosis include a chronic dry or hacking cough, fatigue, weakness, chest pain or discomfort, loss of appetite, unexplained weight loss and clubbing of the tips of the fingers and toes. The scarring caused by pulmonary fibrosis is permanent and the loss of lung function cannot be restored.
[05] Pulmonary fibrosis may result from a variety of different sources. Known causes of pulmonary fibrosis include autoimmune diseases that produce inflammation or scarring in the lungs, such as rheumatoid arthritis, scleroderma and autoimmune muscle diseases; occupational exposure to small inorganic particles, such as asbestos, beryllium, coal dust, silica and heavy metal dusts; environmental exposure to small organic particles, such as animal proteins, bacteria and molds; radiation exposure, including environmental radiation and cancer radiotherapy; bacterial or viral infections; and exposure to medications, such as nitrofurantoin, sulfasalazine, amiodarone, propranolol, phenytoin, methotrexate, bleomycin and oxaliplatin (Pulmonary Fibrosis Foundation, “About PF”, available online at www.pulmonaryfibrosis.org/life-with-pf/about-pf, accessed on July 18, 2017). When the specific cause of pulmonary fibrosis cannot be identified, the condition is referred to as idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis may result from DNA abnormalities, and inheritable forms of idiopathic pulmonary fibrosis include familial pulmonary fibrosis (FPF) and familial interstitial pneumonia (FIP) (Id ).
[06] There is no standard treatment for pulmonary fibrosis. Lifestyle changes such as not smoking and maintaining a healthy weight can improve symptoms of
pulmonary fibrosis. Pulmonary rehabilitation exercise programs can help to preserve lung function. Oxygen therapy may be used to improve oxygen delivery to the body. Various pharmacotherapies have been investigated for treating pulmonary fibrosis including corticosteroids (immunosuppressant/anti-inflammatory), cyclophosphamide (anti-inflammatory), azathioprine (immunosuppressant), mycophenolate mofetil (immunosuppressant), N-acetylcysteine (antioxidant) and proton pump inhibitors (gastric acid reducer). Nintedanib (OFEV®) and pirfenidone (ESBRIET®) are the only U.S. Food and Drug Administration-approved medications for treating idiopathic pulmonary fibrosis. However, these medications slow the progression of idiopathic pulmonary fibrosis, but do not treat the disease or prevent its onset. Severe cases of pulmonary fibrosis may be treated with lung transplantation. There are no pharmacotherapies for treating or preventing the onset of pulmonary fibrosis.
[07] Liver fibrosis is the formation of fibrous tissue in the liver. Cirrhosis is the most well-known fibrotic liver disease and may be caused by alcoholism, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, hereditary hemochromatosis, Wilson’s disease, Indian childhood cirrhosis, alpha 1-antitrypsin deficiency (A1AD), cardiac cirrhosis, galactosemia, glycogen storage disease type IV, cystic fibrosis and exposure to hepatoxic drugs or toxins. Cirrhosis may lead to complications such as ascites, esophageal variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis, portal hypertensive gastropathy, infection and hepatocellular carcinoma.
[08] The possibility of developing cirrhosis may be reduced by vaccination against specific diseases that cause cirrhosis, such as hepatitis B or hepatitis C. Similarly, cirrhosis that develops as a side effect may be managed by treating the underlying disease, such as by administering interferon and corticosteroids to patients experiencing cirrhosis due to hepatitis. Treatment options for cirrhosis are limited. Further liver damage may be prevented with lifestyle changes including abstaining from alcohol, avoiding acetaminophen and maintaining a healthy diet. Liver transplantation may ultimately be necessary for patients who experience liver failure
or cannot control the complications of cirrhosis. There are no pharmacotherapies for treating or preventing the onset of cirrhosis.
[09] Dermal fibrosis is the formation of fibrous tissue in the skin. Fibrotic skin disorders include keloid scarring, hypertrophic scarring, scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema and eosinophilic fasciitis. Dermal fibrosis may be a minor aesthetic inconvenience, or may result in severe health complications. For example, scleroderma may affect major organs such as the lungs (loss of lung function, severe lung disease and lung tissue scarring), heart (scarring and weakness of the heart, swelling of the heart muscle and irregular heartbeat) and kidneys (high blood pressure and kidney failure) (“Scleroderma Living With It”, National Institute of Arthritis and Musculoskeletal and Skin Diseases, available online at www.niams.nih.gov/health-topics/scleroderma#tab-living-with (2016)).
[10] Many treatments for dermal fibrosis address only the local fibrous tissue. For example, keloid and hypertrophic scars may be treated with local steroid injections, pressure dressings, topical chemotherapy drugs, laser light therapy, pulsed-dye laser therapy, radiation therapy, surgical excision, silicone gel sheeting application and administration of hyaluronic acid (WO 2014/179262). Other treatments for dermal fibrosis focus on the symptoms and complications of the specific fibrotic disorder. For example, scleroderma therapies include calcium channel blockers, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), COX-2 inhibitors, acetaminophen, corticosteroids, narcotics, antacids, histamine H2-receptor antagonists, proton pump inhibitors, prokinetic agents, somatostatin agonists, antibiotics, prostaglandin derivatives, endothelin receptor antagonists, IP receptor agonists, phosphodiesterase type 5 (PDE5) inhibitors, anti-fibrotic agents, anti-inflammatory agents, tyrosine kinase inhibitors, immunosuppressants and alkylating agents (“Current treatments available for scleroderma patients”, Scleroderma Research Foundation, available online at www.srfcure.org/for-patients/current-treatments (2018)). These various treatments fail to address the underlying causes of dermal fibrosis.
[11] The formation of fibrous tissue in the urinary system may occur in the kidneys, ureter, bladder or the urethra. Kidney fibrosis may be further classified based on the location of the affected tissue, such as nephrosclerosis (the nephron), glomerulosclerosis (the glomerulus) or tubulointerstitial renal fibrosis (the interstitium). Chronic kidney disease (CKD), a progressive disease, is frequently caused by kidney fibrosis. Two primary factors that promote CKD are diabetes and high blood pressure (“About chronic kidney disease: symptoms and causes”, National Kidney Foundation, available online at www.kidney.org/atoz/content/about- chronic-kidney-disease (2020)).
[12] The damage caused by urinary fibrosis is permanent. Further damage may be reduced by managing underlying conditions that contribute to urinary fibrosis, especially diabetes and high blood pressure. Lifestyle changes such as not smoking, limiting alcohol intake and maintaining a healthy weight can prevent further worsening of kidney fibrosis. Dietary changes such as adopting a low-salt and low- fat diet may also help. If untreated, urinary fibrosis may lead to loss of kidney function, end-stage renal disease or kidney failure. Individuals with kidney failure must undergo regular dialysis to cleanse the blood or receive a kidney transplant, if they are healthy enough for the procedure and are able to find a suitable donor. Pharmacotherapies for treating urinary fibrosis are limited and primarily focus on controlling symptoms, reducing complications and slowing the progression of the disease.
[13] Desmoplasia refers to growth of dense connective tissue or stroma, and it may occur as result of injury or neoplasia. The stromal reaction in cancer is similar to the stromal reaction induced by injury or wound repair, causing scar-like tissue to be built around the cancer. Thus, the surrounding stroma plays a very important role in the progression of cancer. It has been suggested that tumor cells cause the proliferation of fibroblasts and subsequent secretion of collagen (El-Torky, M., et al., Collagens in scar carcinoma of the lung, The American Journal of Pathology, vol. 121, no. 2, pp. 322-326 (1985)). The newly secreted collagen is similar to that of collagen in scar formation, and it inhibits infiltration of cells to the site of injury.
[14] Senescent cells are cells that are partially-functional or non-functional and are in a state of proliferative arrest. Senescence is a distinct state of a cell, and is associated with biomarkers, such as activation of the biomarker p16lnk4a, and expression of p-galactosidase. Senescence begins with damage or stress (such as overstimulation by growth factors) of cells.
[15] Advanced glycation end-products (AGEs; also referred to as AGE-modified proteins or peptides, or glycation end-products) arise from a non-enzymatic reaction of sugars with protein side-chains (Ando, K. et al., Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation, Biochem Biophys Res Commun., Vol. 258, 123, 125 (1999)). This process begins with a reversible reaction between the reducing sugar and the amino group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product. Once formed, the Amadori product undergoes further rearrangement to produce AGEs. Hyperglycemia and oxidative stress promote this post-translational modification of membrane proteins (Lindsey JB, etal., “Receptor For Advanced Glycation End-Products (RAGE) and soluble RAGE (sRAGE): Cardiovascular Implications,” Diabetes Vascular Disease Research, Vol. 6(1), 7-14, (2009)). AGEs may also be formed from other processes. For example, the advanced glycation end product, Ne-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. AGEs have been associated with several pathological conditions including inflammation, atherosclerosis, stroke, endothelial cell dysfunction, and neurodegenerative disorders (Bierhaus A, “AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept,” Cardiovasc Res, Vol. 37(3), 586-600 (1998)).
[16] AGE-modified proteins are also a marker of senescent cells. This association between AGEs and senescence is well known in the art. See, for example, Gruber, L. (WO 2009/143411, 26 Nov. 2009), Ando, K. etal. (Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation, Biochem Biophys Res Commun., Vol. 258, 123, 125 (1999)), Ahmed, E.K. etal. (“Protein Modification and Replicative Senescence of WI-38 Human Embryonic Fibroblasts” Aging Cells, vol. 9, 252, 260 (2010)), Vlassara, H. et al.
(Advanced Glycosylation Endproducts on Erythrocyte Cell Surface Induce Receptor- Mediated Phagocytosis by Macrophages, J. Exp. Med., Vol. 166, 539, 545 (1987)) and Vlassara et al. (“High-affinity-receptor-mediated Uptake and Degradation of Glucose-modified Proteins: A Potential Mechanism for the Removal of Senescent Macromolecules” Proc. Natl. Acad. Sci. USAI, Vol. 82, 5588, 5591 (1985)).
Furthermore, Ahmed, E.K. et al. indicates that glycation end-products are “one of the major causes of spontaneous damage to cellular and extracellular proteins” (Ahmed, E.K. et al., see above, page 353). Accordingly, the accumulation of glycation endproducts is associated with senescence and lack of function.
[17] The damage or stress that causes cellular senescence also negatively impacts mitochondrial DNA in the cells to cause them to produce free radicals which react with sugars in the cell to form methyl glyoxal (MG). MG in turn reacts with proteins or lipids to generate advanced glycation end products. In the case of the protein component lysine, MG reacts to form carboxymethyllysine, which is an AGE.
[18] Damage or stress to mitochondrial DNA also sets off a DNA damage response which induces the cell to produce cell cycle blocking proteins. These blocking proteins prevent the cell from dividing. Continued damage or stress causes mTOR production, which in turn activates protein synthesis and inactivates protein breakdown. Further stimulation of the cells leads to programmed cell death (apoptosis).
[19] p16 is a protein involved in regulation of the cell cycle, by inhibiting the S phase (synthesis phase). It can be activated during ageing or in response to various stresses, such as DNA damage, oxidative stress or exposure to drugs. p16 is typically considered a tumor suppressor protein, causing a cell to become senescent in response to DNA damage and irreversibly preventing the cell from entering a hyperproliferative state. However, there has been some ambiguity in this regard, as some tumors show overexpression of p16, while others show downregulated expression. Evidence suggests that overexpression of p16 is some tumors results from a defective retinoblastoma protein (“Rb"). p16 acts on Rb to inhibit the S phase, and Rb downregulates p16, creating negative feedback. Defective Rb fails to
both inhibit the S phase and downregulate p16, thus resulting in overexpression of p16 in hyperproliferating cells (Romagosa, C. et al., p16lnk4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors, Oncogene, Vol. 30, 2087-2097 (2011)).
[20] Senescent cells are associated with secretion of many factors involved in intercellular signaling, including pro-inflammatory factors; secretion of these factors has been termed the senescence-associated secretory phenotype, or SASP (Freund, A. “Inflammatory networks during cellular senescence: causes and consequences” Trends Mol Med. 2010 May;16(5):238-46). Autoimmune diseases, such as Crohn’s disease and rheumatoid arthritis, are associated with chronic inflammation (Ferraccioli, G. etal. “Interleukin-1 p and lnterleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis” Mol Med. 2010 Nov-Dec; 16(11-12): 552-557). Chronic inflammation may be characterized by the presence of pro- inflammatory factors at levels higher than baseline near the site of pathology, but lower than those found in acute inflammation. Examples of these factors include TNF, IL-1a, IL-1 p, IL-5, IL-6, IL-8, IL-12, IL-23, CD2, CD3, CD20, CD22, CD52, CD80, CD86, C5 complement protein, BAFF, APRIL, IgE, a4 1 integrin and a4|37 integrin. Senescent cells also upregulate genes with roles in inflammation including IL-1 p, IL-8, ICAM1, TNFAP3, ESM1 and CCL2 (Burton, D.G.A. et al., “Microarray analysis of senescent vascular smooth muscle cells: a link to atherosclerosis and vascular calcification”, Experimental Gerontology, Vol. 44, No. 10, pp. 659-665 (October 2009)).
[21] Senescent cells secrete reactive oxygen species (“ROS”) as part of the SASP. ROS are believed to play an important role in maintaining senescence of cells. The secretion of ROS creates a bystander effect, where senescent cells induce senescence in neighboring cells: ROS create the very cellular damage known to activate p16 expression, leading to senescence (Nelson, G., A senescent cell bystander effect: senescence-induced senescence, Aging Cell, Vo. 11, 345-349 (2012)). The p16/Rb pathway leads to the induction of ROS, which in turn activates the protein kinase C delta creating a positive feedback loop that further enhance
ROS, helping maintain the irreversible cell cycle arrest; it has even been suggested that exposing cancer cells to ROS might be effective to treat cancer by inducing cell phase arrest in hyperproliferating cells (Rayess, H. et al., Cellular senescence and tumor suppressor gene p16, Int J Cancer, Vol. 130, 1715-1725 (2012)).
[22] Recent research demonstrates the therapeutic benefits of removing senescent cells. In vivo animal studies at the Mayo Clinic in Rochester, Minnesota, found that elimination of senescent cells in transgenic mice carrying a biomarker for elimination delayed age-related disorders associated with cellular senescence. Eliminating senescent cells in fat and muscle tissues substantially delayed the onset of sarcopenia and cataracts and reduced senescence indicators in skeletal muscle and the eye (Baker, D. J. et al., “Clearance of p16lnk4a-positive senescent cells delays ageing-associated disorders", Nature, Vol. 479, pp. 232-236, (2011)). Mice that were treated to induce senescent cell elimination were found to have larger diameters of muscle fibers as compared to untreated mice. Treadmill exercise tests indicated that treatment also preserved muscle function. Continuous treatment of transgenic mice for removal of senescent cells had no negative side effects and selectively delayed age-related phenotypes that depend on cells. This data demonstrates that removal of senescent cells produces beneficial therapeutic effects and shows that these benefits may be achieved without adverse effects.
[23] Additional In vivo animal studies in mice found that removing senescent cells using senolytic agents treats aging-related disorders and atherosclerosis. Shortterm treatment with senolytic drugs in chronologically aged or progeroid mice alleviated several aging-related phenotypes (Zhu, Y. etal., “The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs”, Aging Cell, vol. 14, pp. 644- 658 (2015)). Long-term treatment with senolytic drugs improved vasomotor function in mice with established atherosclerosis and reduced intimal plaque calcification (Roos, C.M. et al., “Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice”, Aging Cell (2016)). This data further demonstrates the benefits of removing senescent cells.
[24] Vaccines have been widely used since their introduction by Edward Jenner in the 1770s to confer immunity against a wide range of diseases and afflictions. Vaccine preparations contain a selected immunogenic agent capable of stimulating immunity to an antigen. Typically, antigens are used as the immunogenic agent in vaccines, such as, for example, viruses, either killed or attenuated, and purified viral components. Antigens used in the production of cancer vaccines include, for example, tumor-associated carbohydrate antigens (TACAs), dendritic cells, whole cells and viral vectors. Different techniques are employed to produce the desired amount and type of antigen being sought. For example, pathogenic viruses are grown either in eggs or cells. Recombinant DNA technology is often utilized to generate attenuated viruses for vaccines.
[25] Vaccines may therefore be used to stimulate the production of antibodies in the body and provide immunity against antigens. When an antigen is introduced to a subject that has been vaccinated and developed immunity to that antigen, the immune system may destroy or remove cells that express the antigen.
SUMMARY
[26] In a first aspect, the invention is a method of treating or preventing the onset of a fibrotic disease comprising administering to a subject a composition comprising an anti-AGE antibody.
[27] In a second aspect, the invention is a method of treating or preventing the onset of a fibrotic disease comprising administering to a subject a vaccine comprising an AGE antigen.
[28] DEFINITIONS
[29] The term “fibrotic disease” means a disease or disorder characterized by the formation of fibrous tissue. Examples of fibrotic diseases include interstitial lung disease, pulmonary fibrosis, liver fibrosis, cirrhosis, urinary fibrosis, kidney fibrosis, nephrosclerosis, nephrosis, cardiovascular disease, macular degeneration, vitreal retinopathy, scleroderma (systemic and local), hypertrophic scarring, keloid scarring,
restenosis, myelofibrosis, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis. As used herein, “fibrotic disease” does not include atherosclerosis.
[30] The term “pulmonary fibrosis” means a disease or disorder characterized by the formation of fibrous tissue in the lungs. Pulmonary fibrosis includes idiopathic pulmonary fibrosis (IPF), idiopathic nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), sarcoidosis, familial pulmonary fibrosis (FPF), familial interstitial pneumonia (FIP), asbestosis, silicosis, berylliosis, hypersensitivity pneumonitis, atypical pneumonia, pneumocystis pneumonia, tuberculosis, respiratory syncytial virus, acute interstitial pneumonitis/pneumonia (also known as Hamman-Rich syndrome), chronic obstructive pulmonary disease (COPD), emphysema and mesothelioma.
[31] The term “liver fibrosis" means a disease or disorder characterized by the formation of fibrous tissue in the liver. Liver fibrosis includes cirrhosis.
[32] The term “dermal fibrosis” means a disease or disorder characterized by the formation of fibrous tissue in the skin. Dermal fibrosis includes keloid scarring, hypertrophic scarring, scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema and eosinophilic fasciitis.
[33] The term “urinary fibrosis” means a disease or disorder characterized by the formation of fibrous tissue in the kidneys, ureter, bladder or the urethra. Urinary fibrosis includes kidney fibrosis, nephrosclerosis, nephrosis, glomerulosclerosis, tubulointerstitial renal fibrosis, bladder fibrosis and urethral stricture. Urinary fibrosis may also be referred to as “renal fibrosis”.
[34] The term “peptide” means a molecule composed of 2-50 amino acids.
[35] The term “protein” means a molecule composed of more than 50 amino acids.
[36] The terms “advanced glycation end-product”, “AGE”, “AGE-modified protein”, “AGE-modified peptide” and “glycation end-product” refer to modified proteins or peptides that are formed as the result of the reaction of sugars with protein side
chains that further rearrange and form irreversible cross-links. This process begins with a reversible reaction between a reducing sugar and an amino group to form a Schiff base, which proceeds to form a covalently-bonded Amadori rearrangement product. Once formed, the Amadori product undergoes further rearrangement to produce AGEs. AGE-modified proteins and antibodies to AGE-modified proteins are described in U.S. 5,702,704 to Bucala (“Bucala”) and U.S. 6,380,165 to Al-Abed et al. (“Al-Abed”). Glycated proteins or peptides that have not undergone the necessary rearrangement to form AGEs, such as N-deoxyfructosyllysine found on glycated albumin, are not AGEs. AGEs may be identified by the presence of AGE modifications (also referred to as AGE epitopes or AGE moieties) such as 2-(2- furoyl)-4(5)-(2-furanyl)-1 H-imidazole ("FFI"); 5-hydroxymethyl-1-alkylpyrrole-2- carbaldehyde ("Pyrraline"); 1-alkyl-2-formyl-3,4-diglycosyl pyrrole ("AFGP"), a non- fluorescent model AGE; carboxymethyllysine; carboxyethyllysine; and pentosidine. ALI, another AGE, is described in Al-Abed.
[37] The term “AGE antigen” means a substance that elicits an immune response against an AGE-modified protein or peptide of a cell. The immune response against an AGE-modified protein or peptide of a cell does not include the production of antibodies to the non-AGE-modified protein or peptide.
[38] “An antibody that binds to an AGE-modified protein on a cell”, “anti-AGE antibody” or “AGE antibody” means an antibody, antibody fragment or other protein or peptide that binds to an AGE-modified protein or peptide which preferably includes a constant region of an antibody, where the protein or peptide which has been AGE-modified is a protein or peptide normally found bound on the surface of a cell, preferably a mammalian cell, more preferably a human, cat, dog, horse, camelid (for example, camel or alpaca), cattle, sheep, pig, or goat cell. “An antibody that binds to an AGE-modified protein on a cell”, “anti-AGE antibody” or “AGE antibody” does not include an antibody or other protein which binds with the same specificity and selectivity to both the AGE-modified protein or peptide, and the same non-AGE- modified protein or peptide (that is, the presence of the AGE modification does not increase binding). AGE-modified albumin is not an AGE-modified protein on a cell, because albumin is not a protein normally found bound on the surface of cells. “An
antibody that binds to an AGE-modified protein on a cell”, “anti-AGE antibody” or “AGE antibody” only includes those antibodies which lead to removal, destruction, or death of the cell. Also included are antibodies which are conjugated, for example to a toxin, drug, or other chemical or particle. Preferably, the antibodies are monoclonal antibodies, but polyclonal antibodies are also possible.
[39] The term “senescent cell” means a cell which is in a state of proliferative arrest and expresses one or more biomarkers of senescence, such as activation of p16lnk4a or expression of senescence-associated P-galactosidase. Also included are cells which express one or more biomarkers of senescence, do not proliferate in vivo, but may proliferate in vitro under certain conditions, such as some satellite cells found in the muscles of ALS patients.
[40] The term “senolytic agent” means a small molecule with a molecular weight of less than 900 daltons that destroys senescent cells. The term “senolytic agent" does not include antibodies, antibody conjugates, proteins, peptides or biologic therapies.
[41] The term “variant” means a nucleotide, protein or amino acid sequence different from the specifically identified sequences, wherein one or more nucleotides, proteins or amino acid residues is deleted, substituted or added. Variants may be naturally-occurring allelic variants, or non-naturally-occurring variants. Variants of the identified sequences may retain some or all of the functional characteristics of the identified sequences.
[42] The term "percent (%) sequence identity" is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Preferably, % sequence identity values are generated using the sequence comparison computer program
ALIGN-2. The ALIGN-2 sequence comparison computer program is publicly available from Genentech, Inc. (South San Francisco, CA), or may be compiled from the source code, which has been filed with user documentation in the U.S. Copyright Office and is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
[43] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. Where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained using the ALIGN-2 computer program.
BRIEF DESCRIPTION OF THE DRAWINGS
[44] FIG. 1 is a graph of the response versus time in an antibody binding experiment.
[45] FIG. 2 is a graph illustrating the effect of senescent cell clearance on peripheral capillary oxygen saturation (SpCh) in bleomycin exposed mice.
[46] FIG. 3A is a graph illustrating the effect of senescent cell clearance with ganciclovir on lung elastance in 3MR mice exposed to bleomycin.
[47] FIG. 3B is a graph illustrating the effect of senescent cell clearance with ganciclovir on dynamic lung compliance in 3MR mice exposed to bleomycin.
[48] FIG. 3C is a graph illustrating the effect of senescent cell clearance with ganciclovir on static lung compliance in 3MR mice exposed to bleomycin.
[49] FIG. 4 is a graph illustrating the effect of senescent cell clearance on peripheral capillary oxygen saturation (SpOa) in mice after 2 months and 4 months of cigarette smoke (CS) exposure. AP=AP20187; GAN=ganciclovir; Navi=Navitoclax (ABT-263); and Nutlin=Nutlin 3A.
DETAILED DESCRIPTION
[50] Studies of fibrotic diseases have established that inflammation is involved in fibrosis. Pro-inflammatory factors, such as TGF , PDGF, IL-1 p, IL-6, IL-10, IL-13 and IFN-y, and reactive oxygen species have been recognized as mediators of fibrosis (Bataller, R. et al., “Liver fibrosis”, The Journal of Clinical Investigation, Vol. 115, No. 2, p. 209-218 (2005)). Similarly, inflammatory cells and their secreted inflammatory factors have been recognized as the primary factors in activating dermal fibroblasts to become fibrotic (Shaw, T. J. et al., “Wound-associated skin fibrosis: mechanisms and treatments based on modulating the inflammatory response”, Endocrine, Metabolic & Immune Disorders, Vol. 10, No. 4, pp. 320-330 (2010)). These studies have led to the development of therapies that treat fibrotic diseases by targeting pro-inflammatory factors. Administration of resveratrol, a known anti-inflammatory agent, and an inhibitor of the inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1) was shown to inhibit fibroplasia in wound healing and reduce or prevent scar formation (WO 2016/057831). Similarly, interference with TGF signaling was found to influence liver fibrosis in mouse models (Weiler-Normann, C., et al., “Mouse models of liver fibrosis”, Zeitschrift fur Gastroenterologie, Vol. 45, p. 43-50 (2007)). However, treatments that target the inflammatory cascade have been unsuccessful (Wynn). Recent research into the pathogenesis of fibrotic diseases suggests that senescent cells, which secrete pro-
inflammatory factors as part of the SASP, may be a more appropriate therapeutic target than pro-inflammatory factors.
[51] Senescent cells have been implicated in a number of fibrotic diseases.
Senescent biomarkers such as p16, p21 and senescence-associated - galactosidase (SA-0-gal) have been observed in fibroblasts and epithelial cells in human and mouse idiopathic lung fibrosis tissue (Schafer, M. J. et al., “Cellular senescence mediates fibrotic pulmonary disease”, Nature Communications, Vol. 8, No. 14532, 11 pages (2017)). Pathogenic models of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis both involve premature cellular senescence of progenitor cells, which results in stem cell exhaustion and disease progression (Chilosi, M. et al., “Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema”, Translational Research, Vol. 162, p. 156-173 (2013)). Senescent cells in the lungs contribute to excess extracellular matrix deposition in an aged mouse model and in elderly human samples (Calhoun, C. et al., “Senescent cells contribute to the physiological remodeling of aged lungs”, Journals of Gerontology: Biological Sciences, Vol. 71 , No. 2, p. 153-160 (2016)). The cell surface protein vimentin has been recognized as a marker of cellular senescence in mice that have been immunized with senescent mouse lung fibroblasts, and the IgM antibody clone 9H4 was found to bind to cell surface vimentin on senescent cells (Frescas, D. et al., “Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody", Proceedings of the National Academy of Sciences, p. E1668- E1677 (2017)). Cellular senescence and the SASP participate in the pathological process of CKD, and CKD accelerates the progression of cellular senescence and the secretion of inflammatory factors through the SASP (Wang, W-J. et al., “Cellular senescence, senescence-associated secretory phenotype, and chronic kidney disease", Oncotarget, Vol. 8, No. 38, pp. 64520-64533 (2017)). Senescent cells increase in the glomeruli in response to renal injury and aging, and increased senescent markers have been detected in glomerulosclerosis (Valentijn, F.A. et al., “Cellular senescence in the aging and diseased kidney”, Journal of Cell Communication and Signaling, Vol. 12, pp. 69-82 (2018)).
[52] Advanced glycation end-products, known markers of senescent cells, have also been implicated in fibrotic diseases. RAGE, a receptor for advanced glycation end-products, is expressed by hepatic stellate cells and myofibroblasts, both of which are involved in the pathogenesis of liver fibrosis and cirrhosis (Yagmur, E. et al., “Elevation of A/£-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis”, Clinical Biochemistry, Vol. 39, p. 39-45 (2006)). In addition, serum levels of carboxymethyllysine, the most well-studied advanced glycation end-product, were significantly affected by the stage of liver cirrhosis and were closely associated with liver function capacity (Yagmur et al.). AGE exposure followed by binding to RAGE results in tubulointerstitial fibrosis in the diabetic kidney (Oldfield, M.D. et al., “Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)”, The Journal of Clinical Investigation, Vol. 108, No. 12, pp. 1853-1863 (2001)). CML and pentosidine have also been identified in glomerulosclerosis, FSGS, hypertensive nephrosclerosis and lupus nephritis (Tanji, N. et al., “Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease”, Journal of the American Society of Nephrology, Vol. 11 , pp. 1656-1666 (2000)).
[53] Desmoplasia forms around tumors, acting as a barrier to drugs and even small molecules. The tumor cells are maintained by the cancer-associated fibroblasts that form the desmoplasia, and the tumor cells contribute to the growth of the desmoplasia. Senescent fibroblasts are present in the desmoplasia. AGEs have been detected in higher staining of surrounding fibroblast foci in fibrotic lungs of IPF patients, compared to control patients (Machahua, C., et aL, Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis, Respiratory Research, vol. 17, no. 144, pp. 1-
11 (2016)). Eliminating or reducing the senescent fibroblasts would reduce the size of the desmoplasia, and it would enhance the permeability of the tumor to antibodies, natural killer cells (NK), immune effectors and other therapeutics, which would enhance the efficacy of the immune response or pharmaceuticals for treating cancer.
[541 Recent studies have found that elimination of senescent cells can be used to treat fibrotic diseases. Elimination of senescent fibroblasts in mice by administration of a combination of the senolytic agents dasatinib and quercetin improved lung function (Schafer, M. J. et al.). Dasatinib alone attenuated bleomycin-induced lung fibrosis in vivo in mice, and suppressed TGFp-induced endothelial mesenchymal transition in vitro (Kato, M. et al., “Dasatinib suppresses TFG0-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis”, European Respiratory Journal, Vol. 44, No. Suppl. 58, p. 742 (2014); Yilmaz, O. et al., “Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice”, Growth Factors, Vol. 33, No. 5, p. 366-375 (2015)). Ablation of p19ARF-expressing cells in transgenic mice using a toxin receptor-mediated cell knockout system improved aging-associated lung hypofunction (Hashimoto, M. etal., “Elimination of p19ARF-expressing cells enhances pulmonary function in mice”, Journal of Clinical Investigation Insight, Vol.
1 , No. 12, 15 pages (2016)). In addition, the elimination of p19ARF reversed the expression of other aging-associated genes. Administration of oral rapamycin to mice prevented cellular senescence in the vasculature and limited collagen deposition in the lungs (Calhoun, C. et al.). Removing senescent cells by administration of senolytic agents treated pulmonary fibrosis resulting from ionizing radiation (Pan, J. etal., “Inhibition of Bcl-2/xl with ABT-263 selectively kills senescent type II pneumocytes and reverses pulmonary fibrosis induced by ionizing radiation in mice”, International Journal of Radiation Oncology Biology Physics, Vol. 99, No. 2, pp. 353-361 (2017)). Clearance of senescent cells by induction of apoptosis in transgenic animal models attenuated glomerulosclerosis (Valentijn, F.A. etal.).
These studies validate the selection of senescent cells as a target for treating fibrotic diseases.
[55] The therapeutic benefits of removing senescent cells has been demonstrated in vivo in an art-accepted model in treating age-related diseases such as sarcopenia (US 9,161,810) and treating metastatic cancer (WO 2017/143073). The identification of a link between cellular senescence and fibrotic diseases allows for similar treatment possibilities. The present invention uses enhanced clearance of cells expressing AGE-modified proteins or peptides (AGE-modified cells) to treat,
ameliorate or prevent the onset of fibrotic diseases by removing or killing senescent cells. This may be accomplished by administering anti-AGE antibodies to a subject.
[56] Vaccination against AGE-modified proteins or peptides of a cell may also be used to control the presence of AGE-modified cells in a subject. The continuous and virtually ubiquitous surveillance exercised by the immune system in the body in response to a vaccination allows maintaining low levels of AGE-modified cells in the body. Vaccination against AGE-modified proteins or peptides of a cell removes or kills senescent cells. The process of senescent cell removal or destruction allows vaccination against AGE-modified proteins or peptides of a cell to be used to treat or prevent the onset of fibrotic diseases. Individuals may receive repeated vaccinations or boosters on a periodic basis to maintain their immunity.
[57] Anti-AGE antibodies are known in the art and are commercially available. Examples include those described in U.S. 5,702,704 (Bucala) and U.S. 6,380,165 (Al-Abed et al.). The antibody may bind to one or more AGE-modified proteins or peptides having an AGE modification such as FFI, pyrraline, AFGP, ALI, carboxymethyllysine (CML), carboxyethyllysine (CEL) and pentosidine, and mixtures of such antibodies. Preferably, the antibody is non-immunogenic to the animal in which it will be used, such as non-immunogenic to humans; companion animals including cats, dogs and horses; and commercially important animals, such camels (or alpaca), cattle (bovine), sheep, pig, and goats. More preferably, the antibody has the same species constant region as antibodies of the animal to reduce the immune response against the antibody, such as being humanized (for humans), felinized (for cats), caninized (for dogs), equuinized (for horses), camelized (for camels or alpaca), bovinized (for cattle), ovinized (for sheep), porcinized (for pigs), or caperized (for goats). Most preferably, the antibody is identical to that of the animal in which it will be used (except for the variable region), such as a human antibody, a cat antibody, a dog antibody, a horse antibody, a camel antibody, a bovine antibody, a sheep antibody, a pig antibody, or a goat antibody. Details of the constant regions and other parts of antibodies for these animals are described below. The antibody may be monoclonal or polyclonal. Preferably, the antibody is a monoclonal antibody.
[58] Preferred anti-AGE antibodies include those which bind to proteins or peptides that exhibit a carboxymethyllysine or carboxyethyllysine AGE modification. Carboxymethyllysine (also known as N(epsilon)-(carboxymethyl)lysine, N(6)- carboxymethyllysine, or 2-Amino-6-(carboxymethylamino)hexanoic acid) and carboxyethyllysine (also known as N-epsilon-(carboxyethyl)lysine) are found on proteins or peptides and lipids as a result of oxidative stress and chemical glycation. CML- and CEL-modified proteins or peptides are recognized by the receptor RAGE which is expressed on a variety of cells. CML and CEL have been well-studied and CML- and CEL-related products are commercially available. For example, Cell Biolabs, Inc. sells CML-BSA antigens, CML polyclonal antibodies, CML immunoblot kits, and CML competitive ELISA kits (www.cellbiolabs.com/cml-assays) as well as CEL-BSA antigens and CEL competitive ELISA kits (www.cellbiolabs.com/cel-n- epsilon-carboxyethyl-lysine-assays-and-reagents). A preferred antibody includes the variable region of the commercially available mouse anti-glycation end-product antibody raised against carboxymethyl lysine conjugated with keyhole limpet hemocyanin, the carboxymethyl lysine MAb (Clone 318003) available from R&D Systems, Inc. (Minneapolis, MN; catalog no. MAB3247), modified to have a human constant region (or the constant region of the animal into which it will be administered). Commercially-available antibodies, such as the carboxymethyl lysine antibody corresponding to catalog no. MAB3247 from R&D Systems, Inc., may be intended for diagnostic purposes and may contain material that is not suited for use in animals or humans. Preferably, commercially-available antibodies are purified and/or isolated prior to use in animals or humans to remove toxins or other potentially-harmful material.
[59] The anti-AGE antibody preferably has a low rate of dissociation from the antibody-antigen complex, or ka (also referred to as kback or off-rate), preferably at most 9 x 10-3, 8 x 10-3, 7 x 10'3 or 6 x 103 (sec1). The anti-AGE antibody preferably has a high affinity for the AGE-modified protein of a cell, which may be expressed as a low dissociation constant KD of at most 9 x 10’6, 8 x 10'6, 7 x 10’6, 6 x 10’6, 5 x 10’6, 4 x 10-6 or 3 x 10‘6 (M). Preferably, the binding properties of the anti-AGE antibody are similar to, the same as, or superior to the carboxymethyl lysine MAb (Clone
318003) available from R&D Systems, Inc. (Minneapolis, MN; catalog no.
MAB3247), illustrated in FIG. 1.
[60] The anti-AGE antibody may destroy AGE-modified cells through antibodydependent cell-mediated cytotoxicity (ADCC). ADCC is a mechanism of cell- mediated immune defense in which an effector cell of the immune system actively lyses a target cell whose membrane-surface antigens have been bound by specific antibodies. ADCC may be mediated by natural killer (NK) cells, macrophages, neutrophils or eosinophils. The effector cells bind to the Fc portion of the bound antibody. The anti-AGE antibody may also destroy AGE-modified cells through complement-dependent cytotoxicity (CDC). In CDC, the complement cascade of the immune system is triggered by an antibody binding to a target antigen.
[61] The anti-AGE antibody may be conjugated to an agent that causes the destruction of AGE-modified cells. Such agents may be a toxin, a cytotoxic agent, magnetic nanoparticles, and magnetic spin-vortex discs.
[62] A toxin, such as pore-forming toxins (PFT) (Aroian R. et al., “Pore-Forming Toxins and Cellular Non-lmmune Defenses (CNIDs),” Current Opinion in Microbiology, 10:57-61 (2007)), conjugated to an anti-AGE antibody may be injected into a patient to selectively target and remove AGE-modified cells. The anti-AGE antibody recognizes and binds to AGE-modified cells. Then, the toxin causes pore formation at the cell surface and subsequent cell removal through osmotic lysis.
[63] Magnetic nanoparticles conjugated to the anti-AGE antibody may be injected into a patient to target and remove AGE-modified cells. The magnetic nanoparticles can be heated by applying a magnetic field in order to selectively remove the AGE- modified cells.
[64] As an alternative, magnetic spin-vortex discs, which are magnetized only when a magnetic field is applied to avoid self-aggregation that can block blood vessels, begin to spin when a magnetic field is applied, causing membrane disruption of target cells. Magnetic spin-vortex discs, conjugated to anti-AGE antibodies specifically target AGE-modified cell types, without removing other cells.
[65] Antibodies are Y-shaped proteins composed of two heavy chains and two light chains. The two arms of the Y shape form the fragment antigen-binding (Fab) region while the base or tail of the Y shape forms the fragment crystallizable (Fc) region of the antibody. Antigen binding occurs at the terminal portion of the fragment antigen-binding region (the tips of the arms of the Y shape) at a location referred to as the paratope, which is a set of complementarity determining regions (also known as CDRs or the hypervariable region). The complementarity determining regions vary among different antibodies and gives a given antibody its specificity for binding to a given antigen. The fragment crystallizable region of the antibody determines the result of antigen binding and may interact with the immune system, such as by triggering the complement cascade or initiating antibody-dependent cell-mediated cytotoxicity (ADCC). When antibodies are prepared recombinantly, it is also possible to have a single antibody with variable regions (or complementary determining regions) that bind to two different antigens, with each tip of the Y shape being specific to one of the antigens; these are referred to as bi-specific antibodies.
[66] A humanized anti-AGE antibody according to the present invention may have the human constant region sequence of amino acids shown in SEQ ID NO: 22. The heavy chain complementarity determining regions of the humanized anti-AGE antibody may have one or more of the protein sequences shown in SEQ ID NO: 23 (CDR1H), SEQ ID NO: 24 (CDR2H) and SEQ ID NO: 25 (CDR3H). The light chain complementarity determining regions of the humanized anti-AGE antibody may have one or more of the protein sequences shown in SEQ ID NO: 26 (CDR1L), SEQ ID NO: 27 (CDR2L) and SEQ ID NO: 28 (CDR3L).
[67] The heavy chain of a humanized anti-AGE antibody may have or may include the protein sequence of SEQ ID NO: 1. The variable domain of the heavy chain may have or may include the protein sequence of SEQ ID NO: 2. The complementarity determining regions of the variable domain of the heavy chain (SEQ ID NO: 2) are shown in SEQ ID NO: 41, SEQ ID NO: 42 and SEQ ID NO: 43. The kappa light chain of a humanized anti-AGE antibody may have or may include the protein sequence of SEQ ID NO: 3. The variable domain of the kappa light chain may have or may include the protein sequence of SEQ ID NO: 4. Optionally, the arginine (Arg
or R) residue at position 128 of SEQ ID NO: 4 may be omitted. The complementarity determining regions of the variable domain of the light chain (SEQ ID NO: 4) are shown in SEQ ID NO: 44, SEQ ID NO: 45 and SEQ ID NO: 46. The variable regions may be codon-optimized, synthesized and cloned into expression vectors containing human immunoglobulin G1 constant regions. In addition, the variable regions may be used in the preparation of non-human anti-AGE antibodies.
[68] The antibody heavy chain may be encoded by the DNA sequence of SEQ ID NO: 12, a murine anti-AGE immunoglobulin G2b heavy chain. The protein sequence of the murine anti-AGE immunoglobulin G2b heavy chain encoded by SEQ ID NO: 12 is shown in SEQ ID NO: 16. The variable region of the murine antibody is shown in SEQ ID NO: 20, which corresponds to positions 25-142 of SEQ ID NO: 16. The antibody heavy chain may alternatively be encoded by the DNA sequence of SEQ ID NO: 13, a chimeric anti-AGE human immunoglobulin G1 heavy chain. The protein sequence of the chimeric anti-AGE human immunoglobulin G1 heavy chain encoded by SEQ ID NO: 13 is shown in SEQ ID NO: 17. The chimeric anti-AGE human immunoglobulin includes the murine variable region of SEQ ID NO: 20 in positions 25-142. The antibody light chain may be encoded by the DNA sequence of SEQ ID NO: 14, a murine anti-AGE kappa light chain. The protein sequence of the murine anti-AGE kappa light chain encoded by SEQ ID NO: 14 is shown in SEQ ID NO: 18. The variable region of the murine antibody is shown in SEQ ID NO: 21, which corresponds to positions 21-132 of SEQ ID NO: 18. The antibody light chain may alternatively be encoded by the DNA sequence of SEQ ID NO: 15, a chimeric anti- AGE human kappa light chain. The protein sequence of the chimeric anti-AGE human kappa light chain encoded by SEQ ID NO: 15 is shown in SEQ ID NO: 19. The chimeric anti-AGE human immunoglobulin includes the murine variable region of SEQ ID NO: 21 in positions 21-132.
[69] A humanized anti-AGE antibody according to the present invention may have or may include one or more humanized heavy chains or humanized light chains. A humanized heavy chain may be encoded by the DNA sequence of SEQ ID NO: 30, 32 or 34. The protein sequences of the humanized heavy chains encoded by SEQ ID NOs: 30, 32 and 34 are shown in SEQ ID NOs: 29, 31 and 33, respectively. A
humanized light chain may be encoded by the DNA sequence of SEQ ID NO: 36, 38 or 40. The protein sequences of the humanized light chains encoded by SEQ ID NOs: 36, 38 and 40 are shown in SEQ ID NOs: 35, 37 and 39, respectively. Preferably, the humanized anti-AGE antibody maximizes the amount of human sequence while retaining the original antibody specificity. A complete humanized antibody may be constructed that contains a heavy chain having a protein sequence chosen from SEQ ID NOs: 29, 31 and 33 and a light chain having a protein sequence chosen from SEQ ID NOs: 35, 37 and 39.
[70] Particularly preferred anti-AGE antibodies may be obtained by humanizing murine monoclonal anti-AGE antibodies. Murine monoclonal anti-AGE antibodies have the heavy chain protein sequence shown in SEQ ID NO: 47 (the protein sequence of the variable domain is shown in SEQ ID NO: 52) and the light chain protein sequence shown in SEQ ID NO: 57 (the protein sequence of the variable domain is shown in SEQ ID NO: 62). A preferred humanized heavy chain may have the protein sequence shown in SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 or SEQ ID NO: 51 (the protein sequences of the variable domains of the humanized heavy chains are shown in SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55 and SEQ ID NO: 56, respectively). A preferred humanized light chain may have the protein sequence shown in SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60 or SEQ ID NO: 61 (the protein sequences of the variable domains of the humanized light chains are shown in SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65 and SEQ ID NO: 66, respectively). Preferably, a humanized anti-AGE monoclonal antibody is composed a heavy chain having a protein sequence selected from the group consisting of SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51 and a light chain having a protein sequence selected from the group consisting of SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60 and SEQ ID NO: 61. Humanized monoclonal anti-AGE antibodies composed of these protein sequences may have better binding and/or improved activation of the immune system, resulting in greater efficacy.
[71] The protein sequence of an antibody from a non-human species may be modified to include the variable domain of the heavy chain having the sequence
shown in SEQ ID NO: 2 or the kappa light chain having the sequence shown in SEQ ID NO: 4. The non-human species may be a companion animal, such as the domestic cat or domestic dog, or livestock, such as cattle, the horse or the camel. Preferably, the non-human species is not the mouse. The heavy chain of the horse (Equus caballus) antibody immunoglobulin gamma 4 may have or may include the protein sequence of SEQ ID NO: 5 (EMBL/GenBank accession number AY445518). The heavy chain of the horse (Equus caballus) antibody immunoglobulin delta may have or may include the protein sequence of SEQ ID NO: 6 (EMBL/GenBank accession number AY631942). The heavy chain of the dog (Canis familiaris) antibody immunoglobulin A may have or may include the protein sequence of SEQ ID NO: 7 (GenBank accession number L36871). The heavy chain of the dog (Canis familiaris) antibody immunoglobulin E may have or may include the protein sequence of SEQ ID NO: 8 (GenBank accession number L36872). The heavy chain of the cat (Felis catus) antibody immunoglobulin G2 may have or may include the protein sequence of SEQ ID NO: 9 (DDBJ/EMBL/GenBank accession number KF811175).
[72] Animals of the camelid family, such as camels (Camelus dromedarius and
Camelus bactrianus), llamas (Lama glama, Lama paces and Lama vicugna), alpacas (Vicugna paces) and guanacos (Lama guanicoe), have a unique antibody that is not found in other mammals. In addition to conventional immunoglobulin G antibodies composed of heavy and light chain tetramers, camelids also have heavy chain immunoglobulin G antibodies that do not contain light chains and exist as heavy chain dimers. These antibodies are known as heavy chain antibodies, HCAbs, single-domain antibodies or sdAbs, and the variable domain of a camelid heavy chain antibody is known as the VHH. The camelid heavy chain antibodies lack the heavy chain CH1 domain and have a hinge region that is not found in other species. The variable region of the Arabian camel (Camelus dromedarius) single-domain antibody may have or may include the protein sequence of SEQ ID NO: 10 (GenBank accession number AJ245148). The variable region of the heavy chain of the Arabian camel (Camelus dromedarius) tetrameric immunoglobulin may have or may include the protein sequence of SEQ ID NO: 11 (GenBank accession number AJ245184).
[73] In addition to camelids, heavy chain antibodies are also found in cartilaginous fishes, such as sharks, skates and rays. This type of antibody is known as an immunoglobulin new antigen receptor or IgNAR, and the variable domain of an IgNAR is known as the VNAR. The IgNAR exists as two identical heavy chain dimers composed of one variable domain and five constant domains each. Like camelids, there is no light chain.
[74] The protein sequences of additional non-human species may be readily found in online databases, such as the International ImMunoGeneTics Information System (www.imgt.org), the European Bioinformatics Institute (www.ebi.ac.uk), the DNA Databank of Japan (ddbj.nig.ac.jp/arsa) or the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov).
[75] An anti-AGE antibody or a variant thereof may include a heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 or SEQ ID NO: 51, including post-translational modifications thereof. A heavy chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-AGE antibody including that sequence retains the ability to bind to AGE.
[76] An anti-AGE antibody or a variant thereof may include a heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 41 , SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, or SEQ ID NO: 56, including post-translational modifications thereof. A variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-AGE antibody
including that sequence retains the ability to bind to AGE. The substitutions, insertions, or deletions may occur in regions outside the variable region.
[77] An anti-AGE antibody or a variant thereof may include a light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60 or SEQ ID NO: 61, including post-translational modifications thereof. A light chain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-AGE antibody including that sequence retains the ability to bind to AGE. The substitutions, insertions, or deletions may occur in regions outside the variable region.
[78] An anti-AGE antibody or a variant thereof may include a light chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4, SEQ ID NO: 21, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65 or SEQ ID NO: 66, including post-translational modifications thereof. A variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity may contain substitutions (e.g., conservative substitutions), insertions, or deletions relative to the reference sequence, but an anti-AGE antibody including that sequence retains the ability to bind to AGE. The substitutions, insertions, or deletions may occur in regions outside the variable region.
[79] Alternatively, the antibody may have the complementarity determining regions of commercially available mouse anti-glycation end-product antibody raised against carboxymethyl lysine conjugated with keyhole limpet hemocyanin (CML-KLH), the carboxymethyl lysine MAb (Clone 318003) available from R&D Systems, Inc. (Minneapolis, MN; catalog no. MAB3247).
[80] The antibody may have or may include constant regions which permit destruction of targeted cells by a subject’s immune system.
[81] Mixtures of antibodies that bind to more than one type AGE of AGE-modified proteins may also be used.
[82] Bi-specific antibodies, which are anti-AGE antibodies directed to two different epitopes, may also be used. Such antibodies will have a variable region (or complementary determining region) from those of one anti-AGE antibody, and a variable region (or complementary determining region) from a different antibody.
[83] Antibody fragments may be used in place of whole antibodies. For example, immunoglobulin G may be broken down into smaller fragments by digestion with enzymes. Papain digestion cleaves the N-terminal side of inter-heavy chain disulfide bridges to produce Fab fragments. Fab fragments include the light chain and one of the two N-terminal domains of the heavy chain (also known as the Fd fragment). Pepsin digestion cleaves the C-terminal side of the inter-heavy chain disulfide bridges to produce F(ab’)2 fragments. F(ab’)2 fragments include both light chains and the two N-terminal domains linked by disulfide bridges. Pepsin digestion may also form the Fv (fragment variable) and Fc (fragment crystallizable) fragments. The Fv fragment contains the two N-terminal variable domains. The Fc fragment contains the domains which interact with immunoglobulin receptors on cells and with the initial elements of the complement cascade. Pepsin may also cleave immunoglobulin G before the third constant domain of the heavy chain (CH3) to produce a large fragment F(abc) and a small fragment pFc’. Antibody fragments may alternatively be produced recombinantly. Preferably, such antibody fragments are conjugated to an agent that causes the destruction of AGE-modified cells.
[84] If additional antibodies are desired, they can be produced using well-known methods. For example, polyclonal antibodies (pAbs) can be raised in a mammalian host by one or more injections of an immunogen, and if desired, an adjuvant. Typically, the immunogen (and adjuvant) is injected in a mammal by a subcutaneous or intraperitoneal injection. The immunogen may be an AGE-modified protein of a
cell, such as AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE- ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin such as AGE-bovine serum albumin (AGE-BSA), AGE-human serum albumin and ovalbumin, AGE- crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE- apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-l and II, AGE- hemoglobin, AGE-Na7K+-ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-p-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-fh-microglobulin, AGE- sorbitol dehydrogenase, AGE-ai -antitrypsin, AGE-carbonate dehydratase, AGE- RNAse, AGE-hexokinase, AGE-apo C-l, AGE-hemoglobin such as AGE-human hemoglobin, AGE-low density lipoprotein (AGE-LDL) and AGE-collagen IV. AGE- modified cells, such as AGE-modified erythrocytes, whole, lysed, or partially digested, may also be used as AGE antigens. Examples of adjuvants include Freund’s complete, monophosphoryl Lipid A synthetic-trehalose dicorynomycolate, aluminum hydroxide (alum), heat shock proteins HSP 70 or HSP96, squalene emulsion containing monophosphoryl lipid A, a2-macroglobulin and surface active substances, including oil emulsions, pleuronic polyols, polyanions and dinitrophenol. To improve the immune response, an immunogen may be conjugated to a polypeptide that is immunogenic in the host, such as keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, cholera toxin, labile enterotoxin, silica particles or soybean trypsin inhibitor. A preferred immunogen conjugate is AGE- KLH. Alternatively, pAbs may be made in chickens, producing IgY molecules.
[85] Monoclonal antibodies (mAbs) may also be made by immunizing a host or lymphocytes from a host, harvesting the mAb-secreting (or potentially secreting) lymphocytes, fusing those lymphocytes to immortalized cells (for example, myeloma cells), and selecting those cells that secrete the desired mAb. Other techniques may be used, such as the EBV-hybridoma technique. Non-human antibodies may be made less immunogenic to humans by engineering the antibodies to contain a
combination of non-human and human antibody components. A chimeric antibody may be produced by combining the variable region of a non-human antibody with a human constant region. A humanized antibody may be produced by replacing the complementarity determining regions (CDRs) of a human antibody with those of a non-human antibody. Similarly, antibodies may be made less immunogenic to other species by being substantially “ized” to a given animal, such as cat, dog, horse, camel or alpaca, cattle, sheep, pig, or goat, at the amino acid level. If desired, the mAbs may be purified from the culture medium or ascites fluid by conventional procedures, such as protein A-sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, ammonium sulfate precipitation or affinity chromatography. Additionally, human monoclonal antibodies can be generated by immunization of transgenic mice containing a third copy IgG human trans-loci and silenced endogenous mouse Ig loci or using human-transgenic mice. Production of humanized monoclonal antibodies and fragments thereof can also be generated through phage display technologies.
[86] A "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Preferred examples of such carriers or diluents include water, saline, Ringer’s solutions and dextrose solution. Supplementary active compounds can also be incorporated into the compositions. Solutions and suspensions used for parenteral administration can include a sterile diluent, such as water for injection, saline solution, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[87] The antibodies may be administered systemically, such as by intravenous injection or infusion. Alternatively, the antibodies may be administered locally with a
pharmaceutically acceptable carrier suitable for the administration site, such as by percutaneous injection into an affected organ, topical administration at the site of dermal fibrosis or administration via nebulizer for pulmonary fibrosis.
Pharmaceutical compositions suitable for injection include sterile aqueous solutions or dispersions for the extemporaneous preparation of sterile injectable solutions or dispersion. Various excipients may be included in pharmaceutical compositions of antibodies suitable for injection. Suitable carriers include physiological saline, bacteriostatic water, CREMOPHOR EL® (BASF; Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid so as to be administered using a syringe. Such compositions should be stable during manufacture and storage and must be preserved against contamination from microorganisms such as bacteria and fungi. Various antibacterial and anti-fungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, and thimerosal, can contain microorganism contamination. Isotonic agents such as sugars, polyalcohols, such as mannitol, sorbitol, and sodium chloride can be included in the composition. Compositions that can delay absorption include agents such as aluminum monostearate and gelatin. Sterile injectable solutions can be prepared by incorporating antibodies, and optionally other therapeutic components, in the required amount in an appropriate solvent with one or a combination of ingredients as required, followed by sterilization. Methods of preparation of sterile solids for the preparation of sterile injectable solutions include vacuum drying and freeze-drying to yield a solid.
[88] For administration by inhalation, the antibodies may be delivered as an aerosol spray from a nebulizer or a pressurized container that contains a suitable propellant, for example, a gas such as carbon dioxide. Antibodies may also be delivered via inhalation as a dry powder, for example using the iSPERSE™ inhaled drug delivery platform (PULMATRIX, Lexington, Mass.). The use of anti-AGE antibodies which are chicken antibodies (IgY) may be non-immunogenic in a variety of animals, including humans, when administered by inhalation.
[89] An appropriate dosage level of each type of antibody will generally be about 0.01 to 500 mg per kg patient body weight. Preferably, the dosage level will be
about 0.1 to about 250 mg/kg; more preferably about 0.5 to about 100 mg/kg. A suitable dosage level may be about 0.01 to 250 mg/kg, about 0.05 to 100 mg/kg, or about 0.1 to 50 mg/kg. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg. Although each type of antibody may be administered on a regimen of 1 to 4 times per day, such as once or twice per day, antibodies typically have a long half-life in vivo. Accordingly, each type of antibody may be administered once a day, once a week, once every two or three weeks, once a month, or once every 60 to 90 days.
[90] A subject that receives administration of an anti-AGE antibody may be tested to determine if the administration has been effective to treat fibrotic diseases. A subject may be considered to have received an effective antibody treatment if he or she demonstrates an improvement in symptoms between subsequent measurements or over time. The efficacy of treatment may be determined with a diagnostic test that is suitable for a given fibrotic disease. For example, liver fibrosis may be monitored with a liver biopsy and pulmonary fibrosis may be monitored with high-resolution computed tomography, pulmonary function tests, bronchoscopy or bronchoalveolar lavage. Alternatively, the concentration and/or number of senescent cells may be measured over time. Administration of antibody and subsequent testing may be repeated until the desired therapeutic result is achieved.
[91] Unit dosage forms can be created to facilitate administration and dosage uniformity. Unit dosage form refers to physically discrete units suited as single dosages for the subject to be treated, containing a therapeutically effective quantity of one or more types of antibodies in association with the required pharmaceutical carrier. Preferably, the unit dosage form is in a sealed container and is sterile.
[92] Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients. Examples of AGE antigens include AGE-modified proteins or peptides such as AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin such as AGE-bovine serum albumin (AGE-BSA), AGE-human serum albumin and ovalbumin, AGE-crystallin, AGE-plasminogen activator, AGE-
endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-l and II, AGE-hemoglobin, AGE-Na+/K+-ATPase, AGE- plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-0-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE- fibrinogen, AGE- 2-microglobulin, AGE-sorbitol dehydrogenase, AGE-cu -antitrypsin, AGE-carbonate dehydratase, AGE-RNAse, AGE-hexokinase, AGE-apo C-l, AGE- hemoglobin such as AGE-human hemoglobin, AGE-low density lipoprotein (AGE- LDL) and AGE-collagen IV. AGE-modified cells, such as AGE-modified erythrocytes, whole, lysed, or partially digested, may also be used as AGE antigens. Suitable AGE antigens also include proteins or peptides that exhibit AGE modifications (also referred to as AGE epitopes or AGE moieties) such as carboxymethyllysine (CML), carboxyethyllysine (CEL), pentosidine, pyrraline, FFI, AFGP and ALL The AGE antigen may be an AGE-protein conjugate, such as AGE conjugated to keyhole limpet hemocyanin (AGE-KLH). Further details of some of these AGE-modified proteins or peptides and their preparation are described in Bucala.
[93] Particularly preferred AGE antigens include proteins or peptides that exhibit a carboxymethyllysine or carboxyethyllysine AGE modification. Carboxymethyllysine (also known as N(epsilon)-(carboxymethyl)lysine, N(6)-carboxymethyllysine, or 2- Amino-6-(carboxymethylamino)hexanoic acid) and carboxyethyllysine (also known as N-epsilon-(carboxyethyl)lysine) are found on proteins or peptides and lipids as a result of oxidative stress and chemical glycation, and have been correlated with juvenile genetic disorders. CML- and CEL-modified proteins or peptides are recognized by the receptor RAGE which is expressed on a variety of cells. CML and CEL have been well-studied and CML- and CEL-related products are commercially available. For example, Cell Biolabs, Inc. sells CML-BSA antigens, CML polyclonal antibodies, CML immunoblot kits, and CML competitive ELISA kits (www.cellbiolabs.com/cml-assays) as well as CEL-BSA antigens and CEL
competitive ELISA kits (www.cellbiolabs.com/cel-n-epsilon-carboxyethyl-lysine- assays-and-reagents).
[94] AGE antigens may be conjugated to carrier proteins to enhance antibody production in a subject. Antigens that are not sufficiently immunogenic alone may require a suitable carrier protein to stimulate a response from the immune system. Examples of suitable carrier proteins include keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, cholera toxin, labile enterotoxin, silica particles and soybean trypsin inhibitor. Preferably, the carrier protein is KLH (AGE-KLH). KLH has been extensively studied and has been identified as an effective carrier protein in experimental cancer vaccines. Preferred AGE antigen-carrier protein conjugates include CML-KLH and CEL-KLH.
[95] The administration of an AGE antigen allows the immune system to develop immunity to the antigen. Immunity is a long-term immune response, either cellular or humoral. A cellular immune response is activated when an antigen is presented, preferably with a co-stimulator to a T-cell which causes it to differentiate and produce cytokines. The cells involved in the generation of the cellular immune response are two classes of T-helper (Th) cells, Th1 and Th2. Th1 cells stimulate B cells to produce predominantly antibodies of the lgG2A isotype, which activates the complement cascade and binds the Fc receptors of macrophages, while Th2 cells stimulate B cells to produce IgG 1 isotype antibodies in mice, lgG4 isotype antibodies in humans, and IgE isotype antibodies. The human body also contains “professional” antigen-presenting cells such as dendritic cells, macrophages, and B cells.
[96] A humoral immune response is triggered when a B cell selectively binds to an antigen and begins to proliferate, leading to the production of a clonal population of cells that produce antibodies that specifically recognize that antigen and which may differentiate into antibody-secreting cells, referred to as plasma-cells or memory-B cells. Antibodies are molecules produced by B-cells that bind a specific antigen. The antigen-antibody complex triggers several responses, either cell-mediated, for example by natural killers (NK) or macrophages, or serum-mediated, for example by
activating the complement system, a complex of several serum proteins that act sequentially in a cascade that result in the lysis of the target cell.
[97] Immunological adjuvants (also referred to simply as “adjuvants”) are the component(s) of a vaccine which augment the immune response to the immunogenic agent. Adjuvants function by attracting macrophages to the immunogenic agent and then presenting the agent to the regional lymph nodes to initiate an effective antigenic response. Adjuvants may also act as carriers themselves for the immunogenic agent. Adjuvants may induce an inflammatory response, which may play an important role in initiating the immune response.
[98] Adjuvants include mineral compounds such as aluminum salts, oil emulsions, bacterial products, liposomes, immunostimulating complexes and squalene. Aluminum compounds are the most widely used adjuvants in human and veterinary vaccines. These aluminum compounds include aluminum salts such as aluminum phosphate (AIPO4) and aluminum hydroxide (AI(OH)3) compounds, typically in the form of gels, and are generically referred to in the field of vaccine immunological adjuvants as "alum." Aluminum hydroxide is a poorly crystalline aluminum oxyhydroxide having the structure of the mineral boehmite. Aluminum phosphate is an amorphous aluminum hydroxyphosphate. Negatively charged species (for example, negatively charged antigens) can absorb onto aluminum hydroxide gels at neutral pH, whereas positively charged species (for example, positively charged antigens) can absorb onto aluminum phosphate gels at neutral pH. It is believed that these aluminum compounds provide a depot of antigen at the site of administration, thereby providing a gradual and continuous release of antigen to stimulate antibody production. Aluminum compounds tend to more effectively stimulate a cellular response mediated by Th2, rather than Th1 cells.
[99] Emulsion adjuvants include water-in-oil emulsions (for example, Freund's adjuvants, such as killed mycobacteria in oil emulsion) and oil-in-water emulsions (for example, MF-59). Emulsion adjuvants include an immunogenic component, for example squalene (MF-59) or mannide oleate (Incomplete Freund's Adjuvants),
which can induce an elevated humoral response, increased T cell proliferation, cytotoxic lymphocytes and cell-mediated immunity.
[100] Liposomal or vesicular adjuvants (including paucilamellar lipid vesicles) have lipophilic bilayer domains and an aqueous milieu which can be used to encapsulate and transport a variety of materials, for example an antigen. Paucilamellar vesicles (for example, those described in U.S. Pat. No. 6,387,373) can be prepared by mixing, under high pressure or shear conditions, a lipid phase comprising a nonphospholipid material (for example, an amphiphile surfactant; see U.S. Pat. Nos. 4,217,344; 4,917,951 ; and 4,911 ,928), optionally a sterol, and any water-immiscible oily material to be encapsulated in the vesicles (for example, an oil such as squalene oil and an oil-soluble or oil-suspended antigen); and an aqueous phase such as water, saline, buffer or any other aqueous solution used to hydrate the lipids. Liposomal or vesicular adjuvants are believed to promote contact of the antigen with immune cells, for example by fusion of the vesicle to the immune cell membrane, and preferentially stimulate the Th1 sub-population of T-helper cells.
[101] Other types of adjuvants include Mycobacterium bovis bacillus Calmette- Guerin (BCG), quill-saponin and unmethylated CpG dinucleotides (CpG motifs). Additional adjuvants are described in U.S. Patent Application Publication Pub. No. US 2010/0226932 (September 9, 2010) and Jiang, Z-H. et al. “Synthetic vaccines: the role of adjuvants in immune targeting”, Current Medicinal Chemistry, Vol. 10(15), pp. 1423-39 (2003). Preferable adjuvants include Freund’s complete adjuvant and Freund’s incomplete adjuvant.
[102] The vaccine may optionally include one or more preservatives, such as antioxidants, antibacterial and antimicrobial agents, as well as combinations thereof. Examples include benzethonium chloride, ethylenediamine-tetraacetic acid sodium (EDTA), thimerosal, phenol, 2-phenoxyethanol, formaldehyde and formalin; antibacterial agents such as amphotericin B, chlortetracycline, gentamicin, neomycin, polymyxin B and streptomycin; antimicrobial surfactants such as polyoxyethylene-9, 10-nonyl phenol (Triton N-101 , octoxynol-9), sodium deoxycholate and polyoxyethylated octyl phenol (Triton X-I00). The production and
packaging of the vaccine may eliminate the need for a preservative. For example, a vaccine that has been sterilized and stored in a sealed container may not require a preservative.
[103] Other components of vaccines include pharmaceutically acceptable excipients, such as stabilizers, thickening agents, toxin detoxifiers, diluents, pH adjusters, tonicity adjustors, surfactants, antifoaming agents, protein stabilizers, dyes and solvents. Examples of such excipients include hydrochloric acid, phosphate buffers, sodium acetate, sodium bicarbonate, sodium borate, sodium citrate, sodium hydroxide, potassium chloride, potassium chloride, sodium chloride, polydimethylsilozone, brilliant green, phenol red (phenolsulfon-phthalein), glycine, glycerin, sorbitol, histidine, monosodium glutamate, potassium glutamate, sucrose, urea, lactose, gelatin, sorbitol, polysorbate 20, polysorbate 80 and glutaraldehyde. A variety of these components of vaccines, as well as adjuvants, are described in www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf and Vogel, F. R. et al., “A compendium of vaccine adjuvants and excipients”, Pharmaceutical Biotechnology, Vol. 6, pp. 141-228 (1995).
[104] The vaccine may contain from 1 pg to 100 mg of at least one AGE antigen, including 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 400, 800 or 1000 pg, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80 or 90 mg. The amount used for a single injection corresponds to a unit dosage.
[105] The vaccine may be provided in unit dosage form or in multidosage form, such as 2-100 or 2-10 doses. The unit dosages may be provided in a vial with a septum, or in a syringe with or without a needle. The vaccine may be administered intravenously, subdermally or intraperitoneally. Preferably, the vaccine is sterile.
[106] The vaccine may be administered one or more times, such as 1 to 10 times, including 2, 3, 4, 5, 6, 7, 8 or 9 times, and may be administered over a period of time ranging from 1 week to 1 year, 2-10 weeks or 2-10 months. Furthermore, booster vaccinations may be desirable, over the course of 1 year to 20 years, including 2, 5, 10 and 15 years.
[107] A subject that receives a vaccine for AGE-modified proteins or peptides of a cell may be tested to determine if he or she has developed an immunity to the AGE- modified proteins or peptides. Suitable tests may include blood tests for detecting the presence of an antibody, such as immunoassays or antibody titers. An immunity to AGE-modified proteins or peptides may also be determined by monitoring the concentration and/or number of senescent cells over time. In addition to testing for the development of an immunity to AGE-modified proteins or peptides, a subject may also be tested to determine if the vaccination has been effective to treat fibrotic diseases. A subject may be considered to have received an effective vaccination if he or she demonstrates an improvement in symptoms between subsequent measurements or overtime, or by measuring the concentration and/or number of senescent cells. Vaccination and subsequent testing may be repeated until the desired therapeutic result is achieved.
[108] The vaccination process may be designed to provide immunity against multiple AGE moieties. A single AGE antigen may induce the production of AGE antibodies which are capable of binding to multiple AGE moieties. Alternatively, the vaccine may contain multiple AGE antigens. In addition, a subject may receive multiple vaccines, where each vaccine contains a different AGE antigen.
[109] Any mammal that could develop fibrotic diseases may be treated by the methods herein described. Humans are a preferred mammal for treatment. Other mammals that may be treated include mice, rats, goats, sheep, pigs, cows, horses and companion animals, such as dogs or cats. Alternatively, any of the mammals or subjects identified above may be excluded from the patient population in need of treatment for fibrotic diseases.
[110] A subject may be identified as in need of treatment based on a diagnosis with at least one fibrotic disease, or with a disease that is known to contribute to fibrosis. Fibrotic diseases include interstitial lung disease, pulmonary fibrosis, liver fibrosis, cirrhosis, urinary fibrosis, kidney fibrosis, kidney disease, chronic kidney disease (CKD), nephrosclerosis, nephrosis, glomerulosclerosis, bladder fibrosis, urethral stricture, cardiovascular disease, macular degeneration, vitreal retinopathy,
scleroderma (systemic and local), restenosis, myelofibrosis (bone marrow cancer), keloid scarring, hypertrophic scarring, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema and eosinophilic fasciitis. Fibrotic diseases include desmoplasia, as fibrotic tissue in the surrounding stroma plays a very important role in the progression of cancer. Diagnosis may involve any suitable diagnostic test or procedure for a given disease or disorder. A subject may also be identified as in need of treatment after experiencing physical trauma that is known to result in fibrosis, such as surgical complications, administration of chemotherapeutic drugs, exposure to radiation, burns or physical injury.
[111] Subjects may also be identified as in need of treatment based on detection of advanced glycation end products in a sample obtained from the subject. Suitable samples include blood, skin, serum, saliva and urine. The diagnostic use of anti- AGE antibodies is discussed in more detail in International Publication No. WO 2018/204679.
[112] The Present Application includes 66 nucleotide and amino acid sequences in the Sequence Listing filed herewith. Variants of the nucleotide and amino acid sequences are possible. Known variants include substitutions, deletions and additions to the sequences shown in SEQ ID NO: 4, 16 and 20. In SEQ ID NO: 4, the arginine (Arg or R) residue at position 128 may optionally be omitted. In SEQ ID NO: 16, the alanine residue at position 123 may optionally be replaced with a serine residue, and/or the tyrosine residue at position 124 may optionally be replaced with a phenylalanine residue. SEQ ID NO: 20 may optionally include the same substitutions as SEQ ID NO: 16 at positions 123 and 124. In addition, SEQ ID NO: 20 may optionally contain one additional lysine residue after the terminal valine residue.
[113] EXAMPLES
[114] Example 1 : In vivo study of the administration of anti-glycation end-product antibody
[115] To examine the effects of an anti-glycation end-product antibody, the antibody was administered to the aged CD1(ICR) mouse (Charles River Laboratories), twice daily by intravenous injection, once a week, for three weeks (Days 1, 8 and 15), followed by a 10 week treatment-free period. The test antibody was a commercially available mouse anti-glycation end-product antibody raised against carboxymethyl lysine conjugated with keyhole limpet hemocyanin, the carboxymethyl lysine MAb (Clone 318003) available from R&D Systems, Inc. (Minneapolis, MN; catalog no. MAB3247). A control reference of physiological saline was used in the control animals.
[116] Mice referred to as “young” were 8 weeks old, while mice referred to as “old” were 88 weeks (±2 days) old. No adverse events were noted from the administration of the antibody. The different groups of animals used in the study are shown in Table 1.
- = Not Applicable, Pre = Subset of animals euthanized prior to treatment start for collection of adipose tissue.
[118] P16lNK4a mRNA, a marker for senescent cells, was quantified in adipose tissue of the groups by Real Time-qPCR. The results are shown in Table 2. In the table AACt = ACt mean control Group (2) - ACt mean experimental Group (1 or 3 or 5); Fold Expression= 2 ~AACt.
[120] The table above indicates that untreated old mice (Control Group 2) express 2.55-fold more p16lnk4a mRNA than the untreated young mice (Control Group 1), as expected. This was observed when comparing Group 2 untreated old mice euthanized at end of recovery Day 85 to Group 1 untreated young mice euthanized at end of treatment Day 22. When results from Group 2 untreated old mice were compared to results from Group 3 treated old mice euthanized Day 85, it was observed that p16lnk4a mRNA was 1.23-fold higher in Group 2 than in Group 3. Therefore, the level of p16lnk4a mRNA expression was lower when the old mice were treated with 2.5 pg/gram/BID/week of antibody.
[121] When results from Group 2 (Control) untreated old mice were compared to results from Group 5 (5 pg/gram) treated old mice euthanized Day 22, it was observed that p16lnk4a mRNA was 3.03-fold higher in Group 2 (controls) than in Group 5 (5 pg/gram). This comparison indicated that the Group 5 animals had lower levels of p16lnk4a mRNA expression when they were treated with 5.0 pg/gram/BID/week, providing pl6lnk4a mRNA expression levels comparable to that of the young untreated mice (i.e. Group 1). Unlike Group 3 (2.5 pg/gram) mice that were euthanized at end of recovery Day 85, Group 5 mice were euthanized at end of treatment Day 22.
[122] These results indicate the antibody administration resulted in the killing of senescent cells.
[123] The mass of the gastrocnemius muscle was also measured, to determine the effect of antibody administration on sarcopenia. The results are provided in Table 3. The results indicate that administration of the antibody increased muscle mass as compared to controls, but only at the higher dosage of 5.0 pg/gm/BID/ week.
[124] Table 3: Effect of antibody administration on mass of the gastrocnemius muscle
Summary Absolute weight of Weight relative to body mass of
Group Information Gastrocnemius Muscle (g) Gastrocnemius Muscle (%)
1 Mean 0.3291 1.1037
SD 0.0412 0.1473
N 20 20
2 Mean 0.3304 0.7671
SD 0.0371 0.1246
N 20 20
3 Mean 0.3410 0.7706
SD 0.0439 0.0971
N 19 19
5 Mean 0.4074 0.9480
SD 0.0508 0.2049
N 9 9
[125] These results demonstrate that administration of antibodies that bind to AGEs of a cell resulted in a reduction of cells expressing p16,nk4a, a biomarker of senescence. The data show that reducing senescent cells leads directly to an increase in muscle mass in aged mice. These results indicate that the loss of muscle mass, a classic sign of sarcopenia, can be treated by administration of antibodies that bind to AGEs of a cell. The results suggest that administration of the antibodies would be effective in treating or preventing the onset of fibrotic diseases by removing senescent cells.
[126] Example 2: Affinity and kinetics of test antibody
[127] The affinity and kinetics of the test antibody used in Example 1 were analyzed using Na,Na-bis(carboxymethyl)-L-lysine trifluoroacetate salt (Sigma-Aldrich, St. Louis, MO) as a model substrate for an AGE-modified protein of a cell. Label-free
interaction analysis was carried out on a BIACORE™ T200 (GE Healthcare, Pittsburgh, PA), using a Series S sensor chip CM5 (GE Healthcare, Pittsburgh, PA), with Fc1 set as blank, and Fc2 immobilized with the test antibody (molecular weigh of 150,000 Da). The running buffer was an HBS-EP buffer (10 mM HEPES, 150 mM NaCI, 3 mM EDTA and 0.05% P-20, pH of 7.4), at a temperature of 25 °C. Software was BIACORE™ T200 evaluation software, version 2.0. A double reference (Fc2-1 and only buffer injection), was used in the analysis, and the data was fitted to a Langmuir 1:1 binding model.
[129] A graph of the response versus time is illustrated in FIG. 1. The following values were determined from the analysis: ka (1/Ms) = 1.857 x 103; kd (1/s) = 6.781 x 10'3; KD (M) = 3.651 x 10'6; Rmax (RU) = 19.52; and Chi2 = 0.114. Because the Chi2 value of the fitting is less than 10% of Rmax, the fit is reliable.
[130] Example 3: Construction and production of murine anti-AGE lgG2b antibody and chimeric anti-AGE lgG1 antibody
[131] Murine and chimeric human anti-AGE antibodies were prepared. The DNA sequence of murine anti-AGE antibody lgG2b heavy chain is shown in SEQ ID NO: 12. The DNA sequence of chimeric human anti-AGE antibody lgG1 heavy chain is
shown in SEQ ID NO: 13. The DNA sequence of murine anti-AGE antibody kappa light chain is shown in SEQ ID NO: 14. The DNA sequence of chimeric human anti- AGE antibody kappa light chain is shown in SEQ ID NO: 15. The gene sequences were synthesized and cloned into high expression mammalian vectors. The sequences were codon optimized. Completed constructs were sequence confirmed before proceeding to transfection.
[132] HEK293 cells were seeded in a shake flask one day before transfection, and were grown using serum-free chemically defined media. The DNA expression constructs were transiently transfected into 0.03 liters of suspension HEK293 cells. After 20 hours, cells were sampled to obtain the viabilities and viable cell counts, and titers were measured (Octet QKe, ForteBio). Additional readings were taken throughout the transient transfection production runs. The cultures were harvested on day 5, and an additional sample for each was measured for cell density, viability and titer.
[133] The conditioned media for murine and chimeric anti-AGE antibodies were harvested and clarified from the transient transfection production runs by centrifugation and filtration. The supernatants were run over a Protein A column and eluted with a low pH buffer. Filtration using a 0.2 pm membrane filter was performed before aliquoting. After purification and filtration, the protein concentrations were calculated from the OD280 and the extinction coefficient A summary of yields and aliquots is shown in Table 5:
[134] Table 5: Yields and aliquots
[135] Antibody purity was evaluated by capillary electrophoresis sodium-dodecyl sulfate (CE-SDS) analysis using LabChip® GXII, (PerkinElmer).
[136] Example 4: Binding of murine (parental) and chimeric anti-AGE antibodies
[137] The binding of the murine (parental) and chimeric anti-AGE antibodies described in Example 3 was investigated by a direct binding ELISA. An anti- carboxymethyl lysine (CML) antibody (R&D Systems, MAB3247) was used as a control. CML was conjugated to KLH (CML-KLH) and both CML and CML-KLH were coated overnight onto an ELISA plate. HRP-goat anti-mouse Fc was used to detect the control and murine (parental) anti-AGE antibodies. HRP-goat anti-human Fc was used to detect the chimeric anti-AGE antibody.
[138] The antigens were diluted to 1 pg/mL in 1x phosphate buffer at pH 6.5. A 96- well microtiter ELISA plate was coated with 100 pL/well of the diluted antigen and let sit at 4°C overnight. The plate was blocked with 1x PBS, 2.5% BSA and allowed to sit for 1-2 hours the next morning at room temperature. The antibody samples were prepared in serial dilutions with 1x PBS, 1% BSA with the starting concentration of 50 pg/mL. Secondary antibodies were diluted 1 :5,000. 100 pL of the antibody dilutions was applied to each well. The plate was incubated at room temperature for 0.5-1 hour on a microplate shaker. The plate was washed 3 times with 1x PBS. 100 pL/well diluted HRP-conjugated goat anti-human Fc secondary antibody was applied to the wells. The plate was incubated for 1 hour on a microplate shaker. The plate was then washed 3 times with 1x PBS. 100 pL HRP substrate TMB was added to each well to develop the plate. After 3-5 minutes elapsed, the reaction was terminated by adding 100 pL of 1N HCL A second direct binding ELISA was performed with only CML coating. The absorbance at OD450 was read using a microplate reader.
[139] The OD450 absorbance raw data for the CML and CML-KLH ELISA is shown in the plate map below. 48 of the 96 wells in the well plate were used. Blank wells in the plate map indicate unused wells.
[140] Plate map of CML and CML-KLH ELISA:
Cone.
[141] The OD450 absorbance raw data for the CML-only ELISA is shown in the plate map below. 24 of the 96 wells in the well plate were used. Blank wells in the plate map indicate unused wells.
[142] Plate map of CML-only ELISA:
Cone.
[143] The control and chimeric anti-AGE antibodies showed binding to both CML and CML-KLH. The murine (parental) anti-AGE antibody showed very weak to no binding to either CML or CML-KLH. Data from repeated ELISA confirms binding of the control and chimeric anti-AGE to CML. All buffer control showed negative signal.
[144] Example 5: Humanized antibodies
[145] Humanized antibodies were designed by creating multiple hybrid sequences that fuse select parts of the parental (mouse) antibody sequence with the human framework sequences. Acceptor frameworks were identified based on the overall sequence identity across the framework, matching interface position, similarly classed CDR canonical positions, and presence of N-glycosylation sites that would have to be removed. Three humanized light chains and three humanized heavy chains were designed based on two different heavy and light chain human acceptor frameworks. The amino acid sequences of the heavy chains are shown in SEQ ID NO: 29, 31 and 33, which are encoded by the DNA sequences shown in SEQ ID NO:
30, 32 and 34, respectively. The amino acid sequences of the light chains are shown in SEQ ID NO: 35, 37 and 39, which are encoded by the DNA sequences shown in SEQ ID NO: 36, 38 and 40, respectively. The humanized sequences were methodically analyzed by eye and computer modeling to isolate the sequences that would most likely retain antigen binding. The goal was to maximize the amount of human sequence in the final humanized antibodies while retaining the original antibody specificity. The light and heavy humanized chains could be combined to create nine variant fully humanized antibodies.
[146] The three heavy chains and three light chains were analyzed to determine their humanness. Antibody humanness scores were calculated according to the method described in Gao, S. H., et al., “Monoclonal antibody humanness score and its applications”, BMC Biotechnology, 13:55 (July 5, 2013). The humanness score represents how human-like an antibody variable region sequence looks. For heavy chains a score of 79 or above is indicative of looking human-like; for light chains a score of 86 or above is indicative of looking human-like. The humanness of the three heavy chains, three light chains, a parental (mouse) heavy chain and a parental (mouse) light chain are shown below in Table 6:
[148] Full-length antibody genes were constructed by first synthesizing the variable region sequences. The sequences were optimized for expression in mammalian cells. These variable region sequences were then cloned into expression vectors that already contain human Fc domains; for the heavy chain, the lgG1 was used.
[149] Small scale production of humanized antibodies was carried out by transfecting plasmids for the heavy and light chains into suspension HEK293 cells using chemically defined media in the absence of serum. Whole antibodies in the conditioned media were purified using MabSelect SuRe Protein A medium (GE Healthcare).
[150] Nine humanized antibodies were produced from each combination of the three heavy chains having the amino acid sequences shown in SEQ ID NO: 29, 31 and 33 and three light chains having the amino acid sequences shown in SEQ ID NO: 35, 37 and 39. A comparative chimeric parental antibody was also prepared. The antibodies and their respective titers are shown below in Table 7:
[152] The binding of the humanized antibodies may be evaluated, for example, by dose-dependent binding ELISA or cell-based binding assay.
[153] Example 6 (Prophetic): An AGE-RNAse containing vaccine in a human subject.
[154] AGE-RNAse is prepared by incubating RNAse in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-RNAse solution is dialyzed and the protein content is measured. Aluminum hydroxide or aluminum phosphate, as an adjuvant, is added to 100 pg of the AGE-RNAse. Formaldehyde or formalin is added as a preservative to the preparation. Ascorbic acid is added as an antioxidant. The vaccine also includes phosphate buffer to adjust the pH and glycine as a protein stabilizer. The composition is injected intravenously into a subject with idiopathic pulmonary fibrosis.
[155] Example 7 (Prophetic): Injection regimen for an AGE-RNAse containing vaccine in a human subject.
[156] The same vaccine as described in Example 6 is injected intraperitoneally into a subject with liver cirrhosis. The titer of antibodies to AGE-RNAse is determined by ELISA after two weeks. Additional injections are performed after three weeks and six weeks, respectively. Further titer determination is performed two weeks after each injection.
[157] Example 8 (Prophetic): An AGE-hemoglobin containing vaccine in a human subject
[158] AGE-hemoglobin is prepared by incubating human hemoglobin in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-hemoglobin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 6, except AGE-hemoglobin is substituted for AGE-RNAse. Administration is carried out as in Example 6, or as in Example 7.
[159] Example 9 (Prophetic): An AGE-human serum albumin containing vaccine in a human subject.
[160] AGE-human serum albumin is prepared by incubating human serum albumin in a phosphate buffer solution containing 0.1-3 M glucose, glucose-6-phosphate, fructose or ribose for 10-100 days. The AGE-human serum albumin solution is dialyzed and the protein content is measured. All vaccine components are the same as in Example 6, except AGE-human serum albumin is substituted for AGE-RNAse. Administration is carried out as in Example 6, or as in Example 7.
[161] Example 10 (Prophetic): Carboxymethyllysine-modified protein vaccine for a human subject
[162] A vaccine is prepared by combining a carboxymethyllysine-modified protein as an AGE antigen, aluminum hydroxide as an adjuvant, formaldehyde as a preservative, ascorbic acid as an antioxidant, a phosphate buffer to adjust the pH of the vaccine and glycine as a protein stabilizer. The vaccine is injected subcutaneously into a subject with myelofibrosis.
[163] Example 11 (Prophetic): Carboxyethyllysine-modified peptide vaccine for a human subject
[164] A vaccine is prepared by combining a carboxyethyllysine-modified peptide conjugated to KLH as an AGE antigen, aluminum hydroxide as an adjuvant, formaldehyde as a preservative, ascorbic acid as an antioxidant, a phosphate buffer
to adjust the pH of the vaccine and glycine as a protein stabilizer. The vaccine is injected subcutaneously into a subject with chronic kidney disease.
[165] Example 12: In vivo study of the administration of a carboxymethyl lysine monoclonal antibody
[166] The effect of a carboxymethyl lysine antibody on tumor growth, metastatic potential and cachexia was investigated. In vivo studies were carried out in mice using a murine breast cancer tumor model. Female BALB/c mice (BALB/cAnNCrl, Charles River) were eleven weeks old on Day 1 of the study.
[167] 4T1 murine breast tumor cells (ATCC CRL-2539) were cultured in RPM1 1640 medium containing 10% fetal bovine serum, 2 mM glutamine, 25 pg/mL gentamicin, 100 units/mL penicillin G Na and 100 pg/mL streptomycin sulfate. Tumor cells were maintained in tissue culture flasks in a humidified incubator at 37 °C in an atmosphere of 5% CO2 and 95% air.
[168] The cultured breast cancer cells were then implanted in the mice. 4T1 cells were harvested during log phase growth and re-suspended in phosphate buffered saline (PBS) at a concentration of 1 x 106 cells/mL on the day of implant. Tumors were initiated by subcutaneously implanting 1 x 1054T1 cells (0.1 mL suspension) into the right flank of each test animal. Tumors were monitored as their volumes approached a target range of 80-120 mm3. Tumor volume was determined using the formula: tumor volume = (tumor width)2(tumor length)/2. Tumor weight was approximated using the assumption that 1 mm3 of tumor volume has a weight of 1 mg. Thirteen days after implantation, designated as Day 1 of the study, mice were sorted into four groups (n=15/group) with individual tumor volumes ranging from 108 to 126 mm3 and a group mean tumor volume of 112 mm3. The four treatment groups are shown in Table 8 below:
[170] An anti-carboxymethyl lysine monoclonal antibody was used as a therapeutic agent. 250 mg of carboxymethyl lysine monoclonal antibody was obtained from R&D Systems (Minneapolis, MN). Dosing solutions of the carboxymethyl lysine monoclonal antibody were prepared at 1 and 0.5 mg/mL in a vehicle (PBS) to provide the active dosages of 10 and 5 pg/g, respectively, in a dosing volume of 10 mL/kg. Dosing solutions were stored at 4 °C protected from light.
[171] All treatments were administered intravenously (i.v.) twice daily for 21 days, except on Day 1 of the study where the mice were administered one dose. On Day 19 of the study, i.v. dosing was changed to intraperitoneal (i.p.) dosing forthose animals that could not be dosed i.v. due to tail vein degradation. The dosing volume was 0.200 mL per 20 grams of body weight (10 mL/kg), and was scaled to the body weight of each individual animal.
[172] The study continued for 23 days. Tumors were measured using calipers twice per week. Animals were weighed daily on Days 1-5, then twice per week until the completion of the study. Mice were also observed for any side effects. Acceptable toxicity was defined as a group mean body weight loss of less than 20% during the study and not more than 10% treatment-related deaths. Treatment efficacy was determined using data from the final day of the study (Day 23).
[173] The ability of the anti-carboxymethyl lysine antibody to inhibit tumor growth was determined by comparing the median tumor volume (MTV) for Groups 1-3. Tumor volume was measured as described above. Percent tumor growth inhibition (%TGI) was defined as the difference between the MTV of the control group (Group 1) and the MTV of the drug-treated group, expressed as a percentage of the MTV of the control group. %TGI may be calculated according to the formula: %TGI = (1- MTVtreated/MTVcontrol) X 100.
[174] The ability of the anti-carboxymethyl lysine antibody to inhibit cancer metastasis was determined by comparing lung cancer foci for Groups 1-3. Percent inhibition (%lnhibition) was defined as the difference between the mean count of metastatic foci of the control group and the mean count of metastatic foci of a drug- treated group, expressed as a percentage of the mean count of metastatic foci of the control group. %l nhibition may be calculated according to the following formula: %lnhibition = (1-Mean Count of Focitreated/Mean Count of Focicontroi) x 100.
[175] The ability of the anti-carboxymethyl lysine antibody to inhibit cachexia was determined by comparing the weights of the lungs and gastrocnemius muscles for Groups 1-3. Tissue weights were also normalized to 100 g body weight.
[176] Treatment efficacy was also evaluated by the incidence and magnitude of regression responses observed during the study. Treatment may cause partial regression (PR) or complete regression (CR) of the tumor in an animal. In a PR response, the tumor volume was 50% or less of its Day 1 volume for three consecutive measurements during the course of the study, and equal to or greater than 13.5 mm3 for one or more of these three measurements. In a CR response, the tumor volume was less than 13.5 mm3 for three consecutive measurements during the course of the study.
[177] Statistical analysis was carried out using Prism (GraphPad) for Windows 6.07. Statistical analyses of the differences between Day 23 mean tumor volumes (MTVs) of two groups were accomplished using the Mann-Whitney (7 test. Comparisons of metastatic foci were assessed by ANOVA-Dunnett. Normalized tissue weights were
compared by ANOVA. Two-tailed statistical analyses were conducted at significance level P = 0.05. Results were classified as statistically significant or not statistically significant.
[178] The results of the study are shown below in Table 9:
[180] All treatment regimens were acceptably tolerated with no treatment-related deaths. The only animal deaths were non-treatment-related deaths due to metastasis. The %TGI trended towards significance (P > 0.05, Mann-Whitney) for the 5 pg/g (Group 2) or 10 pg/g treatment group (Group 3). The %lnhibition trended towards significance (P > 0.05, ANOVA-Dunnett) for the 5 pg/g treatment group. The %lnhibition was statistically significant (P < 0.01, ANOVA-Dunnett) for the 10 pg/g treatment group. The ability of the carboxymethyl lysine antibody to treat cachexia trended towards significance (P > 0.05, ANOVA) based on a comparison of the organ weights of the lung and gastrocnemius between treatment groups and the control group. The results indicate that administration of an anti-carboxymethyl lysine monoclonal antibody is able to reduce cancer metastases. This data provides additional evidence that in vivo administration of anti-AGE antibodies can provide therapeutic benefits safely and effectively.
[181] Example 13: Treatment of fibrotic lung diseases by removal of senescent cells
[182] The following example was obtained from International Publication no. WO 2015/116740 and describes research carried out by parties other than the inventor and applicant of the Present Application regarding therapeutic removal of senescent cells in vivo by administration of senolytic agents in a mouse model, as well as potential future studies that could be carried out.
[183] One animal model study assessed the effect of clearance of senescence cells in the transgenic mouse strain 3MR that has bleomycin induced lung injury. In the bleomycin injury model for idiopathic pulmonary fibrosis, mice develop lung fibrosis within 7-14 days after bleomycin treatment (see, e.g., Limjunyawong et al., 2014, Physiological Reports 2:e00249; Daniels et al, 2004, J. Clin. Invest. 114: 1308- 1316). Bleomycin was administered to anesthetized 6-8 week old 3MR mice by intratracheal aspiration (2.5U/kg of bleomycin in 50 pT PBS) using a microsprayer syringe (Penn- Century, Inc.) as described in Daniels et al. (2004, J. Clin. Invest 114: 1308-1316). Control mice were administered saline. The day following bleomycin treatment, ganciclovir (GCV) (25mg/kg in PBS) was administered. 3MR mice were treated via intraperitoneal injection with ganciclovir for 5 consecutive days, followed by 5 days of rest, followed by a second treatment cycle of 5 consecutive days. Untreated mice received an equal volume of vehicle. At 7, 14, and 21 days post-bleomycin treatment, lung function was assessed by monitoring oxygen saturation using the MouseSTAT PhysioSuite pulse oximeter (Kent Scientific). Animals were anesthetized with isoflurane (1.5%) and a toe clip was applied. Mice were monitored for 30 seconds and the average peripheral capillary oxygen saturation (SpOz) measurement over this duration was calculated. As shown in Figure 2, bleomycin administration significantly reduced SpOa levels in vehicle treated mice, and removal of senescent cells resulted in higher Sp02 levels, which approached normal levels at 21 days post bleomycin administration. At 21 days post- bleomycin treatment, airway hyper-reactivity (AHR) of mice was examined. AHR of mice was measured by methacholine challenge while other parameters of lung function (airway mechanics, lung volume and lung compliance) were determined using a SCIREQ flexiVent ventilator. While under ketamine/xylazine anesthesia and
subjected to cannulation of the trachea via a tracheostomy (19Fr blunt Luer cannula), airway resistance (elastance) and compliance of mice were assessed at baseline and in response to increasing concentrations of methacholine (0 to 50 mg/ml in PBS) delivered via nebulization (AeroNeb) as described in Aravamudan et al. (Am. J. Physiol. Lung Cell. Mol. Physiol. (2012) 303:L669-L681). Animals were maintained at 37°C, and while under muscle paralysis (pancuronium); airway function was measured by using the FlexiVent™ ventilator and lung mechanics system (SCIREQ, Montreal, Quebec, Canada), which was housed on Stabile 8. As shown in Figure 3A, in vehicle treated mice, bleomycin administration increased lung elastance, whereas ganciclovir treatment reduced lung elastance. As shown in Figures 3B-C, bleomycin administration reduced static compliance and (dynamic) compliance in vehicle treated mice. Clearance of senescent cells with ganciclovir in bleomycin exposed mice improved compliance values significantly (Figures 3B-C). Although not statistically significant because the animal group size was too small, data suggested that clearance of senescent cells with a senolytic agent (Nutlin-3A) also reduced lung elastance and increased lung compliance in a bleomycin exposed mouse. Mice were euthanized by i.p injection of pentobarbital.
[184] Bronchoalveolar lavage (BAL) fluids and lungs is obtained and analyzed.
Hydroxyproline content of lungs is measured as described in Christensen et al. (1999, Am . J. Pathol. 155: 1773-1779), and quantitative histopathology is performed. RNA is extracted from lung tissue to measure senescence cell markers by qRT-PCR in treated and control mice. The effect of clearance of senescence cells in the bleomycin induced lung injury model of IPF may also be studied in INK- ATT AC transgenic mice in the study design described above. INK- ATT AC (pl6lnk4a apoptosis through targeted activation of caspase) transgenic mice have an FK506- binding protein (FKBP)-caspase 8 (Casp8) fusion polypeptide under the control of the pl6lnk4a promoter (see, e.g., Baker et al, Nature, supra; Int'l Patent Application Publication No. WO/2012/177927). In the presence of AP20187, a synthetic drug that induces dimerization of a membrane bound myristoylated FKBP-Casp8 fusion protein, senescent cells specifically expressing the FKBP-Casp8 fusion protein via
the pl6lnk4a promoter undergo programmed cell death (apoptosis) (see, e.g., Baker, Nature, supra, Figure 1 therein).
[185] A second study also assesses the effect of clearance of senescence cells using a senolytic agent in C57BL6/J mice that have bleomycin induced lung injury. Bleomycin is administered to 6 week old C57BL6/J mice as described above. A senolytic agent is administered during the first and third week post-bleomycin treatment. Control mice are treated with vehicle. At 21 days post-bleomycin treatment, clearance of senescent cells and lung function/histopathology is assessed.
[186] In a second animal model for pulmonary diseases (e.g., COPD), mice were exposed to cigarette smoke. The effect of a senolytic agent on the mice exposed to smoke is assessed by senescent cell clearance, lung function, and histopathology.
[187] Six week-old 3 MR (n=35) or INK-ATTAC (n=35) mice were chronically exposed to cigarette smoke generated from a Teague TE-10 system, an automatically-controlled cigarette smoking machine that produces a combination of side-stream and mainstream cigarette smoke in a chamber, which is transported to a collecting and mixing chamber where varying amounts of air is mixed with the smoke mixture. The COPD protocol was adapted from the COPD core facility at Johns Hopkins University (at Internet site web
.jhu.edu/Biswal/exposure_core/copd. html#Cigarette_Smoke) (Rangasamy et al, 2004, J. Clin. Invest. 114: 1248-1259; Yao et al, 2012, J. Clin. Invest. 122:2032- 2045). Mice received a total of 6 hours of cigarette smoke exposure per day, 5 days a week for 6 months. Each lighted cigarette (3R4F research cigarettes containing 10.9 mg of total particulate matter (TPM), 9.4 mg of tar, and 0.726 mg of nicotine, and 11.9 mg carbon monoxide per cigarette [University of Kentucky, Lexington, KY]) was puffed for 2 seconds and once every minute for a total of 8 puffs, with the flow rate of 1.05 L/min, to provide a standard puff of 35 cm3. The smoke machine was adjusted to produce a mixture of side stream smoke (89%) and mainstream smoke (11%) by smoldering 2 cigarettes at one time. The smoke chamber atmosphere was monitored for total suspended particulates (80-120 mg/m3) and carbon monoxide
(350 ppm). Beginning at day 7, (10) INK-ATTAC and (10) 3 MR mice were treated with AP20187 (3x per week) or ganciclovir (5 consecutive days of treatment followed by 16 days off drug, repeated until the end of the experiment), respectively. An equal number of mice received the corresponding vehicle. The remaining 30 mice (15 INK- ATTAC and 15 3 MR) were evenly split with 5 of each genetically modified strain placed into three different treatment groups. One group (n=10) received Nutlin-3A (25 mg/kg dissolved in 10% DMSO/3%) Tween-20 in PBS, treated 14 days consecutively followed by 14 days off drug, repeated until the end of the experiment). One group (n=10) received ABT-263 (Navitoclax) (100 mg/kg dissolved in 15% DMSO/5% Tween-20, treated 7 days consecutively followed by 14 days off drug, repeated until the end of the experiment), and the last group (n=10) received only the vehicle used for ABT-263 (15% DMSO/5% Tween-20), following the same treatment regimen as ABT-263. An additional 70 animals that did not receive exposure to cigarette smoke were used as controls for the experiment.
[188] After two months of cigarette smoke exposure, lung function was assessed by monitoring oxygen saturation using the MouseSTAT PhysioSuite pulse oximeter (Kent Scientific). Animals were anesthetized with isoflurane (1.5%) and the toe clip was applied. Mice were monitored for 30 seconds and the average peripheral capillary oxygen saturation (SpOz) measurement over this duration was calculated. As shown in Figure 4, clearance of senescent cells via AP20187, ganciclovir, ABT- 263 (Navi), or Nutlin-3A resulted in statistically significant increases in Sp02 levels in mice after 2 months of cigarette smoke exposure compared to untreated controls.
[189] At the end of the experimental period, airway hyper-reactivity (AHR) of mice to methacholine challenge using a SCIREQ flexiVent ventilator and lung mechanics system is examined as described above. After AHR measurement, mice are killed by i.p. injection of pentobarbital for in-depth analysis of lung histopathology as previously described (Rangasamy et al, 2004, J. Clin. Invest. 114: 1248-1259). Briefly, lungs are inflated with 0.5% low-melting agarose at a constant pressure of 25 cm. Part of the lung tissue is collected for RNA extraction and qRT-PCR analysis of senescent markers. Other parts of lungs are fixed in 10% buffered formalin and embedded in paraffin. Sections (5 urn) are stained with hematoxylin and eosin. Mean
alveolar diameter, alveolar length, and mean linear intercepts are determined by computer- assisted morphometry with Image Pro Plus software (Media Cybernetics).
[190] The potential therapeutic effect of clearance of senescent cells after COPD is fully developed may be assessed in 3MR or INK-ATTAC mice. Six week-old 3MR or INK-ATTAC mice are chronically exposed to cigarette smoke for 6 months as described above. At 6 months following the start of smoke exposure, 3MR or INK- ATTAC mice are treated with ganciclovir (5 consecutive days of treatment followed by 16 days off drug) or AP20187 (3x/week), respectively, until 9 months following the start of smoke exposure, when assessment of senescent cell clearance, lung function, and histopathology is performed.
[191] These studies demonstrate that fibrotic lung diseases may be treated by the removal of senescent cells. In addition, these studies confirm that senescent cells are appropriate targets for treating fibrotic diseases.
[192] Example 14 (Prophetic): Treatment of idiopathic pulmonary fibrosis
[193] A patient presents with idiopathic pulmonary fibrosis. She is administered an anti-AGE antibody by inhalation using a nebulizer. The anti-AGE antibody will specifically bind to cells expressing cell-surface AGEs, such as senescent myofibroblasts, and allow her immune system to destroy those cells. Killing and removing senescent cells will treat her idiopathic pulmonary fibrosis and prevent the disease from worsening.
[194] Example 15 (Prophetic): T reatment of scleroderma
[195] A patient presents with scleroderma on his right arm. He is administered a topical cream containing an anti-AGE antibody. The anti-AGE antibody will specifically bind to cells expressing cell-surface AGEs, such as senescent myofibroblasts, and allow his immune system to destroy those cells. Killing and removing senescent cells will treat his scleroderma and prevent further progression of the disease.
REFERENCES
[196] 1. “About PF”, Pulmonary Fibrosis Foundation, available online at www.pulmonaryfibrosis.org/life-with-pf/about-pf, accessed on July 18, 2017.
[197] 2. “Idiopathic pulmonary fibrosis”, available online at en.wikipedia.org/wiki/ldiopathic_pulmonary_fibrosis (April 18, 2017).
[198] 3. “Pulmonary fibrosis” available online at en.wikipedia.org/wiki/Pulmonary_fibrosis (July 12, 2017).
[199] 4. “Epithelial-mesenchymal transition”, available online at en.wikipedia.org/wiki/Epithelial-mesenchymal_transition (July 15, 2017).
[200] 5. Medline Plus, “Pulmonary fibrosis”, National Institute of Health, available online at medlineplus.gov/pulmonaryfibrosis.html (April 21, 2017).
[201] 6. Schafer, M. J. et al., “Cellular senescence mediates fibrotic pulmonary disease”, Nature Communications, Vol. 8, No. 14532, 11 pages (2017).
[202] 7. Yilmaz, O. et a/., “Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice”, Growth Factors, Vol. 33, No. 5, p. 366-375 (2015).
[203] 8. Kato, M. et al., “Dasatinib suppresses TFG0-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis”, European Respiratory Journal, Vol. 44, No. Suppl. 58, p. 742 (2014).
[204] 9. Yagmur, E. et al., “Elevation of /VE-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis”, Clinical Biochemistry, Vol. 39, p. 39-45 (2006).
[205] 10. Chilosi, M. et al., "Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema", Translational Research, Vol. 162, p. 156-173 (2013).
[206] 11. Calhoun, C. et al. , “Senescent cells contribute to the physiological remodeling of aged lungs”, Journals of Gerontology: Biological Sciences, Vol. 71, No. 2, p. 153-160 (2016).
[207] 12. Duffield, J., “Cellular and molecular mechanisms in kidney fibrosis”, The Journal of Clinical Investigation, Vol. 124, No. 6, p. 2299-2306 (2014).
[208] 13. Weiler-Normann, C., et al., “Mouse models of liver fibrosis”, Zeitschrift fur Gastroenterologie, Vol. 45, p. 43-50 (2007).
[209] 14. Harris, W. T. et al., “Myofibroblast differentiation and enhanced TGF-P signaling in cystic fibrosis lung disease”, PLoS One, Vol. 8, No. 8, 8 pages (2013).
[210] 15. Hashimoto, M. et al., “Elimination of p19ARF-expressing cells enhances pulmonary function in mice”, Journal of Clinical Investigation Insight, Vol. 1, No. 12, 15 pages (2016).
[211] 16. Childs, B. G. et al., “Senescent foam cells are deleterious at all stages of atherosclerosis”, Science, Vol. 354, No. 6311, p. 472-477 (2016).
[212] 17. Frescas, D. et al., “Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody”, Proceedings of the National Academy of Sciences, p. E1668-E1677 (2017).
[213] 18. “Targeting pro-inflammatory cells in idiopathic pulmonary fibrosis: a human trial (IPF)”, available online at clinicaltrials.gov/ct2/show/study/NCT02874989 (accessed on February 6, 2017).
[214] 19. “Safety evaluation of dasatinib in subjects with scleroderma pulmonary fibrosis”, available online at clinicaltrials.gov/ct2/show/study/NCT00764309 (accessed on February 6, 2017).
[215] 20. “Beneficial effects of quercetin in chronic obstructive pulmonary disease (COPD) (quercetin)”, available online at clinicaltrials.gov/ct2/show/study/NCT01708278 (accessed on February 6, 2017).
[216] 21. Wynn, T. A., “Fibrotic disease and the TH1/TH2 paradigm”, Nature Reviews Immunology, Vol. 4, No. 8, p. 583-594 (2004).
[217] 22. Dataller, R. et al., “Liver fibrosis”, The Journal of Clinical Investigation, Vol. 115, No. 2, p. 209-218 (2005).
[218] 23. “Myelofibrosis”, Mayo Clinic, available online at www.mayoclinic.org/diseases-conditions/myelofibrosis/home/ovc-20261141 (accessed on February 14, 2017).
[219] 24. Midgley, A. C. et al., “Transforming growth factor-|31 (TGF-p1)- stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)- facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts", Journal of Biological Chemistry, Vol. 288, No. 21 , p. 14824-14838 (2013).
[220] 25. Shaw, T. J. et al., “Wound-associated skin fibrosis: mechanisms and treatments based on modulating the inflammatory response", Endocrine, Metabolic & Immune Disorders, Vol. 10, No. 4, pp. 320-330 (2010).
[221] 26. “Scleroderma Living With It”, National Institute of Arthritis and Musculoskeletal and Skin Diseases, available online at www.niams.nih.gov/health- topics/scleroderma#tab-living-with (2016).
[222] 27. “Current treatments available for scleroderma patients”, Scleroderma Research Foundation, available online atwww.srfcure.org/for-patients/current- treatments (2018).
[223] 28. WO 2014/179262.
[224] 29. Pan, J. et al., “Inhibition of Bcl-2/xl with ABT-263 selectively kills senescent type II pneumocytes and reverses pulmonary fibrosis induced by ionizing radiation in mice”, International Journal of Radiation Oncology Biology Physics, Vol. 99, No. 2, pp. 353-361 (2017).
[225] 30. WO 2015/116740.
[226] 31. Wang, W-J. et al., “Cellular senescence, senescence-associated secretory phenotype, and chronic kidney disease”, Oncotarget, Vol. 8, No. 38, pp. 64520-64533 (2017).
[227] 32. Valentijn, F.A. et al., “Cellular senescence in the aging and diseased kidney”, Journal of Cell Communication and Signaling, Vol. 12, pp. 69-82 (2018).
[228] 33. Oldfield, M.D. et al., “Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)”, The Journal of Clinical Investigation, Vol. 108, No. 12, pp. 1853-1863 (2001).
[229] 34. Tanji, N. et al., “Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease”, Journal of the American Society of Nephrology, Vol. 11 , pp. 1656-1666 (2000).
[230] 35. Machahua, C., et al., Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis, Respiratory Research, vol. 17, no. 144, pp. 1-11 (2016).
[231] 36. El-Torky, M., et al., Collagens in scar carcinoma of the lung, The American Journal of Pathology, vol. 121, no. 2, pp. 322-326 (1985)
Claims
1. A method of treating or preventing the onset of a fibrotic disease, comprising administering to a subject a composition comprising an anti-AGE antibody.
2. A method of treating or preventing the onset of a fibrotic disease, comprising administering to a subject a vaccine comprising an AGE antigen.
3. The method of any of the preceding claims, wherein the composition further comprises a second anti-AGE antibody.
4. The method of any of the preceding claims, wherein the composition further comprises a pharmaceutically acceptable carrier.
5. The method of any of the preceding claims, wherein the subject is selected from the group consisting of humans, goats, sheep, pigs, cows, horses, camels, alpacas, dogs and cats.
6. The method of any of the preceding claims, wherein the subject is a human.
7. The method of any of the preceding claims, wherein the anti-AGE antibody is non-immunogenic to a species selected from the group consisting of humans, cats, dogs, horses, camels, alpaca, cattle, sheep, pigs, and goats.
8. The method of any of the preceding claims, wherein the anti-AGE antibody binds an AGE antigen comprising at least one protein or peptide that exhibits AGE modifications selected from the group consisting of FFI, pyrraline, AFGP, ALI, carboxymethyllysine, carboxyethyl lysine and pentosidine.
- 65 -
9. The method of any of the preceding claims, wherein the anti-AGE antibody binds a carboxymethyllysine-modified protein or peptide.
10. The method of any of the preceding claims, wherein the composition is in unit dosage form.
11. The method of any of the preceding claims, wherein the composition is sterile.
12. The method of any of the preceding claims, wherein the vaccine further comprises an adjuvant, optionally, a preservative, and optionally, an excipient.
13. The method of any of the preceding claims, wherein the AGE antigen is an AGE-modified protein or AGE-modified peptide selected from the group consisting of AGE-RNAse, AGE-human hemoglobin, AGE-albumin, AGE-BSA, AGE- human serum albumin, AGE-ovalbumin, AGE-low density lipoprotein, AGE-collagen IV, AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE- collagen, AGE-cathepsin B, AGE-crystallin, AGE-plasminogen activator, AGE- endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-l and II, AGE-hemoglobin, AGE-Na+/K+-ATPase, AGE- plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-P-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE- fibrinogen, AGE-02-microglobulin, AGE-sorbitol dehydrogenase, AGE-ai-antitrypsin, AGE-carbonate dehydratase, AGE-hexokinase, AGE-apo C-l, AGE-KLH and mixtures thereof.
- 66 -
14. The method of any of the preceding claims, wherein the AGE antigen comprises at least one protein or peptide that exhibits AGE modifications selected from the group consisting of carboxymethyllysine, carboxyethyllysine, pentosidine, pyrraline, FFI, AFGP, and ALL
15. The method of any of the preceding claims, wherein the AGE antigen comprises a carboxymethyllysine-modified protein or peptide.
16. The method of any of the preceding claims, wherein the vaccine is sterile.
17. The method of any of the preceding claims, wherein the vaccine is in unit dosage form.
18. The method of any of the preceding claims, further comprising testing the patient to determine if the fibrotic disease has been ameliorated, and repeating the administering, if necessary.
19. The method of any of the previous claims, wherein the antibody comprises a first complementary determining region comprising the amino acid sequence of SEQ ID NO: 23, a second complementary determining region comprising the amino acid sequence of SEQ ID NO: 24, a third complementary determining region comprising the amino acid sequence of SEQ ID NO: 25, a fourth complementary determining region comprising the amino acid sequence of SEQ ID NO: 26, a fifth complementary determining region comprising the amino acid sequence of SEQ ID NO: 27, and a sixth complementary determining region comprising the amino acid sequence of SEQ ID NO: 28.
- 67 -
20. The method of any of the preceding claims, wherein the antibody comprises a heavy chain, and a light chain, wherein the heavy chain comprises an amino acid sequence having at least 90% sequence identity, preferably at least 95% sequence identity, more preferably at least 98% sequence identity, with an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 17, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, and SEQ ID NO: 51, and the light chain comprises an amino acid sequence having at least 90% sequence identity, preferably at least 95% sequence identity, more preferably at least 98% sequence identity, with an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 19, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, and SEQ ID NO: 61.
21. The method of any of the previous claims, wherein the antibody comprises a constant region from a species selected from the group consisting of humans, goats, sheep, pigs, cows, horses, camels, alpacas, dogs and cats.
22. The method of any of the preceding claims, wherein the antibody is a humanized antibody.
23. The method of any of the preceding claims, wherein the antibody is monoclonal.
24. The method of any of the preceding claims, wherein the antibody is substantially non-immunogenic to humans.
25. The method of any of the preceding claims, wherein the antibody has a rate of dissociation (k ) of at most 9 x 10'3 sec-1.
- 68 -
26. The method of any of the preceding claims, wherein the antibody is conjugated to an agent that causes the destruction of AGE-modified cells, wherein the agent is selected from the group consisting of a toxin, a cytotoxic agent, magnetic nanoparticles, and magnetic spin-vortex discs.
27. The method of any of the preceding claims, wherein the antibody includes constant regions which permit destruction of targeted cells by a subject’s immune system.
28. The method of any of the preceding claims, wherein the AGE antigen comprises carboxymethyllysine conjugated with keyhole limpet hemocyanin (CML- KLH).
29. The method of any of the preceding claims, wherein the fibrotic disease comprises at least one disease or disorder selected from the group consisting of interstitial lung disease, pulmonary fibrosis, liver fibrosis, cirrhosis, kidney fibrosis, kidney disease, nephrosclerosis, nephrosis, glomerulosclerosis, bladder fibrosis, urethral stricture, cardiovascular disease, macular degeneration, vitreal retinopathy, scleroderma, hypertrophic scarring, keloid scarring, restenosis, myelofibrosis, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis.
30. The method of any of the preceding claims, wherein the fibrotic disease is a fibroproliferative disorder.
31. The method of any of the preceding claims, wherein the anti-AGE antibody is administered by inhalation.
32. A method of reducing desmoplasia, comprising: administering to a subject a composition comprising an anti-AGE antibody.
- 69 -
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3229602A CA3229602A1 (en) | 2021-08-20 | 2022-08-19 | Methods and compositions for treating fibrotic diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163235494P | 2021-08-20 | 2021-08-20 | |
US63/235,494 | 2021-08-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023023654A1 true WO2023023654A1 (en) | 2023-02-23 |
Family
ID=83228949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/075226 WO2023023654A1 (en) | 2021-08-20 | 2022-08-19 | Methods and compositions for treating fibrotic diseases |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA3229602A1 (en) |
WO (1) | WO2023023654A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
US11872269B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Method and composition for treating sarcopenia |
US11873345B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Product and method for treating sarcopenia |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US5702704A (en) | 1991-12-20 | 1997-12-30 | The Rockefeller University | Antibodies to in vivo advanced glycosylation endproducts |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
WO2009143411A2 (en) | 2008-05-23 | 2009-11-26 | Siwa Corporation | Methods, compositions and apparatus for facilitating regeneration |
US20100226932A1 (en) | 2006-02-22 | 2010-09-09 | Novavax, Inc. | Adjuvant and Vaccine Compositions |
WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
WO2014179262A1 (en) | 2013-05-01 | 2014-11-06 | Cole Researh & Design, Inc. | Low molecular weight hyaluronic acid for treating keloid scars, hypertrophic scars and burn scars with contracture |
WO2015116740A1 (en) | 2014-01-28 | 2015-08-06 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
WO2016057831A1 (en) | 2014-10-10 | 2016-04-14 | COLE Research & Design, Inc. | Method of reducing scarring |
WO2017143073A1 (en) | 2016-02-19 | 2017-08-24 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
WO2018204679A1 (en) | 2017-05-04 | 2018-11-08 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
-
2022
- 2022-08-19 WO PCT/US2022/075226 patent/WO2023023654A1/en active Application Filing
- 2022-08-19 CA CA3229602A patent/CA3229602A1/en active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US5702704A (en) | 1991-12-20 | 1997-12-30 | The Rockefeller University | Antibodies to in vivo advanced glycosylation endproducts |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US20100226932A1 (en) | 2006-02-22 | 2010-09-09 | Novavax, Inc. | Adjuvant and Vaccine Compositions |
WO2009143411A2 (en) | 2008-05-23 | 2009-11-26 | Siwa Corporation | Methods, compositions and apparatus for facilitating regeneration |
US9161810B2 (en) | 2008-05-23 | 2015-10-20 | Siwa Corporation | Methods, compositions and apparatuses for facilitating regeneration |
WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
WO2014179262A1 (en) | 2013-05-01 | 2014-11-06 | Cole Researh & Design, Inc. | Low molecular weight hyaluronic acid for treating keloid scars, hypertrophic scars and burn scars with contracture |
WO2015116740A1 (en) | 2014-01-28 | 2015-08-06 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
WO2016057831A1 (en) | 2014-10-10 | 2016-04-14 | COLE Research & Design, Inc. | Method of reducing scarring |
WO2017143073A1 (en) | 2016-02-19 | 2017-08-24 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
WO2018204679A1 (en) | 2017-05-04 | 2018-11-08 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
Non-Patent Citations (66)
Title |
---|
"GenBank", Database accession no. AJ245184 |
ABOUT PF, PULMONARY FIBROSIS FOUNDATION, 18 July 2017 (2017-07-18), Retrieved from the Internet <URL:www.pulmonaryfibrosis.org/life-with-pf/about-pf> |
AHMED, E.K. ET AL.: "Protein Modification and Replicative Senescence of WI-38 Human Embryonic Fibroblasts", AGING CELLS, vol. 9, 2010, pages 252,260 |
ANDO, K. ET AL.: "Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products during Aging in the Circulation", BIOCHEM BIOPHYS RES COMMUN, vol. 258, 1999, pages 123,125 |
ARAVAMUDAN ET AL., AM. J. PHYSIOL. LUNG CELL. MOL. PHYSIOL., vol. 303, 2012, pages L669 - L681 |
AROIAN R.: "Pore-Forming Toxins and Cellular Non-Immune Defenses (CNIDs", CURRENT OPINION IN MICROBIOLOGY, vol. 10, 2007, pages 57 - 61, XP005884635 |
BAKER ET AL., NATURE |
BAKER, D. J. ET AL.: "Clearance of p16lnk4a-positive senescent cells delays ageing-associated disorders", NATURE, vol. 479, 2011, pages 232 - 236, XP055074325, DOI: 10.1038/nature10600 |
BATALLER, R. ET AL.: "Liver fibrosis", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 115, no. 2, 2005, pages 209 - 218 |
BENEFICIAL EFFECTS OF QUERCETIN IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) (QUERCETIN, 6 February 2017 (2017-02-06), Retrieved from the Internet <URL:clinicaltrials.gov/ct2/show/study/NCT01708278> |
BIERHAUS A: "AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept", CARDIOVASC RES, vol. 37, no. 3, 1998, pages 586 - 600, XP055399820, DOI: 10.1016/S0008-6363(97)00233-2 |
BITTERMAN, P.B.: "Fibroproliferative disorders", CHEST, vol. 99, no. 3, 1991, pages 81S - 84S |
BURTON, D.G.A. ET AL.: "Microarray analysis of senescent vascular smooth muscle cells: a link to atherosclerosis and vascular calcification", EXPERIMENTAL GERONTOLOGY, vol. 44, no. 10, October 2009 (2009-10-01), pages 659 - 665, XP026640753, DOI: 10.1016/j.exger.2009.07.004 |
CALHOUN, C. ET AL.: "Senescent cells contribute to the physiological remodeling of aged lungs", JOURNALS OF GERONTOLOGY: BIOLOGICAL SCIENCES, vol. 71, no. 2, 2016, pages 153 - 160 |
CHILDS, B. G. ET AL.: "Senescent foam cells are deleterious at all stages of atherosclerosis", SCIENCE, vol. 354, no. 6311, 2016, pages 472 - 477, XP055734560, DOI: 10.1126/science.aaf6659 |
CHILOSI, M. ET AL.: "Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema", TRANSLATIONAL RESEARCH, vol. 162, 2013, pages 156 - 173, XP055250860, DOI: 10.1016/j.trsl.2013.06.004 |
CHRISTENSEN, AM . J. PATHOL., vol. 155, 1999, pages 1773 - 1779 |
CURRENT TREATMENTS AVAILABLE FOR SCLERODERMA PATIENTS, 2018, Retrieved from the Internet <URL:www.srfcure.org/for-patients/current-treatments> |
DUFFIELD, J.: "Cellular and molecular mechanisms in kidney fibrosis", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 6, 2014, pages 2299 - 2306 |
EL-TORKY, M. ET AL.: "Collagens in scar carcinoma of the lung", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 121, no. 2, 1985, pages 322 - 326 |
EPITHELIAL-MESENCHYMAL TRANSITION, 15 July 2017 (2017-07-15), Retrieved from the Internet <URL:en.wikipedia.org/wiki/Epithelial-mesenchymal_transition> |
FERRACCIOLI, G. ET AL.: "Interleukin-1 0 and Interleukin-6 in Arthritis Animal Models: Roles in the Early Phase of Transition from Acute to Chronic Inflammation and Relevance for Human Rheumatoid Arthritis", MOL MED, vol. 16, no. 11-12, November 2010 (2010-11-01), pages 552 - 557 |
FRESCAS, D. ET AL.: "Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 2017, pages E1668 - E1677 |
FREUND, A.: "Inflammatory networks during cellular senescence: causes and consequences", TRENDS MOL MED, vol. 16, no. 5, May 2010 (2010-05-01), pages 238 - 46, XP027048786 |
GAO, S. H. ET AL.: "Monoclonal antibody humanness score and its applications", BMC BIOTECHNOLOGY, vol. 13, 5 July 2013 (2013-07-05), pages 55, XP021156542, DOI: 10.1186/1472-6750-13-55 |
HARRIS, W. T. ET AL.: "Myofibroblast differentiation and enhanced TGF-¡3 signaling in cystic fibrosis lung disease", PLOS ONE, vol. 8, no. 8, 2013, pages 8 |
HARRIS, W. T. ET AL.: "Myofibroblast differentiation and enhanced TGF-β signaling in cystic fibrosis lung disease", PLOS ONE, vol. 8, no. 8, 2013, pages 8 |
HASHIMOTO, M. ET AL.: "Elimination of p19ARF-expressing cells enhances pulmonary function in mice", JOURNAL OF CLINICAL INVESTIGATION INSIGHT, vol. 1, no. 12, 2016, pages 15 |
HERNANDEZ-GONZALEZ FERNANDA ET AL: "Cellular Senescence in Lung Fibrosis", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 13, 29 June 2021 (2021-06-29), Basel, CH, pages 7012, XP055975689, ISSN: 1661-6596, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/ivip/1422-0067/22/13/7012> DOI: 10.3390/ijms22137012 * |
IDIOPATHIC PULMONARY FIBROSIS, 18 April 2017 (2017-04-18), Retrieved from the Internet <URL:en.wikipedia.org/wiki/ldiopathic_pulmonary_fibrosis> |
JIANG, Z-H.: "Synthetic vaccines: the role of adjuvants in immune targeting", CURRENT MEDICINAL CHEMISTRY, vol. 10, no. 15, 2003, pages 1423 - 39, XP009017277, DOI: 10.2174/0929867033457340 |
KATO, M. ET AL.: "Dasatinib suppresses TFGp-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis", EUROPEAN RESPIRATORY JOURNAL, vol. 44, 2014, pages 742 |
KATO, M. ET AL.: "Dasatinib suppresses TFGβ-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis", EUROPEAN RESPIRATORY JOURNAL, vol. 44, 2014, pages 742 |
LIMJUNYAWONG ET AL., PHYSIOLOGICAL REPORTS, vol. 2, 2014, pages e00249 |
LINDSEY JB: "Receptor For Advanced Glycation End-Products (RAGE) and soluble RAGE (sRAGE): Cardiovascular Implications", DIABETES VASCULAR DISEASE RESEARCH, vol. 6, no. 1, 2009, pages 7 - 14, XP055494933, DOI: 10.3132/dvdr.2009.002 |
LIU RUI-MING ET AL: "Cell senescence and fibrotic lung diseases", EXPERIMENTAL GERONTOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 132, 17 January 2020 (2020-01-17), XP086017751, ISSN: 0531-5565, [retrieved on 20200117], DOI: 10.1016/J.EXGER.2020.110836 * |
MACHAHUA, C. ET AL.: "Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis", RESPIRATORY RESEARCH, vol. 17, no. 144, 2016, pages 1 - 11 |
MEDLINE PLUS, PULMONARY FIBROSIS, 21 April 2017 (2017-04-21), Retrieved from the Internet <URL:medlineplus.gov/pulmonaryfibrosis.html> |
MIDGLEY, A. C. ET AL.: "Transforming growth factor-131 (TGF-31)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 21, 2013, pages 14824 - 14838 |
MIDGLEY, A. C. ET AL.: "Transforming growth factor-31 (TGF-β1 )-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 21, 2013, pages 14824 - 14838 |
MYELOFIBROSIS, 14 February 2017 (2017-02-14), Retrieved from the Internet <URL:www.mayoclinic.org/diseases-conditions/myelofibrosis/home/ovc-20261141> |
NELSON, G.: "A senescent cell bystander effect: senescence-induced senescence", AGING CELL, vol. 11, 2012, pages 345 - 349, XP055625700, DOI: 10.1111/j.1474-9726.2012.00795.x |
OLDFIELD, M.D. ET AL.: "Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 108, no. 12, 2001, pages 1853 - 1863 |
PAN, J. ET AL.: "Inhibition of Bcl-2/xl with ABT-263 selectively kills senescent type II pneumocytes and reverses pulmonary fibrosis induced by ionizing radiation in mice", INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol. 99, no. 2, 2017, pages 353 - 361 |
PULMONARY FIBROSIS, 12 July 2017 (2017-07-12), Retrieved from the Internet <URL:en.wikipedia.org/wiki/Pulmonary_fibrosis> |
RANGASAMY ET AL., J. CLIN. INVEST., vol. 114, 2004, pages 1248 - 1259 |
RAYESS, H. ET AL.: "Cellular senescence and tumor suppressor gene p16", INT J CANCER, vol. 130, 2012, pages 1715 - 1725, XP055282399, DOI: 10.1002/ijc.27316 |
ROMAGOSA, C. ET AL.: "p16lnk4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors", ONCOGENE, vol. 30, 2011, pages 2087 - 2097, XP037742979, DOI: 10.1038/onc.2010.614 |
ROOS, C.M. ET AL.: "Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice", AGING CELL, 2016 |
SAFETY EVALUATION OF DASATINIB IN SUBJECTS WITH SCLERODERMA PULMONARY FIBROSIS, 6 February 2017 (2017-02-06), Retrieved from the Internet <URL:clinicaltrials.gov/ct2/show/study/NCT00764309> |
SCHAFER, M. J. ET AL.: "Cellular senescence mediates fibrotic pulmonary disease", NATURE COMMUNICATIONS, vol. 8, no. 14532, 2017, pages 11 |
SCLERODERMA LIVING WITH IT, 2016, Retrieved from the Internet <URL:www.niams.nih.gov/health-topics/scleroderma#tab-living-with> |
SHAW, T. ET AL.: "Wound-associated skin fibrosis: mechanisms and treatments based on modulating the inflammatory response", ENDOCRINE, METABOLIC & IMMUNE DISORDERS, vol. 10, no. 4, 2010, pages 320 - 330 |
TANJI, N. ET AL.: "Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 11, 2000, pages 1656 - 1666 |
TARGETING PRO-INFLAMMATORY CELLS IN IDIOPATHIC PULMONARY FIBROSIS: A HUMAN TRIAL (IPF, 6 February 2017 (2017-02-06), Retrieved from the Internet <URL:clinicaltrials.gov/ct2/show/study/NCT02874989> |
VALENTIJN, F.A. ET AL.: "Cellular senescence in the aging and diseased kidney", JOURNAL OF CELL COMMUNICATION AND SIGNALING, vol. 12, 2018, pages 69 - 82, XP036451280, DOI: 10.1007/s12079-017-0434-2 |
VLASSARA ET AL.: "High-affinity-receptor-mediated Uptake and Degradation of Glucose-modified Proteins: A Potential Mechanism for the Removal of Senescent Macromolecules", PROC. NATL. ACAD. SCI. USAI, vol. 82, 1985, pages 5588,5591 |
VLASSARA, H.: "Advanced Glycosylation Endproducts on Erythrocyte Cell Surface Induce Receptor-Mediated Phagocytosis by Macrophages", J. EXP. MED., vol. 166, 1987, pages 539,545 |
VOGEL, F. R. ET AL.: "A compendium of vaccine adjuvants and excipients", PHARMACEUTICAL BIOTECHNOLOGY, vol. 6, 1995, pages 141 - 228 |
WANG, W-J. ET AL.: "Cellular senescence, senescence-associated secretory phenotype, and chronic kidney disease", ONCOTARGET, vol. 8, no. 38, 2017, pages 64520 - 64533 |
WEILER-NORMANN, C. ET AL.: "Mouse models of liver fibrosis", ZEITSCHRIFT FUR GASTROENTEROLOGIE, vol. 45, 2007, pages 43 - 50 |
WYNN, T. A.: "Fibrotic disease and the T 1/T 2 paradigm", NATURE REVIEWS IMMUNOLOGY, vol. 4, no. 8, 2004, pages 583 - 594, XP009070836, DOI: 10.1038/nri1412 |
YAGMUR, E. ET AL.: "Elevation of NE-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis", CLINICAL BIOCHEMISTRY, vol. 39, 2006, pages 39 - 45, XP025058998, DOI: 10.1016/j.clinbiochem.2005.07.016 |
YAO ET AL., J. CLIN. INVEST., vol. 122, 2012, pages 2032 - 2045 |
YILMAZ, O. ET AL.: "Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice", GROWTH FACTORS, vol. 33, no. 5, 2015, pages 366 - 375, XP008181486, DOI: 10.3109/08977194.2015.1109511 |
ZHU, Y. ET AL.: "The Achilles' heel of senescent cells: from transcriptome to senolytic drugs", AGING CELL, vol. 14, 2015, pages 644 - 658, XP055342891, DOI: 10.1111/acel.12344 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11872269B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Method and composition for treating sarcopenia |
US11873345B2 (en) | 2014-12-18 | 2024-01-16 | Siwa Corporation | Product and method for treating sarcopenia |
US11833202B2 (en) | 2016-02-19 | 2023-12-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (AGE) |
Also Published As
Publication number | Publication date |
---|---|
CA3229602A1 (en) | 2023-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220175916A1 (en) | Methods and compositions for treating chronic effects of radiation and chemical exposure | |
US10858449B1 (en) | Methods and compositions for treating osteoarthritis | |
US11873345B2 (en) | Product and method for treating sarcopenia | |
US20210253737A1 (en) | Methods and compositions for treating disease-related cachexia | |
JP6722293B2 (en) | Methods and compositions for treating cancer, killing metastatic cancer cells, and preventing cancer metastasis using antibodies against advanced glycation end products (AGE) | |
US10961321B1 (en) | Methods and compositions for treating pain associated with inflammation | |
JP2020147574A (en) | Anti-age antibodies for treating inflammation and auto-immune disorders | |
US20210253739A1 (en) | Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells | |
WO2023023654A1 (en) | Methods and compositions for treating fibrotic diseases | |
US20230181730A1 (en) | Methods of treating infections | |
JP2018535953A (en) | Anti-AGE antibody and method of use thereof | |
WO2022093195A1 (en) | Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens | |
WO2021247397A2 (en) | Methods and compositions for enhancing the immune system | |
US11518801B1 (en) | Methods and compositions for treating diabetes and diabetic complications | |
US20240000930A1 (en) | Methods and compositions for treating kidney diseases | |
KR101581517B1 (en) | Antibodies that bind tgf-alpha and epiregulin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22765728 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3229602 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022765728 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022765728 Country of ref document: EP Effective date: 20240320 |